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Structure of the thesis 
This thesis is organised into five chapters:  
Chapter 1 (Introduction): is a review of the literature in which the important subjects 
underlying the initiation of Multiple Sclerosis (MS) have been discussed. In addition, the 
chapter discusses the strengths and limitations of the most commonly used animal models of 
MS and the discord between animal models and the disease in humans. Moreover, the 
rationale behind modification of the existing cuprizone-induced demyelination to model 
human MS has been clarified in this chapter.  
 
Chapter 2 (Materials and Methods): is a detailed account of the materials and methods for 
experiments contained in this thesis. 
 
Chapter 3 Results (Paper 1): is presented as a published paper with an introduction, methods, 
results (Studies I and II) and discussion (Sen MK, Almuslehi MSM, et al 2019, Cells).  The 
work was divided equally between the candidates (50% MKS and 50% MSMA), with 
MSMA taking the lead role in the Study II (prolonged low dose 12 week CPZ feeding) and 
contributing to all aspects of the two studies constituting the paper, including experimental 
design, analysis and manuscript preparation. The only modification included in this thesis is 
Study I (5-week study) and Study II (12 weeks study) nomenclature to harmonise with the 
data presented in Chapter 4 (Studies III-V). This paper (Chapter 3) details the impact of 
combining disruption of the blood brain barrier (pertussis toxin) with short (5 week, Study I) 
or prolonged (12 weeks, Study II) CPZ-feeding on the glial cells in the central nervous system 
(oligodendrocyte, microglia and astrocytes) and peripheral immune organs (e.g., spleen).  
 
Chapter 4 Results (Paper 2): is presented as a paper with an introduction, methods (abridged) 
results (Studies III-V) and discussion (Almuslehi MSM, et al 2020, Frontiers in Cellular 
Neuroscience). The conceptual framework and design of this work originated and led by 
MSMA. MSMA performed 98% of the laboratory experiments and 100% of the data analysis. 
MSMA drafted the manuscript as well as revised it after being reviewed and corrected by 
other authors. This paper details the impact of castration (orchiectomy) on peripheral immune 
organs (thymus and spleen, Study III), combining castration and blood brain barrier 
disruption with CPZ feeding (Study IV) and combining blood brain barrier disruption and 
CPZ-feeding in females (Study V). 
  
Chapter 5 (General Discussion): provides an overarching summary the results and their 
relevance to studying disease initiation in demyelinating disorders like MS; this also includes 
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Multiple sclerosis (MS) is a common disabling neurological disorder affecting about 2.5 
million people worldwide. There are two competing theoretical aetiologies of the disease: 
First, an ‘outside-in’ theory in which peripheral factors (autoreactive T-cells) traverse the 
blood brain barrier (BBB) leading to central nervous system (CNS) demyelination. Second, 
an ‘inside-out’ theory in which central demyelination causes BBB disruption leading to 
autoimmune response. Cuprizone (CPZ)-feeding in mice induces oligodendrocyte loss 
(oligodendrocytosis), demyelination and reactive gliosis of astrocytes and microglia in the 
central nervous system (CNS), similar to that seen in MS; however, the CPZ-induced 
pathology lacks T-cell involvement in the CNS, a hallmark of MS, in particular by CD8+ T-
cells. This thesis explored whether incremental modification of the standard CPZ mouse 
model would yield a pattern of disease development and progression more closely resembling 
that seen in human MS. The first modification tested the hypothesis that blood brain barrier 
(BBB) disruption (using pertussis toxin, PT) would facilitate a T-cell-mediated immune 
response to the myelin antigens in the CNS of CPZ-fed mice. This was tested by using low 
(0.1%) and standard (0.2%) CPZ-feeding for 5 weeks (Study I) and also assessing whether 
similar effects can be initiated by inducing a slow progressive demyelination by prolonged 
feeding of 0.1% CPZ for 12 weeks (Study II). The use of 0.1% CPZ yields a comparable 
CNS pathology to 0.2% but less effect on splenic T-cell (CD4 and CD8, CD4/8) levels and 
no change in spleen mass; thus, only 0.1% CPZ was used in Study II. Although 
oligodendrocytosis, demyelination and gliosis were evident in Studies I and II, no T-cells 
were detected in the CNS. Proteomic analysis of whole brain tissue reveals that CPZ has 
changed the abundance of many proteoforms that are directly involved in metabolism and 
suppression of T-cell function. Importantly, 0.1% and 0.2% CPZ-feeding lead to a reduction 
in splenic T-cells, indicating that the peripheral immune system is suppressed due to the 
effects of CPZ-feeding. In study III, castration (Cx, orchiectomy) is used to protect the 
peripheral immune system against the dose dependent (0.2%>0.1%) effects of CPZ-feeding 
on thymus and spleen size (and T-cell levels) yet produces the same amount of demyelination 
and gliosis in the MCC. Study IV demonstrates that combining Cx induced preservation of 
the thymus and spleen with 0.1% CPZ-feeding and blood brain barrier disruption result in 
CD8+ T-cell recruitment into the brain and spinal cord. In study V, 0.1% CPZ-feeding in 
gonadally intact (Gi) female mice induces peripheral immune organ atrophy, T-cell signal 
suppression, demyelination and gliosis indistinguishable from that seen in males, but no 




Taken together, suppression of the peripheral immune system in male and female mice by 
CPZ-feeding explains why CPZ-induced demyelination does not result in the recruitment of 
peripheral immune cells into the CNS. Moreover, these findings indicate that a short period 
(2 weeks) of 0.1% CPZ-feeding in Cx males (where the peripheral immune structures are 
preserved), induces both demyelination and glial activation that are sufficient to activate and 
recruit CD8+ cells to the CNS, in effect initiating an ‘inside-out’ T-cell mediated immune 
response. The CD8+ T-cell recruitment into the CNS of CPZ-fed mice is a new variant of the 
CPZ model that should prove useful to explore the earliest events involved in CNS 
















1.1 - Chapter structure 
This chapter provides an overview of the main clinical and pathological changes in multiple 
sclerosis (MS). The text focuses on how well the current theories of MS pathophysiology 
account for the initial steps of disease initiation. In this context, the most commonly used 
animal models, experimental autoimmune encephalomyelitis (EAE) and cuprizone (CPZ), 
and their relevance to the disease, are discussed. In particular, the pathological changes in the 
CPZ model are reviewed in detail because this model is used in this thesis as a fundamental 
tool to test the hypothesis that appropriate modification of the CPZ model would allow for 
the resulting demyelination to act as an endogenous trigger (inside) of subsequent T-cell 
responses (outside) that then cause further myelin degeneration and inflammation in the CNS, 
better modelling the “inside-out” initiation recently proposed to underlie Multiple Sclerosis 
(MS). In doing so, this chapter presents the similarities between the standard CPZ model and 
MS, highlights the limitations of this CPZ model, and also introduces the research work to 
be detailed in the following chapters of this thesis that are designed to address the CPZ model 
limitations, thereby developing an animal model that mimics the likely inside-out initiation 
of MS.  
 
1.2 - Background: an overview of Multiple Sclerosis and animal models 
MS is one of the common disabling neurological disorders of young adults (20-30s), affecting 
about 2.5 million people worldwide (Popescu and Lucchinetti, 2012). Pathologically, the 
disease is characterized by degeneration of oligodendrocytes (OLG), loss of neuronal myelin 
sheaths (demyelination) and axonal damage as well as T and B-cell infiltration (Qureshi et 
al., 2017). Yet, the mechanisms that culminate in the demyelination process are not well 
understood, particularly the early stages of the disease (Stys et al., 2012). Therefore, the 
disease remains without cure. However, patients’ quality of life can be improved using 
current immune-suppressive and anti-inflammatory medications. Nevertheless, these 
medications fail to halt the disease progression (Kleinewietfeld et al., 2013, Bielekova et al., 
2009, Naves et al., 2013, Emmanouil et al., 2018). Although an ‘autoimmune’ aetiology of 
MS has been widely promulgated, other hypotheses have focused on how it may commence, 
in particular, whether the disease is a response to a slow progressive myelin degeneration 
(demyelination) that may occur 2-3 decades before the appearance of clinical symptoms 
(Cortese et al., 2016). While neuro-degeneration and autoimmunity are the prominent 




understanding the disease origin, especially the earliest stages of disease initiation, 
prevention or cure seem improbable. Pathological investigation of the early events in humans 
is difficult because the early disease symptoms are rarely fatal. Thus, modelling the early 
pathological changes of MS in animals would increase the opportunity to investigate the early 
factors that trigger disease initiation and subsequent progression. 
 
1.3 - Classification of MS 
The clinical course and the severity of MS vary from patient to patient (Vollmer, 2007, 
Hohlfeld et al., 2016). Relapsing-remitting MS (RRMS) occurs in 85% of patients and 
manifests as relapses (episodes of neurological deficit) that remit (i.e. recover) to variable 
degrees. Over 50% of RRMS patients gradually adopt secondary progressive MS (SPMS) 
and a slight reduction in the number of the relapses episodes (Lublin et al., 2014, Scalfari et 
al., 2014) with a steady impairment of central nervous system (CNS) function (Scalfari et al., 
2010, Tremlett et al., 2008). Clinically, RRMS and SPMS are classically associated with 
relapses (Lublin and Reingold, 1996). Approximately 15% of all cases present as primary 
progressive MS (PPMS) in which the clinical symptoms of the disease progress in a gradual 
but consistent manner. 
A new system of classification was established by consensus in 2013 (Lublin et al., 2014); 
this system sub-classified the disease into PPMS and SPMS, based on the disease activity 
(active or inactive) and progression (progressive versus not progressive). The limit of activity 
can be determined by the presence of CNS lesions via magnetic resonance imaging or clinical 
relapses, whereas the progression of the disease is measured by the sustained accumulation 
of disability. Disease progression can be defined as a continual worsening in neurological 
condition during at least 6-12 months (Compston and Coles, 2008, Lublin and Reingold, 
1996). According to this new system of classification, MS has been classified in to four 
different types (Lublin et al., 2014):  
• Relapsing-remitting RRMS: clearly defined as series of attack episodes followed by 
partial or complete remission. 
• Primary progressive PPMS: gradual worsening of disease without remission and   
possibly followed by temporary relief from clinical symptoms. 
• Secondary progressive SPMS: follows an initial relapsing-remitting course where there 




• Relapsing progressive RPMS: it is a chronic progressive form of the disease. In other 
words, it is a combination of relapses and progression (Rovaris et al., 2006).  
 
1.4 - Pathological features of MS lesions  
The neuropathological changes associated with newly formed lesions in MS patients have 
remained poorly understood because death is rare in early diagnosed patients. Thus, it is hard 
to obtain biopsies from such lesions to investigate the pathological changes (Mando et al., 
2018). Consequently, only the changes that occurred following accidental death have been 
reported. The pattern of demyelination and inflammation (innate immune cell-mediated and 
adaptive immune cell-mediated inflammation) in the lesions is profoundly heterogeneous 
among MS patients (Lucchinetti et al., 2000, Lucchinetti et al., 1996). Notably, it was 
demonstrated that the heterogeneity of MS lesions in the early phase of the disease may 
disappear over the time and turn to be homogenous (Breij et al., 2008). Although the 
examined lesions have the common hallmark of demyelination, these lesions could be 
distinguished from each other by the type of the immune reaction, consisting mainly of T 
lymphocyte infiltration and macrophage activation (Popescu et al., 2013). Accordingly, MS 
lesions were classified into four separate patterns (Lucchinetti et al., 2000, Lucchinetti et al., 
1996).  
• Pattern I lesion: active demyelination sites are dominated by T lymphocytes and 
macrophages. These sites are also characterized by loss of various myelin proteins such 
as myelin basic protein (MBP), proteolipid protein (PLP), myelin OLG protein (MOG) 
and myelin associated glycoprotein (MAG). Lesions are also centered by small veins 
and reveal sharply demarcated margins. 
 
• Pattern II lesion: pattern I lesion plus deposition of myelin specific antibodies (Abs) 
and activated complement system at the regions of active demyelination.  
 
• Pattern III lesion: peripheral immune cell infiltration, mainly T-cells and macrophages, 
and also innate immune cells (microglia) are evident, but there is no deposition of Abs 
or complement. In addition, veins are not located in the centre of the lesions, but a rim 
of myelin preservation is most frequently noticed surrounding an inflamed blood vessel 
inside the demyelinated areas. Lesion borders are ill-defined and characterized by 




fragmented (prominent markers of apoptosis). Inactive centers are almost completely 
free from OLG. Consequently, a severe loss in OLG is revealed at active plaque 
borders.  
 
• Pattern IV lesion: like pattern I, it displays T-cells and microglia/macrophages and 
shares a similar pathology of pattern III lesions in that there is significant OLG 
apoptosis around plaques in white matter.  
 
1.5 - Theories of MS aetiology  
There are two competing hypothesised aetiologies of the initiation and progression of MS: 
“outside-in” and “inside-out”. These terminologies were classically defined according to the 
initial site of lesions within the CNS (Tsunoda and Fujinami, 2002). In the outside-in model, 
MS lesions are first developed in myelin (outside) and extended to axons (inside). 
Conversely, the lesions in the inside-out theory begin in the axons (inside) and spread out 
(outside) to the myelin sheath (Tsunoda and Fujinami, 2002, Sato et al., 2011, Sato et al., 
2015).  
In 2012, Stys and colleagues applied the same terminology when they described the theories 
of MS initiation but with the term ‘outside’ used in reference to the activation of the 
peripheral immune system (and consequent autoimmunity) and ‘inside’ used for the neuro-
degenerative processes that are initiated without the involvement of the peripheral immune 
system (Stys et al., 2012). In the outside-in theory, MS is characterised as an autoimmune 
disease initiated by infiltration of myelin specific auto-reactive T and B-cells from the 
periphery (outside) into the CNS (inside) that attack myelin sheaths and lead to autoimmunity 
directed against myelinated axons. Such processes are hypothesised to occur during a typical 
relapsing course, especially in the initial stages of the disease during which there is an 
increase in inflammatory reactions leading to further myelin damage and neuronal injury.  
The ascendency and scope of the outside-in theory is challenged by an alternative view, the 
inside-out theory, built on many clinical and pathological observations (Hauser and 
Oksenberg, 2006, Trapp and Nave, 2008). These authors argued that the initial trigger of MS 
occurs in the CNS and peripheral immune cells are secondarily responding to the developing 
disease. In this theory, the initial event in MS is primarily neuro-degeneration (possibly the 
myelin-OLG complex), which results in the generation of antigenic myelin debris that then 




antigen presenting cells (APC) and increase the release of nitric oxide and proinflammatory 
molecules that change the function of the blood brain barrier (BBB) (Stys et al., 2012). 
Antigen presentation attracts peripheral T and B-cells and secondarily triggers an 
inflammatory reaction that ultimately leads to an autoimmune response.  
Currently, there is no direct evidence confirming the initial trigger of the early pathological 
changes in MS. Also, it can be argued that infiltration of peripheral immune cells in CNS 
lesions (outside-in) may be the result of a central lesion (inside-out) that has triggered the 
recruitment of peripheral immune cells. Therefore the two theories of MS initiation are not 
mutually exclusive and may work in synergy (Tsunoda and Fujinami, 2002, Tsunoda et al., 
2007). However, the clinical and pathological observations of the early disease stages 
indicated that the inside-out theory is operational in the absence of immune cell involvement. 
Furthermore, there are several limitations of the ‘outside-in’ theory which are discussed in 
the following sections.   
 
1.5.1 - Early changes in myelin are inconsistent with the outside-in theory  
Immunohistochemical analyses of pathological sections from patients in the initial stages of 
MS demonstrated that the earliest abnormalities such as widening or fragmentation of myelin 
lamellae occur at the innermost layers of the myelin sheath with no discernible change in the 
outer layers of myelin. Notably, these changes to the inner myelin lamellae also occur at 
regions beyond the inflammatory foci (Rodriguez and Scheithauer, 1994), where there is 
significant loss in MAG on the inner periaxonal wrappings of the myelin sheath, yet the outer 
wrappings are unaffected (Aboul-Enein et al., 2003). If the pathological changes are driven 
by adaptive (peripheral) auto-reactive T-cells, they would be either homogeneous or start in 
the outer layers of myelin and not be confined to the inner layers (Stys et al., 2012). 
Furthermore, examination of samples taken from patients in a very early stage of the disease 
(after accidental death) revealed limited infiltration of T or B-cells in the demyelinated 
lesions and limited oligodendroglial loss. Notably, these studies did reveal activation of 
microglia and macrophages, indicating the initiation of an innate immune system response 
directed against myelin debris (Barnett and Prineas, 2004, Henderson et al., 2009). In 
addition, the active MS plaques in the cortex show a substantial demyelination with limited 
infiltration of peripheral inflammatory cells (Peterson et al., 2001). Furthermore, 




suggesting that the demyelination precedes the adaptive and innate immune-mediated CNS 
inflammation. 
 
1.5.2 - Peripheral immune cell recruitment during the development of early MS lesions 
Brains of MS patients commonly show a reduced density of myelin in the affected white 
matter even when adaptive immune cell involvement in the CNS is not evident (Seewann et 
al., 2009, Poon et al., 2018). Moreover, in ‘normally appearing’ white matter of MS patients, 
axonal and myelin degeneration were evident with limited peripheral immune cell 
involvement (Trapp et al., 1998, Peterson et al., 2001, Henderson et al., 2009). Detailed 
histopathological examination of the brains from patients with very late stage progressive 
MS found a close relationship between the level of infiltrated T- and B-cells and the amount 
of axonal injury (Frischer et al., 2009). These authors assumed that the adaptive immune cell-
mediated inflammation may drive the progression of cellular degeneration in the CNS. 
Although this is a possibility, such relations may be equally consistent with increasing 
primary cellular degeneration, resulting in ongoing production of myelin and cellular debris 
that in turn drive a subsequent immune response (Boraschi et al., 2010).  
 
1.5.3 - Therapeutic targets and disease progression 
Clinical treatments with commercially available therapeutics that suppress or moderate the 
immune response show further inconsistencies in the outside-in theory. There is strong 
evidence that the widely prescribed immune modulators reduce, or almost eliminate relapses 
and inflammation in patients with RRMS, but are ineffective in patients with PPMS or 
RPMS, in which disease progression is attributed to auto-reactive T-cell-driven 
autoimmunity (Coles et al., 1999, Molyneux et al., 2000, Filippi et al., 2000, Hawker, 2011). 
This highlights an apparent paradox in which immuno-modulator therapies become less 
effective during states attributed to auto-reactive T-cell-driven autoimmunity. Similarly, 
transplantation of autologous haematopoietic stem cells into patients with MS ameliorates 
the adaptive immune response in the CNS (Mancardi and Saccardi, 2008), yet brain atrophy, 
axonal degeneration and demyelination continue to progress (Inglese et al., 2004, Brück, 
2005, Metz et al., 2007, Lu et al., 2010). Likewise, Alemtuzumab (an Ab directed against the 
antigen cluster of differentiation 52 (CD52) expressed on T- and B-cell) can have 




patients with severe adaptive immune cell-mediated inflammation in the CNS, while 
arresting the progression in patients with lower level inflammation (Coles et al., 1999). 
Moreover, the extensive immuno-suppressive effects by Alemtuzumab fail to eliminate all 
adaptive immune responses in the CNS. Therefore, the neurodegeneration driven by adaptive 
immune cell-mediated inflammation continues (Lu et al., 2010, Lassmann, 2011). These 
findings indicate that these therapeutics fail to stop the progression of the disease and raise 
doubt about the role of autoimmune responses in MS initiation. If the autoimmunity is behind 
MS initiation, these therapeutics should alleviate the late progressive course of the disease as 
observed in the early stages of RRMS. Advocates of the outside-in theory argue that the early 
adaptive inflammatory response would prime the brain for a later secondary degeneration 
(Sato et al., 2015, Sato et al., 2011). They claim that suppression of the adaptive inflammatory 
reactions can secondarily evoke axonal injury that increases brain atrophy and sustained 
disease progression (Coles et al., 1999),  in effect demonstrating a mechanism that is not 
dependent on immune function (Meuth et al., 2008).  
The repeated observations that MS progression can occur independently of inflammatory 
relapses makes it difficult to unequivocally identify the contribution of adaptive immune cell 
mediated-inflammation to relapse onset and PPMS (Kremenchutzky et al., 2006, Confavreux 
and Vukusic, 2006, Scalfari et al., 2010). These observations add complexity to the research 
when attempting to define the initial cause of MS. Also, they question whether the 
autoreactive T-cell response occurs first and drives the neuro-degeneration / progression in 
this disease (outside-in theory), or whether disease is initiated by a central demyelination that 
drives an immune response (inside-out theory) that then amplifies the neuro-degeneration 
and progression.  
 
1.5.4 - Genetic susceptibility to MS  
Genetic susceptibility to MS has been widely explored over the past years. The correlation 
of the major histocompatibility complex (MHC) region with MS suggests that variance in 
MHC can account for about 60% of genetic susceptibility (Oksenberg et al., 2008). These 
findings have been confirmed by a detailed study (using genome-wide association) to include 
genes involved in T-cell function (Sawcer et al., 2011). However, given that the vast majority 
(approximately 90%) of the patients involved in the study had the PPMS form of the disease, 




Importantly, an analysis of the PPMS subgroup detected four associations with genes 
(KIF21B, GALC, CYP24A1 and CYP27B1) un-related to the adaptive immune system. 
KIF21B and GALC genes are associated with local inflammation-independent neuro-
degenerative pathways, whereas CYP24A1 and CYP27B1 genes are associated with vitamin 
D deficiency (Pierrot-Deseilligny and Souberbielle, 2010, 2009), mechanisms that plausibly 
make contributions to MS (Kumar et al., 2013, Chauduri et al., 2017).  Intriguingly, despite 
identifying other potential non-immune contributors the authors concluded “that the critical 
disease mechanisms primarily involve immune dysregulation” (Sawcer et al., 2011).  
However, if the outside-in hypothesis is correct, which suggesting that inflammatory 
reactions in RRMS reflect immune responses as the primary process initiating MS, the 
genome studies would present strong data about the detailed mechanisms of such immune 
response but not about the mechanisms underlying the primary cause. Nonetheless, such 
studies only identify associations and cannot themselves confirm anything concerning 
underlying mechanism(s). Thus, using the same reasoning, these studies also cannot 
invalidate the inside-out hypothesis that explains the potential cause underlying the initiation 
of MS. Therefore, although supporters of the outside-in model may be correct, the alternative 
hypothesised inside-out model is equally reasonable and consistent with early clinical 
examination of the disease (Stys et al., 2012). 
 
1.6 - Immune response during MS 
1.6.1 - Humoral immunity  
In 1942, the concept of a process called ‘humoral immunity’ and its role in MS was 
introduced following the detection of intrathecal immunoglobulin G 1 and 3 isotypes (IgG1 
and IgG3) (Kabat et al., 1942). In this process, the binding of IgG to their target epitopes on 
the cell surface membrane or in the extracellular matrix can activate the complement system 
and cellular phagocytosis to clear debris (Kabat et al., 1942). IgGs are key factors for an 
effective humoral immune response to human pathogens (Jackson and Elsawa, 2015). Studies 
using a combination of proteomic analyses and gene sequencing revealed that plasma and B-
cell clones in the blood and cerebrospinal fluid (CSF) are responsible for IgG production 
(Bankoti et al., 2014, Obermeier et al., 2008). In the CNS of MS patients the meninges and 
CSF exhibit high concentrations of plasmablasts, plasma cells and B-cells (Cepok et al., 




these cells in the CNS seems to be supported by cytokines and other proinflammatory factors 
released by microglia (Krumbholz et al., 2005). Immunohistochemical and flow-cytometric 
analysis of plasma and B-cells from CSF and meninges show a strong association between 
these cell numbers and progression of MS (Cepok et al., 2005, Wurth et al., 2017). Although 
these findings were used to support a role for immunoglobulin-mediated damage at MS lesion 
sites based on cross-reactivity of IgG with the cellular antigens (and complement system 
activation), the target antigen(s) is still unknown (Arneth, 2019, Hohlfeld et al., 2016).  
 
1.6.2 - Innate immune response 
The predominant immune cells in the lesions of RRMS and progressive types of MS are 
microglia and macrophages. It is thought that adaptive immune cells (B and T-cells) interact 
with microglia and/or macrophages to activate the inflammatory responses in the CNS. The 
severity of inflammation and/or tissue damage contributes to the interaction between adaptive 
and innate immune cells. For instance, the removal of myelin debris is mediated by 
phagocytes (macrophages and microglia), and the degree of activity is associated with 
severity of myelin damage (Henderson et al., 2009, Lassmann et al., 1998).  Likewise, 
increased phagocytic activity is closely related with increased axon damage (Trapp et al., 
1998, Bitsch et al., 2000). In addition to the increased immune cell numbers at the active MS 
lesions, microglia and/or macrophages adopt an activated form leading to oxidative stress 
and increased production of reactive oxygen species (Fischer et al., 2012), thereby 
contributing to the pathology of white and grey matter lesions (Haider et al., 2011, Witte et 
al., 2013).  
Animal studies showed that the degeneration of axons predominates at the sites where the 
phagocytic cells accumulated (Shechter et al., 2009). Although tissue damage can be driven 
by phagocytes in MS lesion (Henderson et al., 2009, Peterson et al., 2001), studies using EAE 
(Shechter et al., 2009) or spinal cord injury (Shechter et al., 2013) have suggested that the 
phagocytic cells play an important role in tissue repair mechanisms during the resolution of 
the lesion. In the mouse CPZ model, it has been demonstrated that the blockage of activin-A 
(a factor released by polarised immunoregulatory phagocytic microglia) can inhibit the 
differentiation of OLG during the remyelination process (Miron et al., 2013). This indicates 
that phagocytic cells (microglia) play similar roles in CPZ-induced demyelination and MS 




During disease progression in MS patients, the reparative or harmful effects of phagocytosis 
on the CNS are most likely (or at least in part) associated with the origin of phagocytic cells 
and their phenotypes. For example, monocyte-derived phagocytes exhibit an activated 
phenotype that increase the production of proinflammatory molecules such as interferons 
(IFN) and interleukins (IL), thereby facilitating their infiltration into the MS lesion (Bar-Or 
et al., 2003, Kouwenhoven et al., 2001).  Likewise, locally activated microglia-derived 
phagocytic cells produce similar proinflammatory molecules and are hard to distinguish from 
blood borne phagocytic cells in brain tissue sections. Thus, it is still unclear whether these 
two cell populations (derived from different cells types) have similar or divergent functions 
in active MS lesions.  
In EAE animals, however, the use of differential chemokine receptor expression-based 
genetic techniques has enabled researchers to differentiate between microglia-derived or 
monocyte-derived phagocyte cells in the CNS (Yamasaki et al., 2014). These authors 
demonstrated that the phagocyte cells from different backgrounds have different functions 
during inflammation in the CNS. Monocyte derived phagocytes were seen to increase 
demyelination, while microglia derived phagocytes were removing the cellular debris and 
promoting remyelination. 
 
1.6.3 - Adaptive immune response  
CD4+ T lymphocytes can recognise antigens presented by microglia and infiltrated B-cell 
macrophages that express MHC II molecules. In contrast, CD8+ T lymphocytes can recognise 
APC that express MHC I molecules present on all nucleated cells in the body, including 
neuronal cells, OLG and astrocytes. Studies on T-cell receptors isolated from CNS tissue and 
CSF of MS patients revealed a substantial fraction of T lymphocytes (CD4 and CD8) that 
were derived from the clonal expansion. Accordingly, these studies proposed that the 
responses of antigen specific T lymphocytes contribute to disease initiation (Babbe et al., 
2000, Jacobsen et al., 2002). Although CNS auto-antigens may result from clonally expanded 
T lymphocytes in MS patients, T-cell clones can also remain and act as memory cells directed 
against various CNS pathogens. In addition, these cells can be expanded independently of 
their primary antigen in response to specific (see below) cytokine stimulus (Jiang et al., 2012, 
Wakim et al., 2010). Despite investigations in MS to identify T-cell targeted antigens 
(Siewert et al., 2012), these antigens in CNS tissue parenchyma or in the perivascular area 




In the cerebrospinal fluid, the majority of CD4+ T lymphocytes produce IFN-γ and display a 
central memory phenotype, i.e. they express chemokine receptor (CCR7) and memory 
activated T-cells (CD45RO) (Kivisakk et al., 2003). Likewise, the production of IL17 by 
CD4+ T-cells is elevated in the CSF during acute relapse episodes in RRMS patients 
(Brucklacher-Waldert et al., 2009). Many studies have investigated the cytokine profile and 
the response of peripheral T lymphocytes to myelin specific antigens such as MOG, PLP or 
MBP in MS. Yet, no study has established any differences in myelin antigen specific T-cell 
phenotypes between healthy and MS patients (Sospedra and Martin, 2005, Arneth, 2019, 
Hohlfeld et al., 2016). However, following immunisation with a modified form of MBP 
(peptide ligand CGP77116), the number of peripheral T lymphocytes which are specific to 
this protein was increased in the peripheral immune system and the increase in T-cell 
numbers was associated with the severity of MS (Bielekova et al., 2000). Therefore, it has 
been assumed that pathologic events in MS may result from autoreactive T lymphocytes 
following antigen-specific T-cell activation and differentiation to different subsets of T-cells 
in the peripheral lymphoid tissue in the human bronchial system or gastrointestinal tract 
(Berer et al., 2011, Odoardi et al., 2012).  
 
1.7 - Key summary of MS  
• MS is characterized by OLG degeneration, demyelination, axonal damage and innate 
immune cell activation (micro / astrogliosis). 
• There are four types of the disease (RRMS, PPMS, SPMS and RPMS). 
• Due to the heterogenesity of the disease pathology, MS lesions are classified into four 
patterns (I, II, III and IV). 
•  The initial cause of MS is unknown and there are two competing theories attributed to 
the disease aetiology (outside-in and inside-out). Clinical and pathological observations 
indicate that the inside-out theory may be a more likely explanation of disease 
aetiology than the outside-in theory. 
•  MS pathology has been attributed to the combined effects of the humoral and cellular 
immunity (adaptive and innate immune responses), which lead to CNS inflammation 







1.8 - Animal models of MS 
Several experimental animal models have been developed to explore the clinical and 
pathological changes inherent to MS, such as EAE, CPZ, Diphtheria toxin, lysolecithin and 
Theiler’s murine encephalomyelitis virus (TMEV). Each model is subtly different and 
mimics a subset of the symptoms and pathological features of MS (Torre-Fuentes et al., 
2019). For example, EAE is used to model RRMS when the mouse strain is ABH Biozzi (t 
Hart et al., 2011) and PPMS when mice are bred on a C57BL/6 background are used (Pham 
et al., 2010).  
Viral-induced demyelination was used to model some immunological aspects of MS using 
TMEV virus.  In 1934, Max Theiler initially described the TMEV disease and reported that 
the virus can cause flaccid paralysis in mice (Theiler 1934). Experimentally, TMEV can be 
injected intracerebrally in susceptible mouse strains to induce virus-mediated demyelination 
(Denic et al., 2011). This model has been used in MS research for two reasons: first, it shares 
some pathological features with human MS such as demyelination (Dal Canto and Lipton, 
1977; Lipton and Dal Canto, 1979; Denic et al., 2011) and second, the viral infection triggers 
autoimmune responses in the CNS of the mice (Rodriguez et al., 1987). The disease is 
asymptomatic in most mice strains during the early phase. The mouse’s immune system 
attacks the virus and clears it from the brain, while in the spinal cord, the viral replication 
cannot be inhibited by the immune system (Denic et al., 2011). The persistence of the viral 
load in the oligodendrocytes of the white matter in the spinal cord leads to chronic 
demyelination (Rodriguez et al., 1983) and accumulation of macrophages (Lipton et al., 
1995). 
A phospholipase A2 activator toxin (lysolecithin) is widely used in MS research to induce 
demyelination in rodents and has been established as a system to study the processes of de- 
and re-myelination in animals and to investigate the microenvironment of these processes 
(Blakemore and Franklin, 2008). In this model, demyelination induced by injection of 1% 
lysolecithin (2 µl) into the spinal cord of rodents, rabbits or cats (Jeffery and Blakemore, 
1995). In the acute phase (immediately after lysolecithin injection), peripheral immune cells 
(T-, B-cells and macrophages) are found at the lesion sites to clear up the debris (Bieber and 
Rodriguez, 2003). Unlike the TMEV model, demyelination in the lysolecithin model is not 
mediated by the immune system, and thus demyelination was evident when the lysolecithin 




Oligodendrocyte ablation using diphtheria toxin as a driver of oligodendrocyte death is a 
model of primary oligodendrocytopathy that assists in studying of some pathological 
sequelae of MS (Buch et al., 2005; Traka et al., 2010; Pohl et al., 2011). There are many 
different methods that have been used to ablate oligodendrocytes with diphtheria toxin. For 
example, transgenic mice that express human diphtheria toxin receptors (diphtheria toxin-
sensitive) are injected with the toxin to induce oligodendrocytes ablation and subsequent 
demyelination (Buch et al., 2005). In addition, diphtheria toxin-injected mice reveal chronic 
inflammation, irreversible axonal damage and limited remyelination in the CNS. Thus, 
studying remyelination is problematic in this model (Brockschnieder et al., 2004, 2006).  
The following discussion focuses on the most commonly used animal models in MS research 
- EAE and CPZ. The induction of EAE is based on the peripheral immunization of mice with 
myelin antigens, such as MBP, MOG or PLP, in order to activate myelin specific CD4+ T-
cell in the peripheral immune system (Gómez-Pinedo et al., 2017, Madill et al., 2016). The 
infiltration of activated T-cells into the central nervous system (CNS) is limited unless the 
BBB is disrupted by PT (Utz and McFarland, 1994). In the CNS, CD4+ T-cells encounter 
their specific antigens presented by APC and produce proinflammatory mediators such as IL-
17, TNF-ɑ, IFN-γ and. The release of these mediators activates another cascade of local 
inflammation that involves microglia, resulting in an autoimmune response (Kondo et al., 
1987, Benveniste, 1997, Bakker and Ludwin, 1987). 
EAE is the most commonly used animal model in MS research and most of the identified MS 
therapies have been trialled in this model (Lu et al., 2010, Lassmann, 2011, Metz et al., 2007, 
Emmanouil et al., 2018). However, the major limitations of this model are that it does not 
mimic the early events of disease observed in humans and it does not replicate the pattern of 
immune cell responses (i.e. CD4+ vs. CD8+ T-cells) and brain lesion (demyelination) 
observed in human MS. The mechanisms leading to OLG apoptosis and early pathological 
alterations in MS lesions are not clear and have not been effectively modelled in animal 
systems. In EAE the investigations focus primarily on the autoimmune characteristics of MS 
and their apparent relationship to later disease progression (Lassmann and Bradl, 2017).  
CPZ-feeding in mice induces CNS demyelination and has histopathology that is more closely 
related to patterns III and IV MS lesions in the PPMS and SPMS forms of the disease 
(Caprariello et al., 2018, Stys et al., 2012). However, it is still debated whether or not similar 




et al., 2005). Consistent with the complexity of the disease in humans, no current single 
animal model thus covers the entire heterogeneous nature of the disease. Table 1 summarises 
the key differences between MS and the EAE and CPZ animal models.  
Table 1: Comparison between human MS and animal models (EAE and CPZ). 
Disease criteria EAE model MS CPZ model 
Lesion site Mainly spinal cord (Constantinescu et 
al., 2011) 
Brain and spinal cord 
(Lövblad et al., 2010) 
Brain and spinal cord (Sen et 
al., 2020) 
Aetiology Adoptive transfer of myelin antigen 
(Hohlfeld and Steinman, 2017) 
Unknown (Huang et al., 2017)  CPZ-feeding (Pfeifenbring et 
al., 2015) 
T-cell involvement in 
the CNS 
CD4 (Nikić et al., 2011) only, unless 
induced by MBP-specific CD8+ T-cell 
(Huseby et al., 2001) or  
Gfap-specific CD8+ T-cells (Sasaki et 
al., 2014) 
CD8 and CD4 (Correale and 
Villa, 2008) 
Undetectable (Sui et al., 
2018) 
Sensory signs Yes, e.g. cold stimulus increases the 
frequency of paw withdrawal (Schmitz 
et al., 2014),  
 
Yes, e.g. pain (Khan et al., 
2018),vision impairment 
(Sanchez-Dalmau et al., 2018) 
and  fatigue (Mills and Young, 
2011) 
Not reported (Tsukahara et 
al., 2018) 
Motor signs Yes, e.g. mechanical hypersensitivity 
occurs before paralysis during the early 
stage of the EAE (Serizawa et al., 2018) 
tail and hind limbs paralysis (Bjelobaba et 
al., 2018) 
Yes, e.g. abnormal gait and 
walking imbalance (Pellegrino 
et al., 2018) 
Yes, e.g. latency to fall in 
rotarod test (Yamamoto et 
al., 2014) and reduced 
ability to maintain 
balance in walking beam 
test (Hagemeyer et al., 
2012) 
Remyelination Rare (Lassmann and Bradl, 2017) Limited (Franklin, 2002) Spontaneous (Bjelobaba et 
al., 2018) 
Disease form RRMS (Sasaki et al., 2014) All forms (Kamm et al., 2014) PPMS and SPMS 
(Caprariello et al., 2018) 
Pattern of lesion Pattern I and II (Constantinescu et al., 
2011) 
All patterns (Bjelobaba et al., 
2018) 




1.8.1 - EAE: an imperfect animal model of MS  
The earliest MS lesions in patients with known clinical history were found in the brainstem 
within seven days after first relapse (Barnett and Prineas, 2004). These lesions were described 
as active demyelinating lesions in which phagocytes immediately engulfed myelin debris in 
the presence of infiltrating T lymphocytes. Similar lesions were observed in the spinal cord 
of the EAE model, thus appearing to support the theory that CNS tissue damage in MS 
patients resulted from an autoimmune response directed against myelin sheaths (Adams et 
al., 1989, Barnett and Prineas, 2004, Henderson et al., 2009). While some treatments trialled 
in EAE mice successfully ameliorated or prevented the disease progression in EAE, these 




• Tumor necrosis factor (TNF-α): it has been shown that a ‘cytokine storm’ occurs due to 
a mitogenic complex of immunoglobulin against CD28 and CD3 (Beyersdorf et al., 
2005). Animal models, particularly rodents are adapted to tolerate high bacterial loads, 
high levels of endotoxins and cytokines such as lipopolysaccharide and TNF-α. While 
many studies conducted in the mouse EAE model indicated that cytokines could inhibit 
the clinical progression of the disease, a CD28 super-agonist (monoclonal Ab used to 
activate T-regulatory cells) and TNF-α produced a cytokine storm in MS patients 
(Wiendl and Hohlfeld, 2009). TNF-α neutralisation by anti-TNF-ɑ Ab is another 
example in which promising animal experimental results failed to translate, or were 
detrimental in human MS. In EAE, neutralization of TNF-ɑ inhibits and/or prevents 
the induction and progression of the disease (Sicotte and Voskuhl, 2001, 
Kleinewietfeld et al., 2013, Baker et al., 1994), while neutralisation of TNF-α 
exacerbates the disease in MS patients (Van Oosten et al., 1996). Similarly, studies 
have also shown that rolipram (a strong inhibitor of TNF) worsened the disease in 
humans (Ascherio et al., 2012), whereas the disease initiation was completely inhibited 
by rolipram in EAE animals (Baker et al., 1994, Sommer et al., 1995). Likewise, 
rolipram has clearly been shown to ameliorate the symptoms of disease progression in 
progressive chronic EAE, whereas trials in SPMS patients were stopped due to 
worsening of the disease (Bielekova et al., 2009). 
 
• IFN-γ: in vitro studies have demonstrated that the use of IFN- ameliorates  the severity 
of EAE in mice (Naves et al., 2013), whereas using IFN- in MS patients resulted in 
seemingly unpredictable worsening of disease (Panitch et al., 1987, Heremans et al., 
1996). 
 
• MBP83-99 analogue: this analogue is a receptor that anchors myelin specific T-cells and 
forms a tri-molecular complex between T-cells and myelin antigen with MHC to 
inactivate the detrimental function of myelin specific T-cells. The use of altered MBP83-
99 peptide analogues ameliorate or inhibit the severity of encephalomyelitis in EAE 
(Bielekova et al., 2000). However, the clinical trials of this analogue in MS patients 
were halted following exacerbation of the disease outcomes (Bielekova et al., 2000, 
Kim et al., 2002, Emmanouil et al., 2018). 
 
The contradictory observations seen in the EAE model and humans indicate that EAE is not 




irrespective of whether the investigations in EAE have positive effects (Wiendl and Hohlfeld, 
2002). Therefore, translation of positive preclinical experimental results into clinical practice 
requires caution and prudence.  
 
1.8.2 - CPZ model 
I.8.2.1- Pathological features of CPZ model  
In the past few decades, the CPZ model (using a standard dose 0.2% CPZ) in mice has 
attracted very prominent interest in terms of MS research because it evokes reproducible 
primary OLG death (apoptosis) and demyelination (Groebe et al., 2009). The feeding of 0.2% 
CPZ to mice induces well-defined spatial and temporal histopathological changes in the CNS 
(Acs and Kalman, 2012). Mega-mitochondria in the OLG (Arnett et al., 2001, Ludwin, 1978) 
as well as enlarged mitochondria in thymus (Solti et al., 2015)  are the earliest pathological 
feature occurring after 0.2% CPZ-feeding in mice. The detailed mechanism(s) of CPZ-
induced CNS pathology is still not fully understood and is often controversial. It is widely 
accepted that CPZ induces metabolic alterations in OLG which result in caspase-independent 
apoptosis, that includes apoptosis inducing factor (AIF)-mediated cell death, involving a 
mitochondrial mechanism (Kalman et al., 2007, Veto et al., 2010). However, caspase-
dependent OLG apoptosis was also reported in the corpus callosum (CC) following the 
activation of caspase-3 during 10 days of CPZ feeding (Hesse et al., 2010).  
A key histopathological feature associated with OLG apoptosis is the activation of both 
resident microglia and blood-borne macrophages in the demyelinated areas (Remington et 
al., 2007), contributing to the large number of phagocytes observed around demyelinated 
regions induced by CPZ-feeding. The role of these activated microglia and macrophages in 
the CPZ model is still debated (Martin et al., 2018). It has been proposed that these cells are 
responsible for amplifying the process of OLG apoptosis by the release of proinflammatory 
cytokines such as IL-2 TNF-α and IFN-γ (Pasquini et al., 2007). Other studies demonstrated 
that the activated microglia also have a helpful role by stimulating OLG progenitor cells 
(OPC) to remyelinate denuded axons (Acs et al., 2009, Komoly, 2005). When mice return to 
a normal diet after six weeks of 0.2% CPZ-feeding (Figure 1), spontaneous remyelination 
occurs (Tagge et al., 2016, Armstrong, 2007, Zhen et al., 2017). This remyelination has been 
attributed to maturation and repopulation of OPCs (Lindner et al., 2008). If CPZ-feeding is 




diet, limited or no spontaneous remyelination occurs due to the depletion of OPCs (Lindner 
et al., 2009, Mason et al., 2004).  
 
1.8.2.2 - CPZ-feeding effects on glial response  
1.8.2.2.1 - Oligodendrocytes 
The main function of mature OLG in the CNS is production of myelin sheaths that wrap the 
neuronal cell axons. Mature OLG apoptosis and demyelination are the CNS hallmarks of 
CPZ-feeding in mice (Gudi et al., 2014, Hesse et al., 2010). The expression of mRNA was 
found to be down-regulated for myelin proteins such as MBP, PLP and MAG following one 
week of 0.2% CPZ-feeding (Gudi et al., 2011). OLG apoptosis started after 3-7days of CPZ-
feeding (Komoly, 2005, Hesse et al., 2010). Ultrastructural examination of OLG during the 
first week of 0.2% CPZ-feeding showed mega-mitochondria, vacuolated cytoplasm, lipid 
droplets and very dense nuclear chromatin (Komoly, 2005). During the first 10 days of a 
0.2% CPZ diet, increased caspase-3 activity was detected in apoptotic OLG of the CC (Hesse 
et al., 2010). Following three weeks of 0.2% CPZ-feeding, activation of AIF and poly-ADP-
ribose polymerase (PARP) increased suggesting the emergence of caspase-3 independent 
apoptosis (Veto et al., 2010). Similar changes were described in pattern III and IV MS lesions 
in which the activation of PARP and caspase independent apoptosis were observed during 
primary OLG apoptosis (Kipp et al., 2009, Acs and Komoly, 2012, Veto et al., 2010). 
A near complete depletion of mature OLG occurs in the CC after four weeks of 0.2% CPZ-
feeding (Hesse et al., 2010, Skripuletz et al., 2011a). Demyelination can be observed during 
the time of OLG depletion in the CC and cerebral cortex. Myelin loss was noted in the second 
week of CPZ-feeding in the CC of mouse brains (Pfeifenbring et al., 2015, Mason et al., 
2000a). The peak of the demyelination occurs after four weeks of 0.2% CPZ-feeding in the 
CC and after five weeks in the cerebral cortex and hippocampus (Skripuletz et al., 2008, Gudi 
et al., 2009, Koutsoudaki et al., 2009, Gudi et al., 2014, Hesse et al., 2010, Skripuletz et al., 
2011a). Although demyelination in the CPZ model was believed to occur in white matter 
tracts only (e.g. superior cerebellar peduncle and CC (Komoly, 2005, Skripuletz et al., 2008, 
Koutsoudaki et al., 2009)), the gray matter in the cerebrum is also known to be severely 
demyelinated following twelve weeks of CPZ-feeding (Skripuletz et al., 2010). 
The remyelination process comprises highly organised events starting with migration of 




myelination. This process starts very early during CPZ-feeding even before the detection of 
demyelination by immunohistochemistry using MBP Ab (Stangel and Hartung, 2002). 
During the first two weeks of 0.2% CPZ-feeding, proliferation and accumulation of OPCs 
occur in the sub-ventricular zone, which then migrate to the demyelinated lesions (Mason et 
al., 2000a). The regulation of the development of OPCs to mature OLG requires basic 
transcription factors 1 and 2 (Olig1 and Olig2 which expressed by OLG). At the early stages 
Olig2 determines the site of the apoptotic OLG, whereas in the late stages, Olig1 drives the 
differentiation to OLG for remyelination (Zhou and Anderson, 2002, Arnett et al., 2004, 
Ligon et al., 2006).  
Proliferation and differentiation of both migrated and local OPCs start within the first four 
weeks of 0.2% CPZ-induced demyelination in parallel with the clearance of myelin debris in 
the CC (Gudi et al., 2009, Skripuletz et al., 2011b). Newly formed mature OLG can be seen 
in the CC during the first 3-4 days of following cessation of CPZ feeding (Koutsoudaki et 
al., 2010).  
 
1.8.2.2.2 - Astrocytes 
Astrocytes have many functions in the CNS including the genesis and maintenance of the 
BBB as well as regulation of neurogenesis, energy metabolism and synaptic transmission 
(Parpura et al., 2012). Astrocyte activation has been reported in many CNS disorders such as 
Alzheimer’s disease (Parpura et al., 2012), neuromyelitis optica (Kipp et al., 2011a) and MS 
(Nair et al., 2008). 
In MS, astrocyte activation occurs in response to various CNS pathologies that lead to an 
increase in glial fibrillary acidic protein (Gfap) expression and cellular hypertrophy 
(astrogliosis) (Pekny and Nilsson, 2005). As early as 1967, hypertrophy and hyperplasia of 
astrocytes were described in the cerebral regions of mice following CPZ-feeding (Carlton, 
1967). Other studies also reported astrogliosis in response to CPZ-feeding in the CC 
(Beckmann et al., 2018, Gudi et al., 2009), hippocampus, (Norkute et al., 2009), cerebral 
cortex (Skripuletz et al., 2008) and basal ganglia (Pott et al., 2009). 
In control (Ctrl) animals, normal astrocytes are small in size and have short and thin 
processes; in contrast, during the first two weeks of CPZ-feeding, astrocytes display 
hypertrophy and morphological changes in the shape and length of the processes. In addition 




detected, often referred to as astrocyte proliferation, which is evident during demyelination, 
and the extent of astrogliosis is directly proportional with the severity of the demyelination 
(Hiremath et al., 1998, Gudi et al., 2009). 
When CPZ-feeding is continued beyond five weeks, to induce chronic demyelination, there 
is no additional loss of OLG yet astrogliosis remains elevated (Lindner et al., 2009, Kipp et 
al., 2011b). Although protein and gene expression of Gfap remain elevated after five weeks 
of CPZ-feeding compared to the resting state, after this time there is an abatement of the 
initial Gfap expression response (during acute demyelination) (Lindner et al., 2009, Kipp et 
al., 2011b). After 10 weeks of CPZ-feeding, astrocyte activation persists for 2-3 weeks after 
CPZ-feeding was stopped. This effect is in contrast to the microglial activation which appears 
to be transient (Skripuletz et al., 2011a, Hibbits et al., 2012). This persistent activation of 
astrocyte might be required for proliferation and maturation OPCs to remyelinate the denuded 
axons. 
Astrocytes release many growth factors in the CNS following CPZ-induced demyelination 
including fibroblast growth factor (FGF-2), platelet derived growth factor alpha (PDGFα) 
and ciliary neurotrophic factor (CNTF) (Gudi et al., 2011, Messersmith et al., 2000). FGF-2 
and PDGFα promote the proliferation of OPCs and CNTF regulates their differentiation into 
mature OLG (Gudi et al., 2014). During the period of acute demyelination in the CPZ model, 
fatty acid-binding protein (FABP7) expression (a radial glial cell marker) was found to be 
up-regulated in the activated astrocytes, whereas in the chronic demyelination period the 
expression of FABP7 was down-regulated (Kipp et al., 2011a). Interestingly, the expression 
of this marker in astrocytes was found to be associated with remyelination in EAE and MS 
lesions, indicating that FABP7 may play a beneficial role in the activated astrocytes. In 
chronic human MS lesions, astrogliosis is associated with glial scar formation (Holley et al., 
2003, Brosnan and Raine, 2013) but this effect is not observed in chronic CPZ lesions 
(Hibbits et al., 2012).  
 
1.8.2.2.3 - Microglia  
Microglial cells are CNS-resident phagocytes that respond to various pathological changes 
occurring in CNS tissue (Ransohoff and Perry, 2009). During the first two weeks of CPZ-
feeding, microglial activation and proliferation (microgliosis) can be visualized 




et al., 2011b, Mason et al., 2004) of mice. The morphology and distribution of the activated 
microglia in the brain lesions of MS patients varies across different anatomical regions 
(Masuda et al., 2019). Likewise, in CPZ-fed mice, increased microglial number and ionized 
calcium-binding adaptor molecule 1 (Iba 1) staining intensity varies according to the severity 
of demyelination (Masuda et al., 2019), with microgliosis being more marked in the white 
matter area than the gray matter (Skripuletz et al., 2008, Gudi et al., 2009). A genetic cluster 
analysis confirmed that microglia subtypes in human MS lesions (‘human cluster’ namely 
Hu-C2, Hu-C3 and Hu-C8) and in CPZ-induced demyelination (C12) and remyelination 
(C13) clusters in mice have similar gene expression profiles, indicating that microglia 
subtypes in the brain lesions of MS patients are “phenotypically similar” to microglia 
subtypes in the CPZ mouse model (Masuda et al., 2019).  
In addition to changes in the functional morphology of microglia, blood derived monocytes 
differentiate into M1 and M2 macrophages in response to pro-inflammatory (IL-2 TNF-α and 
IFN-γ) and anti-inflammatory (IL-4, IL-10, IL-13) cytokine stimulation (Martinez et al., 
2008, Cassetta et al., 2011). It was suggested in many studies that microglia can produce 
phenotypes similar phenotypes to M1 and M2 (Block et al., 2007, Boche et al., 2013, Chhor 
et al., 2013). In vivo studies have shown that microglia cells fulfil both neuroprotective and 
neurotoxic roles, with both phenotypes acting in concert or adopting an intermediate 
phenotype (Voß et al., 2012, Vogel et al., 2013). Indeed, beneficial and deleterious effects of 
microglia are based on the extent of activation achieved during pathologic events in the CNS 
(Lucin and Wyss-Coray, 2009). Microglial activation induced by TNF-α, IFN-γ or 
lipopolysaccharide produces a phenotype called ‘classically activated’ or M1 (Boche et al., 
2013, Sica and Mantovani, 2012). M1 microglia produce proinflammatory cytokines (IL-1, 
IL-6, TNF-α and IFN-γ) and phagocytose different CNS pathogens such as invading bacteria 
and viral-infected cells (Ransohoff and Cardona, 2010, Fu et al., 2014, Hanisch et al., 2001, 
Magnus et al., 2001). These microglial cytokines may also be toxic to neurons and glia cells 
such as OLG, astrocytes and ependymal cells, thereby contributing to the development of 
certain neurodegenerative disorders such as Alzheimer’s disease (Tarkowski et al., 2003, 
Yamamoto et al., 2007) and MS (Moll et al., 2011, Benveniste, 1997). Conversely, an anti-
inflammatory M2 phenotype ‘alternatively activated’ form of microglia is responsible for 
promotion of angiogenesis and tissue repair in the CNS by releasing anti-inflammatory 
cytokines (IL-4, IL-10 and IL-13) and pro-inflammatory cytokines (Figure 1) such as TNF-




I and fibroblast growth factor that play a crucial role in the remyelination process (Gudi et 
al., 2014).
In CPZ-fed mice, OPCs accumulate in the demyelinated sites of the brain during the time of 
peak demyelination, and this accumulation is tightly associated with microgliosis (Gudi et 
al., 2014). Similarly, these changes were also seen in EAE mice and autopsy samples from 
MS patients (Wolswijk, 2002, Patani et al., 2007). Similar correlations between the presence 
of inflammation, macrophages and accumulation of the OPCs have been observed in the 
lysolecithin-induced demyelination model (Kotter et al., 2001, Kotter et al., 2005). These 
authors demonstrated that the OPC recruitment was delayed following the ablation of 
macrophages when mice exposed to clodronated liposomes in the lysolecithin-induced model 
of demyelination. These findings suggest that the activated microglia in the CNS of CPZ-fed 
mice play an important role in creating a highly controlled environment for clearance of 
myelin debris and production of proinflammatory molecules/growth factors that are essential 
for OPC and OLG regeneration. 
 
1.8.2.2.4 - Inflammation and proinflammatory molecules   
There are many proinflammatory signalling molecules or factors called chemokines and 
cytokines such as nitric oxide, TNF-α, IFN-γ and IL-1β, observed in MS lesions and CPZ-
induced demyelination (Van Oosten et al., 1996, Hiremath et al., 1998, Arnett et al., 2001, 
Sicotte and Voskuhl, 2001). These factors have different roles in the disease pathology in 
humans as well as in the animal models. In this section, the most important factors shared by 
human MS and CPZ model (TNF-α and IFN-γ) will be discussed.  
In the CNS of mice, accumulation of astrocytes and microglia occurs following CPZ-induced 
demyelination leading to an intensive local inflammation (Hiremath et al., 1998) and release 
of various proinflammatory factors including TNF-α and IFN-γ (Mason et al., 2001, Voß et 
al., 2012). These molecules induce irreversible and detrimental effects on the OLG 
(Vartanian et al., 1995, Baerwald and Popko, 1998). However, other studies provided 
evidence showing that the activation of astrocytes and microglia is required for OLG 
regeneration and myelin debris clearance (Biancotti et al., 2008, Merson et al., 2010).  
TNF-α is a potential proinflammatory cytokine that acts via two receptors called TNFR1 and 
TNFR2 (Locksley et al., 2001). These cell membrane receptors trigger opposing effects i.e. 




and leads to apoptosis, whereas binding of TNF-α to the TNFR2 receptor produces 
inflammatory signals (Grell, 1995). In the EAE model, the deleterious roles of TNF-α 
(initiating EAE and exacerbating the disease course) are attributed to TNFR1 activation while 
the regulation and suppression effects of TNF-α are ascribed to TNFR2 (Suvannavejh et al., 
2000, Kassiotis and Kollias, 2001). Consistent with the role of TNFR2, TNF-α-blockade by 
anti-TNF-α Ab in MS patients increased the severity of symptoms in many patients rather 
than ameliorating or eliminating them (Sicotte and Voskuhl, 2001) strongly supporting the 
dual roles (stimulating and suppressive roles) of TNF-α in demyelination and myelin repair 
(Gudi et al., 2014).   
In TNF-α-/- mice, a significant reduction in OLG degeneration and diminished remyelination 
were observed during the first three weeks of CPZ-feeding, suggesting that TNF-α has a 
differential role in de- and re-myelinating processes in the CPZ model (Arnett et al., 2001). 
The same study reported that TNFR2 was upregulated in a gradual manner during 
demyelination and remyelination. Furthermore, TNF-α-/- mice displayed a reduction in OPC 
proliferation and subsequent myelin regeneration, suggesting that TNF-α has beneficial 
effects through TNFR2 pathway. Interestingly, ablation of TNF-α from mice did not affect 
the responses of astrocytes or microglia to CPZ-feeding; however, it induced significant 
alterations in some inflammatory gene expression such as a reduction in MHC-I and II genes 
(Arnett et al., 2003).  
Many contradictory views are reported about the role of IFN-γ in demyelination and 
remyelination in the CPZ model. For example, it was reported that the effects of CPZ-induced 
oligodendrocytosis were diminished in IFN-γ-/- mice, suggesting that IFN-γ normally drives 
demyelination (Gao et al., 2000). Furthermore, the loss of IFN-γ was associated with 
increased insulin-like growth factor 1 expression by astrocytes ─ a factor known to protect 
against OLG death induced by cytokines (Mason et al., 2000b).  In contrast, a reduced 
demyelination and enhanced remyelination was reported in IFN-γ receptor deficient mice, 
indicating that IFN-γ has a detrimental role in the CNS following CPZ-feeding (Mana et al., 
2006).  
It was reported that the number of NG2+ cells (a marker of OPC) in IFN-γ deficient mice was 
increased compared to wild type mice, suggesting that IFN-γ has inhibitory effects on OPCs 
survival and myelin repair (Mana et al., 2006). It was also reported that OPCs were changed 




promoter and tetracycline. Nevertheless, as myelin regeneration was improved in the same 
study in IFN-γ deficient mice, this effect was attributed to the reduction of oxidative stress 
on the endoplasmic reticulum induced via IFN-γ (Lin et al., 2006). Together, these 
contradictory observations in the CPZ model indicate that the effects of TNF-α and IFN-γ, 
whether detrimental or protective, are based on their pattern of expression in the CNS. The 
following schematic (Figure 1) summarizes the pathological changes in the CPZ model: 
 
Figure 1: Schematic of cellular and molecular changes that occur in the CNS during 
CPZ-feeding (demyelination) and after CPZ removal from the diet (remyelination)  
A- At the start of CPZ-feeding neurons, OLG and glial cells appear normal. B- Early OLG 
apoptosis starts during the first week of CPZ-feeding followed by demyelination during the 
second week, and these changes progress to the third week. The microglia and OPCs migrate 
to the demyelinating lesions. Microglia and astrocyte activation occur in response to 
pathological changes in the brain. These cells induce innate inflammatory responses. During 
the process, various proinflammatory molecules (TNF-γ, IFN-ɑ and IL) are released by 
apoptotic OLG that attract microglia and astrocytes and promote their activation and 
proliferation as well as enhance the migration and proliferation of OPCs. In addition, almost 
complete degeneration of OLG occurs at the 4th-5th week of CPZ-feeding. C- Severely 
demyelinated lesions start from the end of the third week of CPZ-feeding to the end of week 
five. During this period, the inflammatory cytokines are up-regulated to maintain the local 
inflammation by increasing the number of activated astrocytes and microglia. At this stage, 
myelin debris are being engulfed by activated microglia to clean up the lesions leading to a 




week 6), activated microglia start to revert to their resting (normal) state and an early 
remyelination process begins. Astrocytes remain activated for more than a week and OPC 
differentiate into immature OLG, then to mature OLG and begin to wrap the denuded axons 
with new myelin.  
 
1.8.2.3 - Key summary of CPZ model 
• CPZ induces OLG degeneration and demyelination and activates the innate immune 
cells (micro / astrogliosis). 
• CPZ lesions are similar to MS lesion patterns III and IV. 
•  Adaptive and innate immune responses (T-cells, B-cells) in the CNS are absent in the 
CPZ model, whereas macrophages, microglia and astrocytes as well as 
proinflammatory molecules such as IL, TNF-ɑ, IFN-γ) contribute to the 
histopathology.  
• CNS inflammation and tissue damage in CPZ-fed mice contribute to the interaction 
between OLG apoptosis and innate immune cells. 
 
1.9 - Relevance and limitations of CPZ pathology to modelling MS  
As outlined throughout this introduction, the pathological characteristics of the CPZ model 
are very similar to those observed in human MS lesions, patterns III and IV  (Lindner et al., 
2009, Kipp et al., 2009, Veto et al., 2010, Liu et al., 2015). The important similarities are: 
extensive OLG death, microglial and astroglial cell activation at sites of demyelination as 
well as ill-defined lesion borders that are not in the perivascular area (Morell et al., 1998).  
Additionally, CNS lesions of CPZ-fed mice shared common features with the early stages of 
MS lesion development. During lesion development, phagocytic microglia and macrophages 
increase in the early demyelinated areas to remove myelin debris (Barnett and Prineas, 2004, 
Henderson et al., 2009). These similarities have prompted researchers to use the CPZ model 
in MS research. However, there are some differences between MS and CPZ: the main one 
being that, in MS patients, the BBB is permeable to the peripheral immune cells (e.g. T-and 
B- cells) and this permeability is attributed to the effects of proinflammatory molecules and 
nitric oxide (Abbott et al., 2010). The observation of a compromised BBB has led to the 
establishment of immunotherapeutic agents that aim to prevent the peripheral immune cells 
from entering the CNS  (Abbott et al., 2010). Conversely, there is no evidence in the literature 




histological analyses of brains from CPZ-fed animals demonstrate that the BBB is intact 
(Kondo et al., 1987, Remington et al., 2007, Tejedor et al., 2017). These observations indicate 
that the intact BBB in CPZ-fed mice contributes at least in part to the absence of T-cell 
recruitment to the demyelinated areas. 
In addition to the intact BBB, many studies have reported CPZ-mediated suppression of T-
cell function in the CPZ model (Torre-Fuentes et al., 2019, J van der Star et al., 2012, Mana 
et al., 2009). It has also been reported that T-cells are suppressed by the direct copper 
chelating effects of CPZ on T-cell subsets (CD4 and CD8) in the blood (Emerson et al., 2001) 
and lymphoid organs (Mana et al., 2009). In addition, Mana and colleagues demonstrated 
that CPZ-feeding induced an increase in the secretion of IL-10 from splenocytes (Mana et 
al., 2009). These authors attributed the suppression of T-cell responses to the presence of IL-
10, which plays a major role in regulatory T-cell-mediated immune tolerance (Li et al., 2008, 
Zhang et al., 2004). Another study revealed that CPZ induced severe thymic organ atrophy 
during the first week of CPZ-feeding due to CD4+ and CD8+ thymocyte apoptosis that 
resulted in reduced T-cell numbers (Solti et al., 2015). Furthermore, recent studies found that 
CPZ-feeding induces splenic atrophy in which both weight and size of spleens were 
decreased (Martin et al., 2018, Sui et al., 2018). Based on these observations, the atrophy of 
thymic and splenic tissue and subsequent reduction in their T-cell levels are the major effects 
of CPZ on the peripheral immune system that limits T-cell recruitment to the demyelinated 
brains.  
Considering all the pathological similarities mentioned above, the CPZ model is suitable for 
exploring the basic mechanisms associated with demyelination and remyelination as well as 
processes associated with OLG apoptosis (Emerson et al., 2001, Liu et al., 2015, J van der 
Star et al., 2012). However, the CPZ-induced demyelination model is still not a ‘perfect’ 
model to replicate the entire complexity of MS due to the absence of T-cell-mediated 
response in the demyelinated lesions. Thus, strategies that modify the CPZ mouse model to 
better enable exploration of the early pathological events in MS will increase the likelihood 
of understanding the fundamental underlying aetiology. The work in this thesis will 
manipulate the limitations of the standard CPZ model, specifically T-cell suppression in 
peripheral immune organs and lack of BBB permeability, in order to provide a new research 





1.10 – Hypothesis and objectives  
The working hypothesis was that appropriate modification of the standard CPZ model (see 
below) would allow for the CPZ-induced demyelination to act as an endogenous trigger for 
T-cell responses that subsequently cause further myelin degeneration and inflammation in 
the CNS, similar to that seen in the human MS. The ultimate aim of the thesis was to establish 
a new variant of the already existing CPZ mouse model that mimics the proposed “inside-
out” initiation of MS.  
Different strategies were applied in five separate studies using CPZ-feeding in male and 
female mice in an attempt to recruit the peripheral T-cells to sites of CNS demyelination as 
follows: 
• In Study I, the BBB was disrupted by intraperitoneal PT injection to test whether 
peripheral immune cells can migrate to the site of demyelination by feeding mice with 
a low (0.1%) or standard (0.2%) dose of CPZ for 5 weeks.  
• In Study II, a low dose of CPZ (0.1%) was used to induce a slow, progressive 
demyelination in the CNS (12 weeks of CPZ feeding) with BBB disruption for the same 
reason as above. 
• In Study III, castration, which is known to reverse age-related involution of the thymus 
and spleen, was performed in an effort to mitigate against the peripheral 
immunosuppressive effects of CPZ.  
• In Study IV, disruption of the BBB in CPZ-fed mice was used following castration-
induced preservation of the size and function of thymus and spleen, and their associated 
T-cells, to test whether T-cells can be recruited to the sites of demyelination.  
• Study V tested whether CPZ-feeding and BBB disruption in female mice can induce 
T-cell infiltration into the CNS.  
• The major experimental analyses (objectives) were performed in each study as follows: 
Assessment of CD4 and CD8 T-cells in CNS and peripheral immune organs (Studies 
I-V). 
• Investigating whole brain tissue proteomic changes (Studies I and II). 
• Quantification of demyelination (Studies I-V) and oligodendrocytosis (Studies I and 
II) in the brain tissue.  





• Histological assessment of the peripheral immune organs (thymus and spleen, Studies 
III-V). 





























2.1 - Chapter structure  
This chapter provides lists of experimental materials including the equipment and chemicals 
that have been used in the thesis. It also describes the details of the methods that are either 
not mentioned or briefly explained in the papers (published or submitted for publication, 
Chapters 3 and 4, respectively). 
 
2.2 - Materials 
2.2.1 - Equipment and chemicals  
All equipment and chemicals used in this thesis are included in the Table 1 and 2, 
respectively. 
Table 1: Equipment 
Equipment Company Country 
6-well plate Sakura USA 
-80 °C freezer (TSE Series) Thermo scientific Australia 
Amicon Ultra 3kDa filter Merck-Millipore USA 
C57BL/6 mice Animal Resources Centre Australia 
Carl Zeiss Brightfield microscope (Axioimager Z1) Zeiss Germany 
Carl Zeiss fluorescent microscope (Axioimager Z1) Zeiss Germany 
CorelDRAW software (version 2018) CorelDRAW Canada 
Cover slip  Knittel Glass Germany 
Cryostat (CM1950) Leica Germany 
Cut-off filter tubes Millipore USA 
Delta 2D software (version 4.0.8) DECODON  Germany 
Electrical balance Adam  Australia 
Falcon tube and Microtips Corning Incorporated  USA 
Gel casting apparatus Bio-Rad  USA 
Gel staining and storage boxes Becto Australia 
Glass cassettes for gels casting Bio-Rad USA 
GraphPad Prism software (Version 7.03) GraphPad prism  USA 
Heating block (TDB-1)  Thermoline Scientific Australia 
ImageJ software NIH  USA 
ImageQuantTM FUJI LAS-4000 GE Healthcare USA 
IPG strips Bio-Rad USA 
Kondziela’s inverted screen test Customized  
Mice cage (GM500)  Tecniplast Italy 
Michel clips  Fine Science Tools Canada 
Microtome (Leica RM2235) Leica Microsystem Germany 
Mikro-Dismembrator S Sartorius Germany 
Mini-PROTEAN Tetra Cell Bio-Rad USA 
MultiGauge software (version 3.0) FUJIFILM Corporation Japan 
NanoAcquity ultra performance liquid 
chromatography (ACQUITY UPLC) 
Waters USA 
Orbital shaker (The Labline 2314) Thermo Fisher Scientific USA 
Peri-StarTM Pro pump  Marshall Scientific UK 
Polyvinylidene difluoride membrane (PVDF) Bio-Rad USA 
PowerPacTM Universal Power Supply Bio-Rad  USA 
Protean IEF cell (526BR) Bio-Rad USA 
Protean IEF focusing tray  Bio-Rad USA 




Rotarod (47650 Rota-Rod NG)  UGO Basile Italy 
Sample tube for Mass spectrometry  Waters USA 
Slide Knittel Glass Germany 
Sonication bath (Soniclean Ultrasonic Bath)  Soniclean Australia 
Speed Vac centrifuge (DNA130115) John Morris Scientific Australia 
Tissue embedding cassettes  Sigma-Aldrich USA 
TyphoonTM FLA-9000 GE Healthcare USA 
Ultracentrifuge (Optima L-100XP) Beckman Coulter USA 
Vortex (VWR 58816-121 Analog Vortex Lab) VWR USA 
Whatman filter paper Millipore USA 
Mass spectrometer (Xevo G2-XS QToF)   Waters USA 
 
 
Table 2: Chemicals 
Chemicals name   Company Country 
10% formalin  Sigma-Aldrich USA 
2DE standard protein Bio-Rad  USA 
2-mercaptoethanol Sigma-Aldrich USA 
4′,6-diamidino-2-phenylindole (DAPI)  Vector Laboratories USA 
Acetic acid Merk Germany 
Acetic anhydride  Merk Germany 
Acetonitrile Merk  Germany 
Acryl/BisTM (Acrylamide solution 40%)  Ameresco USA 
Acrylamide Ameresco USA 
Agarose Bio-Rad USA 
Alexa Fluor 488 conjugated mouse anti-Gfap Merck-Millipore  USA 
Ammonical silver nitrate   Chem-supply Australia 
Ammonium bicarbonate Sigma-Aldrich USA 
Ammonium per sulphate (APS) Ameresco USA 
Ammonium sulphate  Ameresco USA 
Aprotinin Sigma-Aldrich USA 
Avidin-biotin–peroxidase complex (ABC)  Vector Laboratories USA 
Benzamidine Sigma-Aldrich USA 
Bio-Lyte 3/10 Bio-Rad USA 
Bio-Lyte 3/5 Bio-Rad USA 
Bio-Lyte 6/8 Bio-Rad USA 
Bio-Lyte 7/9 Bio-Rad USA 
Bio-Lyte 8/10 Bio-Rad USA 
Bovine serum albumin (BSA) Ameresco USA 
Bromophenol blue Bio-Rad USA 
CHAPS Ameresco USA 
Chromium potassium sulphate dodecahydrate  Sigma-Aldrich USA 
Coomassie brilliant blue (CBB) G 250 Ameresco  USA 
Diaminobenzidine (DAB)  Vector Laboratories USA 
Dithiothreitol  Astral Scientific Australia 
Ethanol  Merck-Millipore USA 
Ethylene glycol-bis (β-aminoethyl ether)-
N,N,N′,N′-tetra acetic acid (EGTA) 
Ameresco USA 
Ethylene diamine tetra acetic acid (EDTA) Ameresco USA 
EZQ™ Protein Quantitation Kit  Life Technologies  USA 
Formic acid Waters  USA 
Gelatine powder  Sigma-Aldrich USA 
Glycerol Ameresco USA 
Glycine Ameresco USA 
Goat anti-rabbit IgG H&L (HRP) antibody Abcam UK 
Goat serum  Sigma-Aldrich USA 




Hydrochloric acid Sigma-Aldrich USA 
Hydroxyethyl-1-piperazineethanesulfonic acid 
buffer (HEPES free acid) 
Ameresco  USA 
IPG strips (pH 3-10 non-linear) Bio-Rad USA 
Isoflurane Cenvet  Australia 
Kaleidoscope prestained protein standards  Bio-Rad USA 
LuminataTM Crescendo Western HRP Substrate Merck-Millipore USA 
meloxicam  Randdolab Australia 
Methanol Merck-Millipore USA 
Mineral oil Ameresco USA 
Mounting medium (DPX)  Merk  Germany 
Mouse anti-CD8 antibody Santa-Cruz Biotechnology  USA 
Mouse anti-mouse IgGκ BP-HRP antibody Santa-Cruz Biotechnology USA 
Mouse CD4 recombinant protein (His Tag) Sino Biological  USA 
Mouse CD8 recombinant protein (His Tag) Sino Biological  USA 
OCT and Cryomold Sakura USA 
Ortho-Phosphoric acid 85% Sigma-Aldrich USA 
Paraffin  SLEE medical GmbH  UK 
Paraformaldehyde (PFA) Sigma-Aldrich USA 
Pepstatin Sigma-Aldrich USA 
Peroxidase blocking solution  Dako  USA 
Pertussis toxin Sigma-Aldrich USA 
Phosphate buffer saline (PBS) tablet Ameresco USA 
Polyvinylpyrrolidone  Sigma-Aldrich USA 
Potassium ferricyanide BDH chemicals  UK 
Precision plus protein standards (unstained) Bio-Rad USA 
Protease inhibitors cocktails Sigma-Aldrich USA 
Pyridine  VWR USA 
Rabbit anti-CD4 antibody Abcam UK 
Rabbit anti-Iba 1 antibody Wako  Japan 
Rabbit anti-NOGO A antibody Merck-Millipore  USA 
Rodent powder chow Gordon's Specialty Stockfeeds Australia 
Scott’s Blueing solution Sigma-Aldrich USA 
Silver nitrate Chem-supply  Australia 
Skimmed milk  Coles Australia 
Sodium azide Ameresco  USA 
Sodium bicarbonate Sigma-Aldrich USA 
Sodium chloride (NaCl) Bio-Chemicals Australia 
Sodium dodecyl sulphate SDS Bio-Rad USA 
Sucrose Coles Australia 
Sulfuric acid  Merck-Millipore USA 
TEMED Ameresco USA 
Thiourea Amresco USA 
Tri-butyl phosphine (TBP) Bio-Rad  USA 
Tris base Ameresco USA 
Tris glycine-SDS buffer Ameresco USA 
Tris-HCl salt Ameresco USA 
Triton X-100 Ameresco USA 
Trypsin  Promega Corporation USA 
Tween 20 Ameresco USA 
Urea Ameresco USA 
Whatman filter paper Camlab UK 






2.3 - Methods 
2.3.1- Animals 
Adult (seven-week-old, n=108) males and weaned (three-week-old, n=143) male and female 
(n=44) C57BL/6 mice were purchased from Animal Resources Centre, Australia 
(www.arc.wa.gov.au). Animal facilities and care are explained further (see Chapter 3 and 4). 
Research and animal care procedures were approved by the Western Sydney University 
animal ethics committee (ethics code for Studies I and II: A10394, for Studies III and V: 
A11938) in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes as laid out by the National Health and Medical Research Council of 
Australia. 
 
2.3.2 - CPZ administration 
CPZ (Bis(cyclohexanone)oxaldihydrazone, Sigma-Aldrich, USA) was used in all studies in 
this thesis as described below (Table 3). CPZ (0.1% and/or 0.2%, w/w) was mixed with 
powdered chow (Gudi et al., 2014, Mason et al., 2000a). Chow was prepared daily with or 
without CPZ and provided in excess in a single shared feeder per cage.  
 
2.3.3 - Pertussis toxin injection 
Intraperitoneal injection of pertussis toxin (PT, 400 nanograms (ng)/mouse, Sigma-Aldrich) 
was used to disrupt the blood brain barrier (BBB) in CPZ model as described earlier 
(Caprariello et al., 2018). The preparation of PT dose was performed in two steps: First, 100 
micrograms (µg)/ millilitre (ml) stock solution was prepared by dissolving 50 µg of the toxin 
powder in 500 microlitre (µl) of distilled water and, second, the stock was diluted 1:50 with 
0.01 M phosphate buffered saline (PBS, Sigma-Aldrich) to obtain 400 ng/mouse (i.e. 200 µl 
containing 400 ng). PT was injected intraperitoneally, in the adult mice (Studies I and II) 
three times during 14, 16, and 23 day of CPZ-feeding, whereas in prepubescent mice (Studies 
VI and V), PT was injected on days 5, 7, and 9 of CPZ-feeding. The disruption of the BBB 
at this time increases the possibility of adaptive immune cells traversing the BBB leading to 
activation and recruitment of T-cells due to myelin antigen presentation by microglia 
following oligodendrocytosis and myelin degeneration induced by CPZ (Caprariello et al., 













































































































































    Main analysis methods  
I 60 10 6  male  0.1 and 0.2 14,16 and 23 — 5   Histology, western blot and 
proteomics 
II 48 12 6  male 0.1 14,16 and 23 — 12   Histology, western blot and 
proteomics 
III 66 11 3  male 0.1 and 0.2 — 4 2 Histology and western blot  
IV 77 11 3  male 0.1 5,7 and 9 4 2 Histology and western blot 
V 44 11 3  female 0.1 5,7 and 9 — 2 Histology and western blot 
 
 
2.3.4 - Experimental Groups  
Age, gender- and weight-matched mice were grouped randomly, according to the 
experimental design of each study as described below (Table 4). The number of mice that 
were assigned to each analysis is described in detail in Chapter 3 and 4. 
  
Table 4: Experimental groups in each study. 
             Studies 
Groups 
I II  III VI V 
Ctrl ✓  ✓  ✓  ✓  ✓  
PT ✓  ✓   ✓  ✓  
0.1% CPZ ✓  ✓  ✓  ✓  ✓  
0.1% CPZ+PT ✓  ✓    ✓  
0.2% CPZ ✓    ✓    
0.2% CPZ+PT ✓       
Cx   ✓  ✓   
Cx+PT    ✓   
Cx+0.1% CPZ   ✓  ✓   
Cx+0.2% CPZ   ✓    
Cx+0.1% CPZ+PT    ✓   
Key: Tick mark indicates the groups that are involved in each study  
2.3.5 - General monitoring  
Mice were inspected daily to assess their activities such as gait, movement, posture, and skin. 
Mice weighing were performed to estimate the body growth response to different treatments 




of the mice was measured weekly, whereas the weight of the prepubescent mice (Studies III, 
VI, V) was measured every three days (as recommended by animal ethics committee due to 
the surgery) using an electrical scale (Adam, Australia).  
 
2.3.6 - Protein estimation  
Protein concentration of each sample was quantified using EZQ™ Protein Quantitation Kit 
(Life Technologies, USA). Bovine serum albumin (BSA, Ameresco) was used as standard 
and prepared by dissolving 120 milligrams (mg) BSA in 10 ml of 2% sodium dodecyl 
sulphate (SDS) solution to obtain the final concentration (12 mg/ml). Serial dilutions from 
the 12 mg/ml BSA were prepared (0.5, 0.4, 0.3, 0.1, 0.05 and 0.025 µg/ml). 2 µl of each 
dilution was spotted (triplicate of each dilution) on Whatman filter paper (Millipore, USA) 
fixed onto EZQ 96 well microplate cassette. Experimental samples were also diluted (1:5, 
1:10, 1:25, 1:50, 1:75, 1:100 and 1:200) in the same buffer (2% SDS). Then, triplicate of 2 
µl of each of these dilutions was spotted on the same filter paper in parallel with BSA spots. 
Filter paper was dried and placed to a container containing 100% methanol (Merk, USA) for 
5 min on an orbital shaker (Thermo Fisher Scientific, USA) at 50 rpm to fix proteins on the 
filter paper and to remove detergent. Methanol was poured out and the filter paper left to dry. 
50 ml of fluorescent dye regent (EZQ) was added to cover the filter paper for 30 min in dark 
place and constant shaking. EZQ reagent was removed and the filter paper rinsed in a fixative 
solution (10% methanol and 7% acetic acid) 3 times for 20 second (s). The filter paper was 
scanned immediately with an ImageQuantTM FUJI LAS-4000 (GE Healthcare, USA). Protein 
spots of both standard and experimental proteins were analysed by Multi Gauge software 
(Fujifilm, Japan). Average of each triplicate values (arbitrary unit, AU) of BSA protein spots 
was calculated to generate a standard calibration curve in Excel software. To ensure the 
accuracy of the technique, when the R value of the standard curve was less than 0.99, the 
whole experiment was repeated. Intercept and slope of the curve were calculated. The 
concentration of the experimental sample proteins was calculated by measuring AU value of 
each dilution (triplicate), then the average number of triplicate from dilution that is located 
around the middle of the standard curve was selected then subtracted from intercept and 
divided by slope value. The resulted number was multiplied by the dilution factor of the 
experimental sample and considered as a final concentration of the protein (Butt and 





2.3.7 - Optimization of the antibodies (Ab) used in the western blot (WB) 
In order to obtain optimum signal bands and to reduce background noise of blots in WB 
analysis, anti-CD4 (Abcam, UK) and anti-CD8 (Santa-Cruz Biotechnology, USA) Abs were 
optimized by using different dilutions of both primary and secondary Abs and different 
incubation time. The serial dilutions of anti-CD4 primary Ab diluted with Tris buffered 
saline-Tween-20 (TBST) were started from 1:100 (1 µl of Ab diluted in 100 µl of TBST) to 
1:1000. Likewise, secondary Ab dilution started from 1:1000, 1:2000 and 1:3000. The 
optimal signal was obtained by using dilutions 1:500 of primary Ab with dilutions 1:2000 
secondary Ab. In contrast, high background was observed when other primary and secondary 
Abs dilutions were used. Time of incubation of both primary and secondary Abs plays an 
important role in the optimization process. For example, when the primary Abs incubated for 
1 h at room temperature (RT), the optimal signal was obtained, while shorter or longer time 
of incubation (at RT or at 4 °C for 8-10 h) created high background noise. Similarly, blocking 
with skimmed milk for 1 h at RT resulted in a desired signal. Collectively, the best CD4 
signal was obtained from 1 h blocking and 1 h incubation with anti-CD4 Ab 1:500 dilution, 
then 1 hr incubation of secondary 1:2000 dilution (Table 5). Likewise, the optimization of 
CD8 signal was performed in the same manner, 1 h blocking followed by 1 h incubations of 
1:75 primary and 1:500 of secondary Abs resulted in a sharp signal of CD8 (Table 5).  
Table 5: Antibodies used for WB analysis.  
Primary Abs  Secondary Abs 
Target Antigen Antibody Species Dilution Antibody Dilution 
CD4 Anti-CD4 (Abcam, 
UK) 
Rabbit monoclonal 1:500 Goat Alexa Fluor 488 conjugated  
anti-rabbit IgG (Invitrogen USA) 
  1:2000 
CD8 Anti-CD8 (Santa-Cruz 
Biotechnology, USA) 
Mouse monoclonal 1:75 Mouse anti-mouse IgGκ BP-HRP 




2.3.8 - Protein fixation, staining and transfer efficiency  
To assess the efficiency with which proteins were transferred from SDS-PAGE (10%) to 
PVDF membrane, 20 µg of spleen samples (taken from naïve mice) were resolved using six 
gels. Three gels (replicate) were fixed with 10% methanol and 7% acetic acid for 1 h at RT 
under continuous shaking (50 rpm) and the remaining gels were transferred onto PVDF 
membrane (as described above). Following transfer, these gels were fixed like the first three 
gels. All gels were then washed with distilled water (3x20 minutes, min) followed by 20 h of 




Blue (CBB, G-250, Ameresco) under constant shaking (Gauci et al., 2013, Wright et al., 
2014a). Gels were then washed with 0.5 M NaCl solution for 3x15 min and imaged 
immediately using a TyphoonTM FLA-9000 (GE Healthcare, USA). The transfer efficiency 
of protein bands was quantified by comparing the staining intensity of triplicate, non-
transferred and transferred gels using Multi Gauge software in order to confirm (i) the 
consistency of protein loads across gels; and (ii) the efficacy with which proteins were 
transferred from gels onto the PVDF membrane. This method was used in all studies (Studies 
I-V; Chapter 3, Supplementary Figure S4b; Chapter 4, Supplementary Figure Sa,b)   
 
2.3.9 - Brain tissue spiking experiment  
The lowest concentrations that were used for CD4 or CD8 detection (both splenic and 
standards) and 60 µg of brain homogenate were resolved using 10% SDS PAGE (each in 
parallel separate lanes) along with 60 µg of brain homogenate spiked (mixed) with the lowest 
concentrations that were used for CD4 or CD8 detection (both splenic and standards,). When 
the electrophoresis was completed, other WB steps such as protein transfer, primary (CD4/8) 
and secondary Abs incubation and imaging were performed (see western blot procedure, 
Chapter 3 and 4). This method was used in Studies I and II (Chapter 3, Figure 3a,b)   
 
2.3.10 - Histology and immunohistochemistry 
2.3.10.1 - Transcardial perfusion 
In order to prepare mice tissue for histology, each mouse was deeply anaesthetized using 
isoflurane. Heart was exposed through longitudinal cutting of the skin and ribs at a midline 
thoracic cage. Saline (0.9%) was injected into the left ventricle via perfusion needle. This 
needle was connected to a Peri-StarTM Pro pump (Marshall Scientific, UK) to control the 
solution flow rate during perfusion. When saline injection started, a small cut by surgical 
scissors was made at the right atrium to allow pumping the blood out of the circulation. 10 
min later, saline was replaced with cold 4% paraformaldehyde (PFA, in 0.1M phosphate 







2.3.10.2- Slide coating 
Gelatine coated glass slides were used to prepare tissue for silver and H&E staining. 5 g of 
gelatine powder (Sigma-Aldrich) was mixed with 1 litre (L) of distilled water and heated to 
45 °C until dissolved. Then 0.5 g of positively charged chromium potassium sulphate 
dodecahydrate (Sigma-Aldrich) was added to the solution to attract the negatively charged 
tissue sections. Solution was filtered by Whatman filter paper. Microscopic slides were rinsed 
into the solution 5 times for 5 s in each rinse, then kept at RT for 48 h to dry. 
 
2.3.10.3 – Optimization of the antibodies used in immunohistochemistry 
All Abs were optimized in a test tissue sections before using experimental samples to obtain 
optimal Ab concentration in certain incubation time. Abs specificity was tested in tissue using 
primary control (without secondary), secondary control (without primary), combination of 
primary and secondary, and blank (no primary and secondary). Abs dilution started from the 
low to high concentration and from short to long time point incubation. For instance, in 
ionized calcium-binding adapter molecule 1 (rabbit anti-Iba 1, 1:1000, Wako, Japan) Ab 
dilution started from 1:250, 1:500, 1:750, 1:1000 and 1:2000 and incubated for 2 to 20 h at 
RT. Secondary Ab (Goat Alexa Fluor 488 conjugated anti-rabbit IgG, Invitrogen USA) was 
also diluted 1:100, 1:250 and 1:500 and incubated from 1 to 5 h. The best signal was obtained 
from 1:1000 dilution of primary Ab for 8-12 h with 1:250 secondary Ab for 2 h (Table 6). 
Similarly, tissue sections were incubated in 5-10% goat serum (Sigma-Aldrich) from 1 to 5 
h at RT for blocking of not specific binding, 2 h of incubation resulted in the best blocking 
results. This strategy was applied to all other Abs prior the use of the experimental tissue 
sections. Alexa Fluor conjugated primary Abs (glial fibrillary acidic protein, mouse anti-
Gfap, Merck-Millipore, USA) does not need to be incubated in secondary Ab, therefore, 
sections were only blocked for 2 h with 10% goat serum and incubated for 12 h with the 
primary Ab (Table 6). DAPI counter staining (Vectasheild plus 4′,6-diamidino-2-
phenylindole, Vector Laboratories, USA, 1.5 µg/ml) was used for visualising the nuclei of 
cells and for further confirmation of the specificity of all Abs. Similarly, all other Abs used 








Table 6: Antibodies used for immunohistochemistry analysis. 
Primary Abs  Secondary Abs 
Target antigen Antibody Species Dilution Antibody Dilution 
Astrocyte Anti-Gfap 
(Merck-Millipore, USA) 
Alexa Fluor 488 
Conjugated mouse 
1:1000 —   — 
Mature OLG Nogo A 
(Merck-Millipore, USA) 
Rabbit 1:500 Goat Alexa Fluor 488 conjugated  
anti-rabbit IgG (Invitrogen USA) 
1:500 
Microglia Anti-Iba 1 
(Wako, Japan) 





Rabbit monoclonal 1:200 Goat Alexa Fluor 488 conjugated  
anti-rabbit IgG 
1:500 
CD8 Anti-CD8 (Santa-Cruz 
Biotechnology, USA) 
Mouse monoclonal 1:100 Mouse anti-mouse IgGκ BP-HRP 
(Santa-Cruz Biotechnology, USA) 
 1:500 





2.3.10.4 - Stereological cells counting  
Stereology was performed by stereoinvestigator optical fractionator workflow software 
(www.mbfbioscience.com/stereology) to count the number of positively stained cells (Nogo 
A, Gfap and Iba 1). The software is installed in a computer that is connected to an Olympus 
Carl Zeiss fluorescence microscope (Olympus Carl Zeiss, Germany) in order to visualise the 
positively stained cells via the software (i.e. live view). The right excitation channel for each 
fluorescent stain was selected (e.g., for Alexa Fluor 488 a green colour was selected). 
Software setting was performed according to manual instructions. The region of interest 
(ROI, e.g. CC) in each section was contoured using low magnification lens (e.g., 10x or 20x). 
Magnification then changed manually to oil immersion lens 63x. Counting frame size was 
set between 50 µ-100 µ according to the number of cells in the frame depending on each Abs. 
Basically, it is recommended by software guideline that the optimal number of cells per frame 
is between 2 to 5 cells for optimum results with error less than 10%. At the end of cell 
counting, the software was automatically transferred the results into an Excel file containing 
the total cells number, co-efficient error, measured tissue thickness and measured tissue 
volume. Total cell density in the ROI was obtained by dividing total cell number by total 
measured volume and the data was expressed as cells/mm3 (Gyengesi et al., 2018, 
Gumusoglu et al., 2017). The positively stained cells with Nogo A, Gfap and Iba 1 (co-stained 
with DAPI) were counted by this method (Chapter 3, Supplementary Figure S3b,c,d; 
Appendix, Figure 1a,b). However, counting of cells in the CNS sections stained with anti-
CD8 Ab did not match the criteria and frame size rule. The reason was there were few cells 




the sections. Therefore, there were no specific ROI and CD8+ T-cells were counted manually 
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3.1 - Abstract  
Cuprizone (CPZ) preferentially affects oligodendrocytes (OLG), resulting in demyelination. 
To investigate whether central oligodendrocytosis and gliosis triggered an adaptive immune 
response, the impact of combining a standard (0.2%) or low (0.1%) dose of ingested CPZ 
with disruption of the blood brain barrier (BBB), using pertussis toxin (PT), was assessed in 
mice. 0.2% CPZ(±PT) for 5 weeks (Study I) produced oligodendrocytosis, demyelination 
and gliosis plus marked splenic atrophy (37%) and reduced levels of CD4 (44%) and CD8 
(61%). Conversely, 0.1% CPZ(±PT) produced a similar oligodendrocytosis, demyelination 
and gliosis but a smaller reduction in splenic CD4 (11%) and CD8 (14%) levels and no 
splenic atrophy. Long-term feeding of 0.1% CPZ(±PT) for 12 weeks (Study II) produced 
similar reductions in CD4 (27%) and CD8 (43%), as well as splenic atrophy (33%), as seen 
with 0.2% CPZ(±PT) for 5 weeks. Collectively, these results suggest that 0.1% CPZ for 5 
weeks may be a more promising model to study the ‘inside-out’ theory of Multiple Sclerosis 
(MS). However, neither CD4 nor CD8 were detected in the brain in CPZ±PT groups, 
indicating that CPZ-mediated suppression of peripheral immune organs is a major 
impediment to studying the ‘inside-out’ role of the adaptive immune system in this model 
over long time periods. Notably, CPZ(±PT) feeding induced changes in the brain proteome 




cellular structure/organization, indicating that demyelinating conditions, such as MS, can be 
initiated in the absence of adaptive immune system involvement. 
Keywords: inside-out; outside-in; oligodendrocytosis; demyelination; gliosis; histology; 
top-down proteomics; bioinformatics; mitochondria 
 
3.2 - Introduction 
Currently, there are two competing theories regarding the pathophysiology underlying the 
initiation of Multiple Sclerosis (MS): ‘outside-in’ and ‘inside-out’ (Partridge et al., 2015, Sen 
et al., 2019b, Stys, 2013, Stys et al., 2012). The former proposes that a dysregulated 
peripheral immune system leads to an autoimmune response against myelin components of 
the central nervous system (CNS). The central concept of this theory has been built mainly 
on the basis of studies using the experimental autoimmune encephalomyelitis (EAE) animal 
model (Gold et al., 2006, Glatigny and Bettelli, 2018, Constantinescu et al., 2011) and 
correlation of the end stage of treatment (e.g., paralysis and demyelination) with clinical tests 
and post-mortem samples from MS patients. In EAE, animals are injected with exogenous 
antigens such as myelin basic protein (MBP), proteolipid protein (PLP) or myelin 
oligodendrocyte glycoprotein (MOG) and complete Freund’s adjuvant (CFA), activating 
peripheral immune cells, including T- and B-cells. When this immune response is combined 
with breach of the blood brain barrier (BBB) by injection of pertussis toxin (PT), autoreactive 
adaptive immune cells from the periphery migrate into the CNS leading to degeneration of 
OLG, demyelination and gliosis (Gold et al., 2006, Bittner et al., 2014, Patel and Balabanov, 
2012, Lu et al., 2012, Evonuk et al., 2015, Constantinescu et al., 2011). It is argued that a 
similar process results in autoimmune cell migration into the CNS of MS patients (t Hart et 
al., 2011, Glatigny and Bettelli, 2018, Lovett-Racke, 2017, Lassmann and Bradl, 2017, Trapp 
and Nave, 2008). The EAE animal model is thus the favourite choice of many researchers 
investigating the autoimmune aspects of MS (Krishnamoorthy and Wekerle, 2009). 
There are, however, key differences between the EAE model and clinical MS. First, EAE 
relies on the use of exogenous antigens (MBP/PLP/MOG), whereas the autoimmune 
response in humans occurs spontaneously and is only detected following repeated episodes 
of clinical symptoms (Sriram and Steiner, 2005, Behan and Chaudhuri, 2014). Second, the 
immune reaction in EAE is driven mainly by CD4+ T-cells (Flugel et al., 2001, Lassmann 




Hauser et al., 1986, Babbe et al., 2000). Moreover, MS is a disease of the human cerebral and 
cerebellar cortices, whereas the effects of EAE are generally localized to the spinal cord 
(Ransohoff, 2012, Gilmore et al., 2009, Gold et al., 2006, Day, 2005, Tanuma et al., 2000, 
Lu et al., 2012), with largely non-overlapping changes in the brain proteomes being reported 
in EAE and MS patients (Broadwater et al., 2011, Rosenling et al., 2011). Although therapies 
developed in EAE improve outcomes in animals, these therapies generally have more limited 
success in clinical MS in terms of halting disease initiation and progression (Sriram and 
Steiner, 2005, Vargas and Tyor, 2017). In contrast to this ‘outside-in’ theory, the ‘inside-out’ 
hypothesis suggests that MS is initiated by an underlying degeneration of OLG and 
consequent demyelination that leads to the production of endogenous myelin antigens (e.g., 
peptidyl arginine deiminase, MBP, MOG and PLP) that then trigger an immune response in 
the CNS (Stys, 2013, Stys et al., 2012, Caprariello et al., 2018). Histological evidence 
indicates that the loss of OLG and glial activation can occur in the absence of, or with only a 
limited number of, peripheral immune cells   (Henderson et al., 2009, Barnett and Prineas, 
2004, Lucchinetti et al., 2000) and myelin injury (Rodriguez and Scheithauer, 1994). The 
possibility of OLG triggering a secondary adaptive immune response has been reported 
following long-term diphtheria toxin exposure (Traka et al., 2016) or following a peripheral 
immune challenge after short-term CPZ-feeding (termed ‘cuprizone autoimmune 
encephalitis’ (Caprariello et al., 2018)). Cuprizone (CPZ) is synthesised by combining 
cyclohexanone and oxaldihydrazone (Carlton, 1967). While the mechanism of its toxic 
actions remain ill-defined, copper chelation (Matsushima and Morell, 2001b) and dis-
homeostasis of iron, zinc, sodium and manganese have been reported (Komoly et al., 1987, 
Zatta et al., 2005, Moldovan et al., 2015, Varga et al., 2018, Venturini, 1973). Such ion 
imbalance leads to endoplasmic reticulum stress, reduced mitochondrial ATP synthesis, and 
increased production of reactive oxygen and nitrogen species (reviewed in Sen et al., 2019b). 
OLG appear to be preferentially susceptible to CPZ toxicity and likely degenerate due to their 
high energy demands and lower levels of anti-oxidant enzymes (McTigue and Tripathi, 2008, 
McLaurin and Yong, 1995, Liblau et al., 2001). 
Intriguingly, longer-term CPZ-feeding did not evoke a peripheral immune response in the 
CNS (Caprariello et al., 2018, Tejedor et al., 2017, Traka et al., 2016). Whether the failure 
of numerous CPZ studies (Caprariello et al., 2018, Tejedor et al., 2017, Traka et al., 2016) to 
observe an immune response associated with long duration feeding (>5 weeks) is due to a 




Caprariello et al., 2018), but CPZ has been shown to have deleterious effects on immune 
organs like the spleen (Partridge et al., 2016) and thymus (Solti et al., 2015). 
To address this issue, this study (Study I) compared whether a low (0.1%) or standard (0.2%) 
dose of CPZ when combined with disruption of the BBB by PT recruited peripheral immune 
cells into the CNS in mice. At first, a low and a standard dose of CPZ were used for 5 weeks 
(Study I) and the amount of oligodendrocytosis (i.e., degeneration or loss of OLG), gliosis 
and demyelination was quantified; the low dose produced significant demyelination of the 
corpus callosum (CC), with limited suppression of splenic CD4/8 and no change in overall 
splenic mass. Having observed that 0.1% CPZ produced comparable oligodendrocytosis, but 
had less severe effects on the peripheral immune system, in the Study IV, 0.1% CPZ-feeding 
was extended to 12 weeks (±PT) to test whether a slower, progressive demyelination (i.e., 
more reminiscent of MS) and less severe effects on the peripheral immune organs could 
trigger an adaptive immune response in the CNS. Histological analyses were used to assess 
oligodendrocytosis, demyelination and gliosis in the CNS, as well as the levels of adaptive 
immune cells (CD4 and CD8) in brain and spleen. 
In a subset of the mice in both experiments, the whole brain proteome was assessed using a 
well-established ‘top-down’ approach (i.e., two-dimensional gel electrophoresis coupled 
with liquid chromatography and tandem mass spectrometry) to identify changes in protein 
abundance correlated with key changes in molecular pathways (Partridge et al., 2016, Butt 
and Coorssen, 2005, Wright et al., 2014a, D'Silva et al., 2018). To best understand the 
underlying molecular/cellular processes, a ‘top-down’ proteomic analysis was critical to 
identifying key protein species or proteoforms, the biologically active entities (Oliveira et al., 
2014, Coorssen and Yergey, 2015, Kurgan et al., 2019). Thus, while much is assumed in the 
literature regarding the actions of CPZ at the molecular level by extrapolation of effects in 
vitro or at the cellular level, only such quantitative analyses can help to directly understand 
the underlying effects of CPZ(±PT). 
 
3.3 - Materials and methods 
3.3.1 - Animals, feeding, injection and monitoring 
Seven-week-old male C57BL/6 mice (n = 108) were purchased from the Animal Resources 




ventilated GM500 cages (Tecniplast, Buguggiate, VA, Italy) in the local animal care facility 
(School of Medicine, Western Sydney University). Animals were allowed to acclimatise for 
one week to the new environment prior to initiation of CPZ-feeding. Mice were maintained 
in a controlled environment (12-hour (h) light/dark cycle: 8am–8pm light, 8pm–8am dark, 
50–60% humidity and at 21–23 °C, room temperature (RT)) throughout the entire period. 
Standard rodent powder chow (Gordon’s specialty stockfeeds, Yanderra, NSW, Australia) 
and water were available ad libitum. Oral feeding of CPZ 
([Bis(cyclohexanone)oxaldihydrazone, Sigma-Aldrich, St. Louis, MO, USA], 0.1–0.2% w/w 
freshly mixed with rodent chow) was used to induce oligodendrocytosis as previously 
described (Kipp et al., 2009, Sen et al., 2019b, Gudi et al., 2014, Hiremath et al., 1998). To 
breach the BBB, the same methods as previously established for EAE were used i.e., 2-3 
intraperitoneal (IP) injections of PT (Mohajeri et al., 2015, Bittner et al., 2014, Hofstetter et 
al., 2002, Gao et al., 2014, Bennett et al., 2010)—but adapted so that the breach of the BBB 
was timed (i.e., 400 ng on days 14, 16, and 23) to coincide with the reported onset of CPZ-
induced oligodendrocytosis, demyelination and gliosis (Gudi et al., 2014, Hiremath et al., 
1998, Kipp et al., 2009, Sen et al., 2019b). The efficacy of BBB breach has been shown using 
immunoglobulin G staining in the CPZ-fed mice (Almuslehi et al., 2018). CPZ groups (0.1% 
and 0.2%) were fed freshly prepared (daily) CPZ in rodent chow for either 5 (Study I, n = 
10/group) or 12 (Study II, n = 12/group) weeks. Age-matched, naïve control (Ctrl, Study I ‘n 
= 10’ and Study II ‘n = 12’) and PT only (Study I ‘n = 10’ and Study II ‘n = 12’) groups were 
used. Mice were weighed at the beginning of the studies, weekly throughout, and prior to 
culling, and the data from both groups (Study I and II) were combined (Figure 1). Research 
and animal care procedures were approved by the Western Sydney University Animal Ethics 
Committee (ethics code: A10394) in accordance with the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes as laid out by the National Health and 
Medical Research Council of Australia. 
 
3.3.2 - Histology and immunohistochemistry 
3.3.2.1 - Tissue preparation 
At the end of each feeding period (5 weeks in Study I or 12 weeks in Study II), all mice were 
terminally overdosed with sodium pentobarbitone (250 mg/kg, LethobarbTM, Tory 
laboratories, Glendenning, NSW, Australia) and perfused with 30 ml of 0.9% saline followed 




and spleen samples were collected and post fixed with 4% PFA at 4 °C for one week and 
stored in 0.01 M phosphate buffered saline (PBS, Sigma-Aldrich) solution containing 0.02% 
sodium azide (Amresco, Solon, OH, USA) at 4 °C for ≤1 month or until sectioned. Spleen 
weights were measured (n = 3 and 5 from Studies I and II, respectively) and expressed as a 
function of body weight (Supplementary Figure S5c). Prior to sectioning, whole brain and 
spleen were immersed in 30% sucrose for 48 h at RT for cryo-protection followed by 
embedding in 4% gelatine (Chem-Supply, Gillman, SA, Australia) at −20 °C. Brains (Study 
I: 50 µm and Study II: 40 µm) and spleen (20 µm) were sectioned coronally on a Leica 
cryostat (Leica, Wetzlar, HE, Germany). Sections were transferred to either 6-well plate 
(Sakura, Torrance, CA, USA) containing cold (5–6 °C) 0.01 M PBS (free floating) or 
mounted onto 0.5% gelatine-coated slides (Knittel Glass, Braunschweig, NI, Germany) as 
described previously (Gyengesi et al., 2018). 
 
3.3.2.2 - Silver myelin staining and analysis 
Silver staining of myelin was performed at RT as previously described (Gyengesi et al., 2014, 
Pistorio et al., 2006). Briefly, tissue sections were mounted onto 0.5% gelatine-coated slides 
and air dried for 48 h before immersion in 10% formalin (Sigma-Aldrich) for 2 weeks to 
increase the contrast of the staining. Sections were stained in a large glass container in parallel 
to maintain the consistency of staining. Slides were washed with distilled water and pre-
treated with lipid-solvent pyridine and acetic anhydride solution (ratio 2:1) for 30 min. 
Sections were then rehydrated with serial dilutions of ethanol 80, 60, 40 and 20% for 20 s in 
each step followed by two washes with distilled water. Slides were then immersed in 
ammonical silver nitrate (Chem-Supply) containing developing solution (0.2% ammonium 
nitrate, 0.2% silver nitrate and 5% sodium carbonate) for 45 min. Sections were then 
dehydrated by rinsing sequentially using 20, 40, 60, 80, and 100% ethanol for 20 s in each 
step. Sections were cleared by immersing the slides in xylene for 5 min and then sealed using 
cover slips (Knittel Glass) and ~1 ml mounting medium (Merck, Darmstadt, HE, Germany), 
and air dried for 72 h. The sections were viewed with an Olympus Carl Zeiss Bright Field 
Microscope (Zeiss, Jena, TH, Germany) and all images were captured at the same microscope 
settings (i.e., a fixed exposure time, magnification and illumination intensity). In ImageJ 
(https://imagej.nih.gov/) software, the region of interest (ROI) was contoured, and the mean 
optical density quantified (sum of each pixel intensity [range black (0) to white (256)] divided 




black), data were expressed as the reciprocal of the light intensity (i.e., the smaller the value, 
the lower the myelin content) and normalised to the Ctrl groups (n = 3–5 animals/group and 
5–9 sections/animal). The effectiveness of CPZ-feeding is frequently determined by loss of 
myelin from the midline corpus callosum (MCC), in this study the effectiveness of CPZ-
induced demyelination was confirmed in the MCC and lateral corpus callosum (LCC). 
Anatomical landmarks were identified as described previously (Paxinos and Franklin, 2012, 
Taylor et al., 2009). 
 
3.3.2.3 - Immunofluorescence staining and analysis 
All staining was performed at RT. Free floating brain (40–50 µm) and slide-mounted spleen 
(20 µm) coronal tissue sections were washed thrice with warm (40–50 °C) 0.01 M PBS to 
remove the gelatine and then immersed in 5–10% goat serum (Sigma-Aldrich) for 2 h with 
agitation at 50 rpm on a shaker table to block non-specific antibody (Ab) binding sites. 
Sections were then incubated (12 h) with primary monoclonal Ab to either neurite outgrowth 
inhibitor A (rabbit anti-Nogo A, 1:500, Merck-Millipore, Burlington, MA, USA), glial 
fibrillary acidic protein (mouse anti-Gfap-Alexa 488, 1:1000, Merck-Millipore), ionized 
calcium-binding adapter molecule 1 (rabbit anti-Iba 1, 1:1000, Wako, Chuo-Ku, OSA, 
Japan), anti-cluster of differentiation (rabbit anti-CD4, 1:200, Abcam, Cambridge, UK), or 
anti-CD8 (mouse anti-CD8, 1:100, Santa-Cruz Biotechnology, Dallas, TX, USA) diluted in 
0.01 M PBS containing 0.1% Triton X100 (Tx100). Sections were then washed thrice with 
0.01 M PBS and incubated with corresponding Alexa Fluor (either 488 or 555, dilution: 
1:500) secondary Ab (diluted in 0.01 M PBS/0.1% Tx100 solution for 2 h while shaking at 
50 rpm). Sections were then rinsed thrice with 0.01 M PBS and 1.5 µg/ml Vectasheild plus 
4′,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA) to 
counterstain nuclei. Slides were sealed with cover slips and stored in the dark at 4 °C until 
analysis. Images were captured as before (using an Olympus Carl Zeiss Fluorescence 
Microscope) using the same fixed parameters (exposure and magnification). Quantification 
was performed using ImageJ, measuring the fluorescence intensity of Gfap, Iba 1, CD4 and 
CD8 from each ROI as described in silver myelin staining and analysis (n = 3–5 
animals/group and 5–10 sections/animal). Cells positively stained for Gfap, Iba 1 and Nogo 
A (and co-stained with DAPI) were counted using the unbiased stereo investigator optical 




the cell density, total cell number was divided by total measured volume and the data 
expressed as 104 cells/mm3 (n = 3–5 animals/group and 5–9 sections/animal). 
 
3.3.3 - Two-dimensional Gel electrophoresis (2DE) and analysis 
3.3.3.1 - Sample collection, homogenisation and protein estimation 
At the end of each experiment (i.e., Studies I and II) period, mice (n = 5 animals/group) were 
euthanized by overdose of isoflurane (Cenvet, Blacktown, NSW, Australia) exposure. Whole 
brains were collected following decapitation and immediately rinsed with ice cold 0.01 M 
PBS containing a cocktail of protease, kinase, and phosphatase inhibitors (Sigma-Aldrich; 
Butt and Coorssen, 2005, Wright et al., 2014a) to remove any traces of blood. Tissue 
homogenisation was accomplished by automated frozen disruption using a Mikro-
Dismembrator (40 Hz for 1 min, Sartorius, Göttingen, NI, Germany) to facilitate optimal 
protein extraction (Wright et al., 2014a, Butt and Coorssen, 2006). Powdered tissue samples 
were mixed with cold 20 mM HEPES hypotonic lysis buffer (Amresco) containing the 
cocktail of protease, kinase, and phosphatase inhibitors and vortexed for 90 s followed by the 
restoration of isotonicity using the addition of an equivalent volume of ice cold 0.02 M PBS 
and incubated for 5 min on ice. The samples were then centrifuged (Beckman Coulter, 
Indianapolis, IN, USA) at 125,000× g (using a SW 55 Ti rotor) at 4 °C for 2 h. The resulting 
first supernatant (SP1) was collected as total cytosolic soluble protein (SP). The pellet was 
washed with ice cold 0.01 M PBS to extract any remaining cytosolic proteins (SP2) and 
centrifuged 8 h at 125,000× g. The resulting supernatant (SP2) was pooled with the SP1 
fraction, and this combined soluble protein fraction was concentrated using an Amicon Ultra-
4 centrifugal 3 KDa cut-off filter column (Merck-Millipore). To prevent salt interference 
during the 1st dimension isoelectric focussing step, the resulting SP samples were washed 
three times using cold 4 M urea (Ameresco) buffer supplemented with the inhibitor cocktail. 
The pellet containing membrane proteins (MP) was resuspended with cold 2DE solubilisation 
buffer (8 M urea, 2 M thiourea and 4% CHAPS) containing the inhibitor cocktail (Butt and 
Coorssen, 2006, Butt et al., 2007). Total protein concentrations in SP and MP fractions were 
measured using the EZQ™ Protein Quantitation Kit (Life Technologies, Eugene, OR, USA) 






3.3.3.2 - Protein separation 
At first, proteins were separated based on their isoelectric point (1st dimension) as follows: 
100 µg of proteins were loaded onto an immobilised pH gradient (IPG, 7 cm, non-linear, Bio-
Rad, Hercules, CA, USA) strips and passively rehydrated for 16 h at RT. Rehydrated IPG 
strips were placed in the Protean isoelectric focusing (IEF) tray (Bio-Rad) and IEF was 
carried out in a PROTEAN IEF system (Bio-Rad) for high-throughput protein resolution, 
initially at 250 V for 15 min which then increased linearly to 4000 V at 50 µA/gel for 2 h, 
with multiple electrode wick changes during voltage ramping to facilitate desalting. The 
following parameters were used during IEF: focus temperature: 17 °C, desalting: 15 min, 
linear gradient: 2 h, holding voltage: 500 V. Following IEF, IPG strips were either stored at 
−20 °C or immediately resolved in the second dimension using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Second dimension (2D) was carried out 
using 1 × 84 × 70 mm 12.5% acrylamide SDS-PAGE gels. Prior to 2D, IPG strips were 
incubated for 10 min with 130 mM DTT in equilibration buffer (6 M urea, 20% glycerol, 2% 
SDS and 375 mM tris) followed by 10 min alkylation in equilibration buffer containing 350 
mM acrylamide. IPG strips were then inserted on top of the SDS-PAGE gels and covered 
with warm (40–50 °C) ~300 µl agarose solution (0.5% low melting agarose, Bio-Rad) 
containing 2% bromophenol blue (Bio-Rad). Electrophoresis was carried out at 4 °C by 
applying 150 V for 5 min followed by 90 V for 3 h or until the bromophenol dye reached the 
bottom of the gels as described previously (Butt and Coorssen, 2006, Butt and Coorssen, 
2005, Wright et al., 2014a, Wright et al., 2014b). 
  
3.3.3.3 - Protein fixation and staining 
Upon completion of electrophoresis, gels (Study I, n = 180 gels and Study II, n = 120 gels) 
were fixed in 10% methanol and 7% acetic acid solution for 1 h at RT (on a shaker at 50 
rpm). Gels were rinsed with distilled water for 3 × 20 min to remove residual methanol and 
acetic acid followed by staining with 50 ml of high sensitive colloidal Coomassie Brilliant 
Blue (G-250, Amresco) and continuous shaking, as previously described (Gauci et al., 2013, 
Noaman and Coorssen, 2018, Wright et al., 2014a, Butt and Coorssen, 2013, Harris et al., 
2007, Noaman et al., 2017). After 20 h, the solution was discarded and stained gels were 
washed using 50 ml of 0.5 M sodium chloride solution for 3 × 15 min to remove excess 
Coomassie dye. Scanning of gels was carried out at 100 µm resolution using a TyphoonTM 




were 685/>750 nm and the photomultiplier tube was set to 600 V. Gels were preserved in 
20% ammonium sulphate (50 ml/gel) and stored at 4 °C until spot excision (Wright et al., 
2014a). 
 
3.3.3.4 - Protein resolution, detection and image analysis 
Quantitative analysis of gels was carried out using Delta 2D image analysis software 
(www.decodon.com/delta2d-version 4.0.8, DECODON, Greifswald, MV, Germany) as 
described previously (D'Silva et al., 2018, Gauci et al., 2013, Noaman et al., 2017, Partridge 
et al., 2016, Wright et al., 2014a). Briefly, total spot numbers were calculated from the raw 
images using the Delta 2D automated spot detection system, while gel edges and the protein 
ladder were excluded (D’Silva et al., 2017, Wright et al., 2014a). Gel images were warped 
and fused to generate a master image ensuring consistent spot matching. The fluorescent 
volumes of individual spots (i.e., protein abundance) were expressed as a function of all spot 
volumes detected and were measured using Delta 2D to assess changes across the different 
experimental groups. Four spot inclusion criteria were applied: 1) any changes in spot 
volumes were detectable in all biological replicates (n = 5 animals/group) and their associated 
technical replicate gels (n = 3 gels/fraction/animal, i.e., 15 gels/experimental group); 2) the 
relative standard deviation for technical replicates did not exceed 30% within individual 
animals; 3) values had to differ significantly (p < 0.05, t-test) between the naïve Ctrl group 
and at least one test group; and 4) have a fold change of ≥1.5 (increased/decreased 
fluorescence), to be considered genuine changes, and thus candidates for analysis by 
LC/MS/MS. These criteria allowed for reliable and reproducible identification of CPZ, 
CPZ+PT or PT associated proteoform changes. The fold change (p < 0.05, one-way 
ANOVA) of differentially abundant protein spots was calculated by dividing the average 
grey value (i.e., fluorescence intensity of the protein spot of each experimental group 
compared to the naïve Ctrl group) and presented in log2 scale as fold change relative to Ctrl. 
Precision Plus Protein Kaleidoscope molecular weight (MW) and 2DE isoelectric point (pI) 
standard (Bio-Rad) calibration gels (n = 3) were used to calculate the experimental pI and 
MW of resolved proteoforms. The coefficient of variation (standard deviation/mean) for the 
MW and pI migration was 2.6% and 1.4% for 2DE standards, respectively (n = 3), and 4% 
for MW ladders for experimental gels (n = 20). To quantify the gel shift indicative of protein 
post-translational modification (PTM), experimental MW and pI values were plotted relative 




above or below the 95% confidence intervals of the MW and pI calibration curves. The results 
are plotted as the average for both Studies I and II combined. 
 
3.3.3.5 - In-gel protein spot digestion 
Protein spots of interest were excised manually and de-stained for 2 × 15 min with 50 mM 
ammonium bicarbonate (Sigma-Aldrich) solution containing 50% acetonitrile (Sigma-
Aldrich). After complete removal of Coomassie dye, gel pieces were dehydrated using 100% 
acetonitrile. In-gel digestion was carried out by adding 20 µl of freshly prepared trypsin (12.5 
ng/µl, Promega Corporation, Madison, WI, USA) to a solution of 50 mM ammonium 
bicarbonate for 8 h at 4 °C. Digested peptides were removed from the gel by 30 min 
sonication. The solution was then acidified by the addition of 2 µl of 2% formic acid (Merck-
Millipore). The resulting peptide solution was concentrated to 10 µl using a Speed Vac 
vacuum concentrator (1400 rpm for 10–15 min, John Morris Scientific, Chatswood, NSW, 
Australia) and stored at -80 °C for future use or immediately subjected to LC/MS/MS (Wright 
et al., 2014a). 
 
3.3.3.6 - Liquid chromatography tandem mass spectrometry (LC/MS/MS) 
The concentrated peptide solutions were analysed by LC/MS/MS using a nanoAcquity ultra 
performance liquid chromatography system linked to a Xevo QToF mass spectrometer as 
previously described (Wright et al., 2014a, Partridge et al., 2016, Stimpson et al., 2015, 
Stroud et al., 2017). In brief, peptide sample solutions (3 µl) were loaded onto a C18 
symmetry trapping column (20 mm × 180 µm), and desalted for 3 min at 5 μL/min flow rate 
using 1% solvent B (LC/MS grade 1% acetonitrile and 0.1% formic acid) in solvent A (Mili-
Q water + 0.1% formic acid). The peptides were washed off the trapping column at 400 
nL/min onto a C18 BEH analytical column (75 μm × 100 mm), packed with 1.7 μm particles 
of pore size 130 Å using a 60 min ramped LC protocol. The initial solvent composition was 
held at 1% B for 1 min followed by linear ramping to 50% B over 30 min. A further linear 
ramp to 85% B commenced at 31 min and held until 37 min before the solvent composition 
was returned to 1% B. Separated peptides were analysed using tandem mass spectrometry 
with a constant cone voltage of 25 V and source temperature of 100 °C, implementing an 
emitter tip that tapered to 10 µm at 2.3 kV. A data-directed acquisition (DDA) approach was 
performed, which continuously scanned across the m/z range 350–1500 for peptides of charge 




given 3 s scan. Selected peptides were de-isotoped, fragmented and the masses measured. 
The ramped collision energy profile was set to 15–35 V at low mass and 30–40 V at high 
mass. The mass of the precursor peptide was then excluded for 30 s. The DDA was via 
Masslynx software (version 4.1, Micromass, Manchester, UK) and converted to a peak list 
file (PKL) format using the ProteinLynx Global Server (Waters, Milford, CT, USA). Data 
were analysed using MASCOT Daemon (www.matrixscience.com) and queried against the 
SwissProt and MSPnr100 databases (see www.wehi.edu.au) using delimited and species-
specific searches to identify the protein species using the following MASCOT parameter 
settings: the enzyme trypsin and taxonomy Mus musculus (mouse) were fixed. Moreover, no 
fixed modification was selected whereas variable modifications were carbamidomethyl (C), 
deamidated (NQ), oxidation (M) and propionamide (C). Only two missed cleavages of lysine 
or arginine residues were allowed; mass tolerance of parent and MS/MS ions was set to ±0.05 
Da and peptide charge state was 2+–4+. The results of the search were filtered by excluding 
peptide hits with a p-value greater than 0.05. While the SwissProt and MSPnr100 databases 
were both used to best ensure confirmation of a protein identity, the higher of the two scores 
was documented in Table 1. When multiple proteins were detected from the same spot, the 
following criteria were applied to identify the most abundant and thus the most likely to have 
contributed to the originally detected change in spot volume: 1) The highest MASCOT score 
(>100) with a sequence coverage ≥5%; and 2) ≥4 unique matched peptides. 
 
3.3.3.7 - Literature mining and bioinformatics 
A PubMed (www.ncbi.nlm.nih.gov/pubmed/) literature search was carried out for papers 
published in the English language using the identified canonical protein name with either 
CPZ, EAE or MS to find literature relevant to molecular/cellular functions. The UniProt 
(www.uniprot.org) database was used to obtain the gene and UniProt accession number (ID) 
of the identified protein species and analysis of subcellular localization (UniProt Consortium, 
2018). A mapping of genes according to their classification and molecular functions was 
derived from protein analysis through evolutionary relationships (PANTHER, 
www.pantherdb.org) database using gene IDs of each identified protein (D'Silva et al., 2018). 
Cellular components, biological processes and physiological pathways of the identified 
protein species were categorised using the database for annotation, visualization and 
integrated discovery (DAVID, version 6.8, david.ncifcrf.gov) database. UniProt accession 




ontology, www.geneontology.org) cellular components, and biological processes. DAVID 
also characterised the physiological pathways associated with the identified protein species 
according to the Kyoto encyclopaedia of genes and genomes (KEGG, www.genome.jp/kegg) 
category (Sharma et al., 2014). Protein species were further characterised and grouped using 
the search tool for retrieval of interacting genes/proteins (STRING; version 10, string-db.org) 
to identify potential protein–protein interactions (PPI; Szklarczyk et al., 2015). Using the 
STRING database, a PPI map was generated in which each node represents a protein and 
connecting lines represent evidence of association (with line thickness indicating the strength 
of the potential interaction). Such associations are based on text mining, co-expression, co-
occurrence, databases, experiments, neighbourhood and gene fusion of the identified proteins 
(Hossain et al., 2016, De Las Rivas and Fontanillo, 2010). 
 
3.3.4 - Western blot (WB) 
3.3.4.1 - Sample preparation 
Stored brain, spinal cord and spleen samples (n = 3/group) were homogenised in the deep-
frozen state as described earlier. Equal ratios (~1 µl/1 µg tissue) of sample and pre-chilled 
lysis buffer (25 mM Tris, 1 mM EDTA and 1 mM EGTA) containing the inhibitor cocktail 
were used to solubilize the powdered samples and protein was recovered using centrifugation 
(at 125,000× g, 4 °C, for 1 h). Protein quantification was then carried out as previously 
described using the EZQ protein quantitation kit (see above). 
 
3.3.4.2 - Procedure 
Total protein extract (brain, spinal cord and spleen) and CD4/8 recombinant proteins were 
resolved by 10% SDS-PAGE (100 V for 2 h at 4 °C) and transferred (100 V for 2 h at 4 °C) 
onto 0.22 µm pore size polyvinylidene difluoride (PVDF, Merck-Millipore) membrane using 
transfer buffer containing 25 mM tris, 192 mM glycine and 20% methanol. The membranes 
were incubated in blocking buffer containing non-fat dry skimmed milk (5% w/v, Coles, 
Hawthorn East, VIC, Australia) and polyvinylpyrrolidone (1% w/v, Sigma-Aldrich), in 
0.05% Tris buffered saline-Tween-20 (TBST) for 1 h at RT on an orbital shaker (at 50 rpm). 
Primary Abs for CD4 (rabbit anti-CD4, 1:500, Abcam) and CD8 (mouse anti-CD8, 1:75, 
Santa-Cruz Biotechnology) were incubated for 1 h at RT. Blots were then washed thrice with 




Ab (goat anti-rabbit- or goat anti-mouse-HRP: CD8 1:500, Santa-Cruz Biotechnology and 
CD4 1:2000, Abcam) was added and incubated for 1 h at RT. Chemiluminescent 
visualization of the transferred proteins was carried out using an enhanced 
chemiluminescence detection reagent (500 μL/cm2 membrane, Merck-Millipore). Blots were 
scanned for 2 s on the ImageQuantTM FUJI LAS-4000 biomolecular imager (GE Healthcare). 
ImageJ software was used to quantify the density of a band of interest on a blot by using a 
rectangular box to define the band. This band intensity was expressed as a raw value (n = 3 
bands/animal, n = 3 animals/group) and presented relative to Ctrl. 
 
3.3.4.3 - Transfer efficiency 
Replicate 1D SDS-PAGE gels were resolved in parallel and one stained with Coomassie 
Brilliant Blue prior to, and the other after, transfer onto PVDF membrane to determine the 
transfer efficiency of proteins. Imaging was carried out using a TyphoonTM FLA-9000 gel 
imager. The density of the bands (n = 3 bands/gel) with the molecular weights corresponding 
to the known molecular weights of CD4/8 (37 and 50 KDa, respectively) were quantified 
using Multigauge image analysis software-version 3.0 (Fujifilm, Minato-Ku, TYO, Japan). 
 
3.3.4.4 - Cell detection limits in peripheral and CNS tissues 
To measure the detection limit of CD4 and CD8 antibody signals in WBs, spleen samples 
from naïve mice and commercial CD4/8 recombinant proteins (Sino Biological, Wayne, PA, 
USA) were used. For CD4, the lowest detectable signal was achieved using 5 µg of spleen 
protein, whereas 10 µg of total spleen protein was needed to detect a CD8 band. The minimal 
detectable concentrations of the commercial recombinant protein standards were 5 ng and 5 
µg for CD4 and CD8, respectively (Figure 3a). These lowest detectable concentrations for 
both groups (spleen and commercial samples) were used as positive (spike) controls to 
establish the expected minimal detection of CD4 and CD8 in WBs of total brain protein from 
the different experimental groups. 
 
3.3.5 - Statistical analysis and graphing 
Statistical analyses were performed using GraphPad Prism-version 7.03 
(www.graphpad.com, San Diego, CA, USA) software. Data were analysed using either one 




appropriate, Newman-Keuls or Tukey post hoc analyses to determine specific differences 
among groups. Data are presented as means ± standard error of the mean (SEM), otherwise 
indicated in the text. Statistical significance was accepted when p < 0.05. Figures were 
assembled using CorelDRAW-version 2018 (www.coreldraw.com, Ottawa, ON, Canada) 
and Photoshop CS6 (Adobe, San Jose, CA, USA) image processing software. All Nogo A 
images were adjusted only for colour contrast (Supplementary Figures S1 and S2). 
 
3.4 - Results 
3.4.1 - Body weight 
Mice in all groups gained weight over the duration of feeding, but this was significantly 
slower in CPZ(±PT)-fed animals (p < 0.05, Figure 1). Significant reductions in weight gain 
started at week 1 after 0.2% CPZ±PT and week 2 after 0.1% CPZ±PT-feeding and continued 
until week 11. At week 12, 0.1% CPZ±PT groups were significantly (p < 0.05) different 
compared to the Ctrl group but not to the PT group. No direct or combined effect (p > 0.05) 
of PT was found in any group at any time point. 
 
Figure 1: Body weight changes induced by CPZ-feeding.  
All mice gained weight over time. Groups fed the highest dose of CPZ(±PT) in each 
experiment gained weight significantly more slowly compared to other groups. Vertical dash 
lines indicate the timing of individual PT injections (i.e., days 14, 16, and 23). Data are 
expressed as mean ± SEM. Two-way ANOVA and Tukey post hoc analysis were used to 
determine differences among groups (* p < 0.05, ^ p < 0.0001, Study I n = 22 animals/group 




3.4.2 - Marked demyelination, oligodendrocytosis and gliosis 
In both Studies I and II, the Ctrl and PT groups exhibited intense silver staining of myelin in 
the midline corpus callosum (MCC) and lateral corpus callosum (LCC), whereas the 0.1% 
and 0.2% CPZ-fed(±PT) groups displayed a marked, concentration-dependent loss of silver 
staining (p < 0.05, Figure 2a; Supplementary Figures S1a, S2a, S3a). No differences in the 
extent of demyelination were found between the MCC and LCC regions in any of the groups 
with either duration of CPZ-feeding [(p > 0.05, Figure 2a, (MCC); Supplementary Figure 
S3a, (LCC)]. Importantly, prolonged 0.1% CPZ (+PT)-feeding for 12 weeks (Study II) 
produced a similar amount of demyelination to that seen at 5 weeks (Study I) with 0.2% CPZ 
(p < 0.05, Figure 2a; Supplementary Figures S1a, S2a, S3a). Consistent with the significant 
reduction in silver staining, 5 or 12 weeks of CPZ-feeding produced a significant loss (>90%) 
of mature, Nogo A positive OLG in the MCC and LCC; feeding with 0.1% was as effective 
as 0.2% CPZ at inducing OLG loss (p < 0.05, Figure 2b; Supplementary Figures S1b, S2b, 
S3b). Importantly, there were no differences in OLG loss when using 0.1% or 0.2% CPZ for 
5 weeks, and 0.1% CPZ-feeding for 12 weeks produced a comparable loss of OLG to that 
seen at 5 weeks (p > 0.05, Figure 2b; Supplementary Figures S1b, S2b, S3b). Similarly, there 
were marked dose-dependent increases (p < 0.05) in the number and intensity of Gfap and 
Iba 1 staining (Figures 2c,d; Supplementary Figures S1c,d, S2c,d, S3c,d) in the CPZ-
fed(+PT) groups compared to Ctrl or PT only animals (which were not different from each 
other, p > 0.05). Taken together, these results indicate that low dose CPZ-feeding for 5 weeks 
(Study I) produced an almost complete loss of OLG but a more limited (i.e., slower) 
demyelination and gliosis response. When this feeding regime was prolonged for 12 weeks 
(Study II), it produced comparable changes to those seen at 5 weeks (Study I) using 0.2% 
CPZ. PT had no direct or synergistic effects on any of the histological parameters studied at 






Figure 2: Quantification of demyelination, cell death and gliosis in the midline corpus 
callosum.  
(a) Silver staining. CPZ-feeding(±PT) led to significant demyelination and reduced silver 
staining intensity at 5 (Study II) and 12 weeks (Study II). PT alone had no effect. Feeding 
0.1% CPZ for longer (12 weeks) produced a comparable demyelination to that seen with 
0.2% for 5 weeks. (b) Nogo A. CPZ-feeding(±PT) led to significant oligodendrocytosis with 
0.1% CPZ was as effective as 0.2% CPZ at either time point. PT alone had no effect. (c) 
Gfap. Staining intensity increased in a dose dependent manner, in the CPZ(±PT) treated 
groups and this was associated with an increase the number of Gfap positive astrocytes at 
both time points. PT only did not evoke a Gfap response. (d) Iba 1. Increased Iba 1 
fluorescence intensity and number of Iba 1 positive microglia were seen in both Studies I and 
II groups. PT alone produced no microglial response. Data are presented as mean ± SEM. 
One-way ANOVA and Tukey post hoc analysis was used to determine differences among 
groups (* p < 0.05, # p < 0.01, $ p < 0.001 and ^ p < 0.0001). Quantitation based on analysis 




3.4.3 - Detection and localisation of CD4 and CD8 T-Cells 
Immunofluorescence staining of brain sections failed to detect CD4+ and CD8+ positive cells 
in the CC in CPZ(±PT) groups (Supplementary Figure S4a, even when using high antibody 
titres and long incubation times). This was not due to the lack of antibody sensitivity, as 
immunofluorescent CD4 and CD8 positive cells were seen in histological sections of spleen 
(Supplementary Figure S6a). Likewise, CD4/8 signals in whole brain protein samples were 
undetectable by western blot (WB) analysis (Figure 3c), even at high protein loads (up to 120 
µg). This was not due to the lack of protein transfer from SDS-PAGE gel to PVDF membrane, 
as transfer efficacy at the molecular weights corresponding to CD4/8 (37 and 50 KDa, 
respectively) were 93 ± 1.6% and 98 ± 0.7%, respectively (Supplementary Figure S4b). 
Furthermore, CD4/8 signals were also detected by WB analysis when spleen (Figure 3a,c) 
and EAE spinal cord were used as positive controls (Supplementary Figure S4c; EAE was 
induced using an established method (Bittner et al., 2014)). The capacity and sensitivity of 
WB to detect CD4/8 signal was also confirmed by other control experiments in which brain 
homogenates were spiked with spleen homogenate or commercially available CD4/8 
recombinant proteins (Figure 3b). Notably, measurement of splenic weight showed a 
significant (p < 0.05) decrease in splenic mass (37 ± 0.1%) in 0.2% CPZ-fed(±PT) groups 
whereas no change was observed in 0.1% CPZ(±PT) groups at 5 weeks (Study I, 
Supplementary Figure S5a,c). In contrast, a significant (p < 0.05) reduction of splenic mass 
was observed in 0.1% CPZ(±PT) groups at 12 weeks (Study II, Supplementary Figure S5b,c). 
Moreover, 5 weeks of CPZ-feeding also resulted in a significant dose-dependent reduction 
in CD4/8 in spleen compared to Ctrl (Figure 3d, 0.2% > 0.1%, p < 0.05). Following 5 weeks 
of 0.1% CPZ-feeding(±PT), the reduction of CD4 (11 ± 0.03%) and CD8 (14 ± 0.03%) signal 
intensity was less marked than that seen with 0.2% CPZ(±PT) groups (CD4 44 ± 0.03% and 
CD8 61 ± 0.04%). Following 12 weeks of 0.1% CPZ(±PT), further reductions in spleen CD4 
(27 ± 0.01%) and CD8 (43 ± 0.02%) signal intensity and splenic atrophy (33 ± 0.1%) were 
observed. In addition, immunofluorescence staining of spleen sections (n = 10 
sections/animal and n = 3 animals/group) indicated a significant (p < 0.05) reduction of CD4 






Figure 3: Western blot analysis.  
(a) Measurement of the detection limit of CD4/8 signal using naïve Ctrl spleen homogenates 
and CD4/8 recombinant proteins in gels. (b) Confirmation of CD4/8 signal detection using 
brain tissue samples (60 μg) spiked with either 5 µg or 10 µg of spleen homogenate or 5 ng 
and 5 µg commercial CD4 and CD8 recombinant proteins. (c) No CD4/8 signal was detected 
in CPZ(±PT) brain samples whereas a reduced CD4/8 signal intensity was found in spleen. 
(d) Quantification of splenic CD4/8 blots showed a significant reduction of CD4 and CD8 
signal intensity in spleens of specific groups. Cropped CD4/8 western blots are presented 
unaltered and shown in their entirety in Supplementary Figure S7. Data are presented as mean 
(±SEM) relative to the Ctrl mice. One-way ANOVA and Newman-Keuls Multiple 
Comparison post hoc analysis were used to determine differences among groups (* p < 0.05, 













3.4.4 - Brain proteome changes 
All samples yielded well-resolved proteomes encompassing the full MW/pI range of the gels. 
Representative images of soluble (SP) and membrane (MP) proteomes from Ctrl and 0.2% 
CPZ-fed mice are shown in Figure 4a. A total of ~1650 consensus spots (i.e., protein spots 
that resolved consistently and were analysed across all gels) were detected from the combined 
analyses of whole brain soluble and membrane proteomes (Figure 4a; Supplementary Table 
S1). The spot quantification from the different groups from both time points is summarized 
in Supplementary Table S1. The different groups yielded comparable numbers of resolved 
protein spots at 5 weeks (p > 0.05), and this was also true for the 12-week samples (p > 0.05, 
Supplementary Table S1). In total, 845 ± 8 and 793 ± 11 spots were resolved from the soluble 
and membrane fractions, respectively, in the Study I, whereas 824 ± 11 and 717 ± 3 spots 
were resolved from the soluble and membrane fractions, respectively, in the Study II. 
Database hits of high-quality and confidence were returned following LC/MS/MS analysis 
and identified 33 different proteoforms from these spots including 73% in the membrane 
proteome and 27% in the soluble proteome (Table 1). 
Table 1 summarizes the best identified proteoforms within each spot that displayed a 100% 
reproducible change across technical (n = 3 gels/fraction) and biological (n = 5 
animals/group) replicates. All identified proteins had a MASCOT score exceeding 100, with 
46% between 100–200; 21% between 201–300; 9% between 301–400; 6% between 401–
500; and 18% exceeding 500. Moreover, each identification was based on at least 4 unique 
peptides: 61% based on 4–10 peptides; 27% based on 11–20 peptides; and 9% based on over 
30 peptides. Similarly, sequence coverage was always ≥5% with 5–10% for 6 proteins; 11–
20% for 11 proteins; 21–30% for 8 proteins; 31–40% for 5 proteins; and >50% for 3 proteins 
(Table 1). The combination of high MASCOT scores and the presence of ≥4 unique peptides 

















Figure 4: Top-down proteomic analysis.  
(a) Representative two-dimensional gel images of soluble (SP) and membrane (MP) brain 
proteomes from naïve Ctrl and 0.2% CPZ-fed groups used to detect proteoform changes. 
Proteoforms were resolved on the basis of their isoelectric point (pI) and molecular weight 
(MW). The total number of spots across different groups in both 5 and 12 weeks (Studies I 
and II) is given in Supplementary Table S1. Delta 2D software analysis revealed 33 unique 
spots for which the spot volume changed by at least 1.5-fold in at least one experimental 
group; soluble proteoforms are indicated by red circles and membrane proteoforms by green 
circles. The identities of the protein species are shown in Table 1 (n = 15 gels/fraction, n = 5 
animals/fraction, Study I n = 180 gels and Study II n = 120 gels). (b) Comparison between 
theoretical and experimental MW (left) and pI (right) of identified proteoforms. Red 
represents increase, green decrease and blue indicates no statistically significant difference 
between the experimental and theoretical values. Purple dashed lines indicate 95% 
confidence intervals and the solid line represents full agreement between experimental and 
theoretical values. 
 
As also shown in Table 1 and Figure 4b, several of the identified proteoforms displayed a 
mismatch between their theoretical and experimental MW and pI, indicative of post-
translational modifications (e.g., phosphorylation and glycosylation). Only, 1 proteoform 
showed an increase whereas 19 (58%) showed a decrease and 13 (39%) showed the same 
experimental pI relative to the theoretical pI. In contrast, twenty-five (75%) proteoforms 
increased, 4 (12%) decreased, while another 4 remained unchanged in their experimental 
MW relative to theoretical MW. Interestingly, a subset of proteoforms was found showing 
an approximate doubling of the experimental MW relative to theoretical—hexokinase 1, 
aconitate hydratase, ATP synthase subunit-α, ogdhl protein, tyrosine-tRNA ligase and 
dynamin 1—potentially indicative of dimerization, whereas an approximate tripling of MW 
may indicate calreticulin trimers (Table 1) suggesting a possible increase in 
oligomerization/self-association of proteoforms due to CPZ-feeding(±PT). 
Statistical comparisons of the spot intensities between all groups revealed significant and 
reproducible changes (p < 0.05) in 33 spots across Ctrls and experimental groups in the 
Studies I and II (Figure 5). Among the identified proteoforms, not all changes were sustained, 
or shared, between the Studies I and II (Supplementary Figure S8). In total, 23 shared 
proteoform changes were found in both the Studies I and II (i.e., ≥1.5-fold change in both 
studies), whereas 7 proteoforms that changed in the Study I (≥1.5-fold) did not in the Study 
II (<1.5 fold) and 3 other proteoforms were changed by 12 weeks (≥1.5-fold) but not at 5 
weeks (<1.5 fold). The presence of changes at 5 weeks (Study I) that were not evident at 12 




dependent and resolved by 12 weeks. Whether this return to control levels during prolonged 





Table 1: 2DE LC/MS/MS analyses identified 33 proteins from Studies I and II. 
  Spot ID 












Highest Fold Change Data 
Base 
Reference 
Theoretical Experimental CPZ EAE MS 
5 W 12 W 
  A4/MP G3UVV4 Hexokinase 1 Hk1 270/10 10 101.8/6.2 220/6.4 0.66(0.2)↓ 0.48(0.1PT)↓ M - - (De Riccardis et al., 2016) 
  5N3/SP P05063 Fructose-bisphosphate aldolase C Aldoc 510/33 12 39.3/6.6 73.4/5.9 0.32(PT)↓ × S - (Farias et al., 2012) (Menon et al., 2011) 
  D2/MP Q99KI0 Aconitate hydratase Aco2 407/25 18 85.4/8.1 182.9/8.2 2.37(0.2PT)↑ 0.23(PT)↓ M - - (Almeras et al., 2004) 
  A10/MP Q8K2B3 
Succinate dehydrogenase 
flavoprotein subunit 
Sdha 230/12 8 72.5/7 96/6 0.57(0.1PT)↓ 0.61(0.1PT)↓ M (Gat-Viks et al., 2015) - - 
  F2/MP P08249 Malate dehydrogenase Mdh2 983/57 25 36/8.9 70.2/6.9 2.30(0.1PT)↑ × S - (Farias et al., 2012) (Noben et al., 2006) 
  5O5R/MP                     Q91WD5 
NADH dehydrogenase iron-sulfur 
protein 2 
Ndufs2 173/10 5 52.5/6.5 52.2/5.5 0.59(PT)↓ 1.77(0.1PT)↑ M (Gat-Viks et al., 2015) - - 
  5R5/SP Q03265 ATP synthase subunit-α 5O5R/MP Atp5a1 177/26 15 59.7/9.2 117.4/8.2 2.76(PT)↑ 0.37(0.1)↓ S (Gat-Viks et al., 2015) - (Menon et al., 2011) 
  A37/MP Q60930 
Voltage-dependent anion-selective 
channel protein 
Vdac2 155/14 5 31.6/7.4 18.7/6.6 0.42(0.2PT)↓ 0.5(0.1PT)↓ M - - (Almeras et al., 2004) 
  A34/MP P05201 Aspartate aminotransferase Got1 350/26 12 46.2/6.6 29.5/7.4 0.69(0.2PT)↓ 0.38(0.1PT)↓ M - - (Menon et al., 2011) 
  A1/MP B2RXT3 Ogdhl protein Ogdhl 291/10 10 114.5/6.4 243.3/5.9 0.69(0.2)↓ 0.65(0.1PT)↓ M - - - 
  B23/MP Q8VDQ8 NAD-dependent protein 
deacetylase sirtuin-2 
Sirt2 529/36 13 39.4/6.35 27.8/7 0.69(0.1PT)↓ 0.33(0.1PT)↓ M - (Jastorff et al., 2009) (Jastorff et al., 2009) 
  5C1/SP Q9JHI5 Isovaleryl-CoA dehydrogenase Ivd 650/39 17 46.3/8.5 79.4/6.2 0.42(0.2PT)↓ 1.80(PT)↑ S (Partridge et al., 2016) - - 
  5G5/SP Q91WQ3 Tyrosine-tRNA ligase Yars 333/28 17 59/6.57 124.9/6.4 0.32(0.2PT)↓ 1.97(PT)↑ S - - - 
  A22/MP P26443 Glutamate dehydrogenase 1 Glud1 324/12 7 61.3/8 106.8/6.8 2.24(0.2PT)↑ × M - (Linker et al., 2009) (Werner et al., 2001) 
  A16/MP Q99MN9 Propionyl co-enzyme A 
carboxylase-β 
Pccb 277/16 6 50.4/5.7 60.5/6.3 × 0.43(0.1PT)↓ M - - - 
  B20/MP P30275 Creatine kinase U-type Ckmt1 137/22 11 46.9/8.4 83.2/7.5 0.44(0.2PT)↓ 0.35(0.1)↓ S - - - 
  A14/MP P50396 Rab GDP dissociation inhibitor-α Gdi1 227/20 8 50.5/4.9 77/5.9 0.6(0.2)↓ 0.56(0.1PT)↓ M - - (Newcombe et al., 2005) 
  5O4/MP Q61598 Rab GDP dissociation inhibitor-β Gdi2 148/10 5 50.5/5.9 55.6/5.7 0.38(PT)↓ × M - - (Newcombe et al., 2005) 
  5L6/MP P46460 Vesicle-fusing ATPase Nsf 466/36 33 82.6/6.5 116/6.3 0.52(0.2PT)↓ 0.71(0.1PT)↓ S - - - 
  B17/MP P11798 Calcium/calmodulin-dependent 
protein kinase type II subunit-α 





Key: MP, membrane protein; SP, soluble protein; MW, molecular weight; pI, isoelectric point; S, Swiss-Prot; M, MSPnr100; PT, pertussis 
toxin; 0.1, 0.1% CPZ; 0.1PT, 0.1% CPZ+PT; 0.2, 0.2% CPZ; 0.2PT, 0.2% CPZ+PT; W, week; ×, unchanged; ↑, increase; ↓, decrease; -, not 
found or investigated (details are shown in Figure 5). Some of the spots contained more than one clearly identifiable protein; presented here 
are the hits with the highest score, coverage and peptide count. UniProt and gene IDs were derived from the UniProt database. MASCOT 
score, sequence coverage, theoretical (MW/pI), and unique peptides number were acquired from the MASCOT database search. Experimental 
(MW/pI) was derived from 2D gels of identified protein spot. References are from the published literature in PubMed on CPZ, EAE and MS 
and used to compare currently identified proteins with the existing literature. 
 
  A11/MP O08599 Syntaxin-binding protein 1 Stxbp1 244/12 5 68.7/6.3 90.6/6.3 0.71(0.2)↓ 1.61(PT)↑ M - (Linker et al., 2009) - 
  A5/MP A0A0J9Y
UE9 
Dynamin 1 Dnm1 172/9 8 93.9/6.2 200/6.2 1.61(0.2PT)↑ 0.46(0.1PT)↓ M (Partridge et al., 2016) - - 
  E14/MP Q9D8B3 
Charged multivesicular body 
protein 
Chmp4b 176/15 4 24.9/4.6 23.7/5 × 1.65(0.1PT)↑ M - - - 
  5H2R/MP P03995 Glial fibrillary acidic protein Gfap 
1802/7
2 
45 49.8/5.2 83.7/5.0 1.86(0.2PT)↑ 1.58(PT)↑ S (Werner et al., 2010) (Fazeli et al., 2013) (Axelsson et al., 2011) 
  E2/MP P08551 Neurofilament light polypeptide Nefl 
1594/5
7 
92 61.4/4.6 53/4.9 0.71(0.2)↓ 2.08(0.1PT)↑ S - (Jain et al., 2009) (Gresle et al., 2011) 
  5G3/SP Q9D898 
Actin-related protein 2/3 complex 
subunit 5 
Arpc5l 152/26 4 16.9/6.3 26/5.9 0.62(0.2PT)↓ × M - - - 
  5I1/SP P42208 Septin-2 Sept2 180/21 7 41.5/6.1 81/5.7 0.30(PT)↓ 1.53(PT)↑ S - (Jastorff et al., 2009) (De Masi et al., 2009) 
  5I2/SP Q9Z2Q6 Septin-5 Sept5 159/22 9 42.7/6.2 80.4/5.9 0.36(0.2PT)↓ 0.46(0.1PT)↓ S - (Fazeli et al., 2013) - 
  4L1/MP P18872 
Guanine nucleotide-binding protein 
G(o) subunit-α 
Gnao1 186/15 5 40.6/5.3 68.5/4.7 7.35(0.2)↑ 1.48(0.1PT)↑ S - (Fazeli et al., 2010) - 
  4O3/MP Q9D7N9 Adipocyte plasma membrane-
associated protein 
Apmap 148/8 5 46.4/5.9 85/5.6 4.09(0.1)↑ 1.46(0.1PT)↑ M - - - 
  5R1/MP P14211 Calreticulin Calr 187/13 7 47.9/4.3 155/4.4 2.50(0.2PT)↑ 1.83(0.1PT)↑ S - (Fazeli et al., 2010) (Ni Fhlathartaigh et al., 
2013) 
  5G2/SP P62259 14-3-3 protein epsilon Ywhae 110/23 6 29.1/4.6 49.9/4.5 0.66(0.2PT)↓ × S - (Fazeli et al., 2013) (Colucci et al., 2004) 





Figure 5: Log2 fold changes in abundance for 33 proteoforms relative to Ctrl.  
Each point is the average change in spot volume ratio from all treated groups (PT, 0.1% 
CPZ, 0.1% CPZ+PT, 0.2% CPZ and 0.2% CPZ+PT) relative to Ctrls from the triplicate 
gels resolved for each of the Study I and Study II samples. Only significant changes in 
abundance (p < 0.05) that exceeded the established 1.5-fold criteria (dash lines) in at least 
1 experimental group were selected for excision, processing, and protein identification. 




Solid and dashed lines connect the protein changes within each experimental group with 
and without PT injection, respectively. Proteoforms (top left) indicate the different 
functional categories including metabolic (red), synaptic (blue), structural (purple) and 
signalling (green). Analysis was based on n = 180 gels (Study I) and, n = 120 gels (Study 
II); n = 5 animals/group. 
 
3.4.5 - Literature mining 
Literature mining via PubMed was used to assess the likely function(s) of identified 
proteoforms. This confirmed 8 proteoforms (creatine kinase U-type, glutamate 
dehydrogenase 1, vesicle-fusing ATPase, propionyl co-enzyme A carboxylase-β, tyrosine-
tRNA ligase, actin-related protein 2/3 complex subunit 5, charged multi-vesicular body 
protein and adipocyte plasma membrane-associated protein) not previously related to CPZ, 
EAE or MS, and 25 proteins (but not specific proteoforms) previously associated with CPZ 
(8), EAE (13) and MS (16) studies (Table 1). 
 
3.4.6 - Biological processes and pathways 
The 33 differentially expressed proteoforms were subjected to bioinformatic analysis using 
PANTHER, DAVID, UniProt and STRING for association with protein classes, molecular 
functions, physiological pathways, biological processes, cellular components, subcellular 
localizations and protein–protein interactions. Analysis using PANTHER indicated that the 
main protein classes were enzyme modulator (15%), nucleic acid binding (10%), 
oxidoreductase (10%) with 19% unclassified (Supplementary Figure S9a). Molecular 
function analysis using PANTHER indicated catalytic activity (40%) and binding (26%) 
roles with 18% unclassified (Figure 6a). However, the potential functions of all the 
proteoforms were inferred by literature mining for information on the canonical proteins 
(see Discussion). Physiological pathway analysis associated 26% of the proteins with 
KEGG metabolic pathways categories using DAVID (Figure 6b). GO biological process 
analysis showed the main categories were oxidation-reduction (13%) and transportation 
(13%), with 15% unclassified (Supplementary Figure S9b). Moreover, GO cellular 
component analysis (Figure 6c) indicated that most of the proteins were either cytoplasmic 




(20%). Furthermore, subcellular localization analysis using UniProt revealed the main 
categories to be mitochondrial (31%) and cytoplasmic (26%; Supplementary Figure S9c). 
The identified proteoforms were also analysed using STRING software, providing PPI 
maps; this indicated that 15 of the 33 proteoforms (hexokinase 1, fructose-bisphosphate 
aldolase C, aconitate hydratase, succinate dehydrogenase flavoprotein subunit, malate 
dehydrogenase, NADH dehydrogenase iron-sulfur protein 2, ATP synthase subunit-α, 
voltage-dependent anion-selective channel protein, aspartate aminotransferase, ogdhl 
protein, isovaleryl-CoA dehydrogenase, tyrosine-tRNA ligase, glutamate dehydrogenase 
1, propionyl co-enzyme A carboxylase-β and creatine kinase U-type) were potentially 
involved in major ‘functional interactions’ particularly with regard to the metabolic 
proteins (Figure 6d). Strong one-to-one connections were also indicated between synaptic 
(rab GDP dissociation inhibitor-α, rab GDP dissociation inhibitor-β, vesicle-fusing 
ATPase, calcium/calmodulin-dependent protein kinase type II subunit-α and dynamin 1) 
and structural (glial fibrillary acidic protein and neurofilament light polypeptide) 
proteoforms. This therefore, also revealed a second cluster of structural and signalling 
proteoforms. Among the connected proteoforms, 38% showed the highest connecting value 
(0.9), and 29% and 33% were high (0.7) and medium (0.4), respectively; no low value 






Figure 6: Functional clustering and protein–protein interactions.  
Pie charts show the distribution of proteins according to (a) Molecular functions 
(characterized using PANTHER), (b) Physiological pathways (categorised using KEGG), 
(c) GO cellular components. (d) Protein–protein interaction association network maps. The 
strength of connections is based on co-expression, gene fusion, co-occurrence, 
neighbourhood, databases, experiments, and text-mining collated in the STRING database. 
The strength of interactions is indicated by the thickness of the lines. STRING analysis 
revealed 4 protein clusters involved in metabolic (red), synaptic (blue), structural (purple) 
and signalling (green). Collectively, these proteins and their associations suggest that CPZ 





Although the addition of PT injections during CPZ-feeding did not enhance the extent of 
OLG degeneration, demyelination and gliosis, it did produce several proteoform changes 
(Figures 5,7; Supplementary Figure S10a–c, Table S2). This is the first study to assess 
changes in the mouse brain proteome profile when the BBB is compromised by PT. 
Following 5 weeks of CPZ-feeding (Study I), PT injection more than doubled the number 
of significant CPZ-associated changes (18–46%), with PT alone contributing 15% of all 
proteoform changes, including fructose-bisphosphate aldolase C, NADH dehydrogenase 
iron-sulfur protein 2, ATP synthase subunit-α, rab GDP dissociation inhibitor-β, septin-2 
and 5, guanine nucleotide-binding protein G(o) subunit-α, adipocyte plasma membrane-
associated protein and leukocyte elastase inhibitor A. Likewise, in the Study II, the small 
number of proteins identified following CPZ-feeding (6%) increased following the 
addition of PT (52%), with PT alone contributing 21% including aconitate hydratase, 
succinate dehydrogenase flavoprotein subunit, NADH dehydrogenase iron-sulphur protein 
2, isovaleryl-CoA dehydrogenase, tyrosine-tRNA ligase, syntaxin-binding protein 1, glial 
fibrillary acidic protein, neurofilament light polypeptide, septin-2 and calreticulin. 
Statistical comparisons of the CPZ(+PT) groups with the PT only group (Supplementary 
Table S2) revealed that at least 50% of the PT-mediated proteoform changes were either 
increased (or decreased) when combined with CPZ-feeding; in the  Study I, 25% increased 






Figure 7: Highest fold change.  
Pie charts showing the highest increase or decrease fold change in abundance of the 33 
proteoforms relative to Ctrls in the Studies I and II. PT alone or when PT was combined 











3.4.7 - Supplementary  data 
 
 
Figure 1: Histological effects of different treatments on the midline corpus callosum. 
Representative images of silver-stained brain sections from Studies I  and II experimental 






   
   
   
   











   
   
   
   











   
   
   
   











   
   
   
   









mature oligodendrocytes using Nogo A (b), astrocytes using Gfap (c) or microglia using 
Iba 1 (d) antibodies. Dashed lines represent the upper and lower borders of the MCC. 
Arrows indicate Nogo A positive cells. 
 
 






   
   
   
   











   
   
   
   











   
   
   
   











   
   
   
   









Representative images of silver-stained brain sections from Study I and II experimental 
groups to assess demyelination (a), or immunohistochemistry to identify the cell bodies of 
mature oligodendrocytes using Nogo A (b), astrocytes using Gfap (c) or microglia using 
Iba 1 (d) antibodies. Dashed lines represent the upper and lower borders of the LCC. 




Figure 3: Quantification of demyelination, cell death and gliosis in lateral corpus 
callosum. 
a) Silver staining. CPZ-feeding(±PT) led to significant demyelination and reduced silver 
staining intensity at 5 and 12 weeks (Study I and II) in the LCC. PT alone had no effect. 
Feeding 0.1% CPZ for longer (12 weeks) produced a comparable demyelination to that 




oligodendrocytosis with 0.1% CPZ as effective as 0.2% CPZ at either time point. PT alone 
had no effect. c) Gfap. Staining intensity increased in a dose dependent fashion the 
CPZ(±PT) treated groups and this was associated with an increase the number of Gfap 
positive astrocytes at both time points. PT only did not evoke a Gfap response. d) Iba 1. 
Increased Iba 1 fluorescence intensity and number of Iba 1 positive microglia were seen in 
both Studies I and II groups. Significant effects were best seen at the highest doses used at 
each time point. PT only produced no microglial response. Data are presented as mean ± 
SEM. One-way ANOVA and Tukey post hoc analysis was used to determine differences 
among groups (*p<0.05, #p<0.01, $p<0.001 and ^p<0.0001). Quantitation based on 




Figure 4: Immune staining and transfer efficiency. 
a) Immunofluorescence staining of CD4 and CD8 in the corpus callosum from the Study I 
(n=5 sections/animal, n=3 animals/group). No positive cells were detected. b) 1D gels used 










KDa) proteins from gel to PVDF membrane (n=3 bands/gel, n=2 gels). Arrows indicate 
the bands quantified. c) 40 μg spinal cord homogenate was used to detect CD4 signal from 




Figure 5: Dose and time dependent splenic atrophy. 
Representative images (a and b) of spleen from Studies I and II, respectively. Scale bar is 
5 mm. Normalized (spleen tissue mass/body weight) splenic mass is shown in c. Feeding 
with 0.2% CPZ(±PT) for 5 weeks (Study I) or 0.1% CPZ(±PT) for 12 weeks (Study II) 
resulted in a significant reduction of splenic mass. Data are presented as mean ± SEM. 
One-way ANOVA and Tukey post hoc analysis was used to determine differences among 
groups (*p<0.05 and #p<0.01). Quantitation based on analysis of 3 and 5 spleens from 

















Figure 6: Reduction of T-cell fluorescence intensity.  
Representative images of spleen (a) and quantification (b) of CD4 and CD8 from Ctrl and 
0.2% CPZ, respectively. Scale bar is 50 µm. Feeding with 0.2% CPZ showed a significant 
reduction of splenic CD4 and CD8 T-cells. Data are presented as mean ± SEM. Unpaired 
two-tailed t test was used to determine differences between groups (*p<0.05 and #p<0.01). 




Figure 7: Western blot images of CD4 and CD8 from spleen samples from both 
Studies I and II. 








Table 1: Quantification of the total number of protein spots in 2D gels of whole brain 















SP 829±6 830±15 866±12 871±19 860±12 841±12 5 weeks 
MP 766±10 802±12 798±15 835±21 779±13 778±16 
SP 808±6 802±2  791±5  789±4      - - 12 weeks 
MP 719±2 708 ±5   716 ±4 727±5  - - 







Figure 8: Pattern of proteoform change. 
Log2 fold changes in abundance for 33 proteoforms relative to Ctrl showing the pattern of 
changes (colour marked in left Y-axis) at both time points. Changes (increase or decrease) 
in abundance (≥1.5 fold) shared at both 5 and 12 weeks (Studies I and II) are shown in 
orange. Abundance changes observed following 5 weeks (Study I, ≥1.5 fold) but not 12 




weeks (Study II, <1.5 fold) of CPZ-feeding are shown in cyan. Proteoforms unchanged at 
5 weeks (<1.5 fold) but changed after 12 weeks (≥1.5 fold) are shown in blue. 
 
 
Figure 9: Functional clustering. 
Pie charts show the distribution of proteins according to a) Protein classes (characterized 
using PANTHER), b) Biological processes (categorised using GO) and c) Subcellular 

















Figure 10: Duration and treatment-dependent proteoform changes. 
Log2 fold changes in abundance for 33 proteoforms relative to Ctrl showing the changes 
with CPZ (±PT) in the a) Study I or b) Study II. Changes only in PT groups at both 5 and 
12 weeks (Study I and II are shown in c). 
c 




Table 2: Comparison of PT group to the PT+CPZ groups only 
Protein name Study I Study II 
Hexokinase 1 0.1PT=PT=0.2PT 0.1PT<PT 
Fructose-bisphosphate aldolase C 0.1PT>PT<0.2PT 0.1PT=PT 
Aconitate hydratase 0.1PT>PT<0.2PT 0.1PT>PT 
Succinate dehydrogenase flavoprotein subunit 0.1PT<PT>0.2PT 0.1PT<PT 
Malate dehydrogenase 0.1PT=PT>0.2PT 0.1PT=PT 
NADH dehydrogenase iron-sulfur protein 2 0.1PT>PT<0.2PT 0.1PT=PT 
ATP synthase subunit-α 0.1PT=PT=0.2PT 0.1PT<PT 
Voltage-dependent anion-selective channel protein 0.1PT<PT>0.2PT 0.1PT=PT 
Aspartate aminotransferase 0.1PT<PT>0.2PT 0.1PT<PT 
Ogdhl protein 0.1PT=PT=0.2PT 0.1PT<PT 
NAD-dependent protein deacetylase sirtuin-2 0.1PT>PT=0.2PT 0.1PT<PT 
Isovaleryl-CoA dehydrogenase 0.1PT=PT=0.2PT 0.1PT<PT 
Tyrosine-tRNA ligase 0.1PT<PT>0.2PT 0.1PT<PT 
Glutamate dehydrogenase 1 0.1PT=PT<0.2PT 0.1PT<PT 
Propionyl co-enzyme A carboxylase-β 0.1PT=PT=0.2PT 0.1PT<PT 
Creatine kinase U-type 0.1PT=PT>0.2PT 0.1PT=PT 
Rab GDP dissociation inhibitor-α 0.1PT<PT>0.2PT 0.1PT<PT 
Rab GDP dissociation inhibitor-β 0.1PT=PT=0.2PT 0.1PT=PT 
Vesicle-fusing ATPase 0.1PT=PT>0.2PT 0.1PT<PT 
Calcium/calmodulin-dependent protein kinase type II subunit-α  0.1PT=PT<0.2PT 0.1PT=PT 
Syntaxin-binding protein 1 0.1PT=PT=0.2PT 0.1PT<PT 
Dynamin 1 0.1PT>PT<0.2PT 0.1PT<PT 
Charged multivesicular body protein 0.1PT=PT=0.2PT 0.1PT=PT 
Glial fibrillary acidic protein 0.1PT=PT<0.2PT 0.1PT=PT 
Neurofilament light polypeptide 0.1PT<PT=0.2PT 0.1PT=PT 
Actin-related protein 2/3 complex subunit 5 0.1PT<PT>0.2PT 0.1PT=PT 
Septin-2 0.1PT>PT<0.2PT 0.1PT<PT 
Septin-5 0.1PT>PT=0.2PT 0.1PT<PT 
Guanine nucleotide-binding protein G(o) subunit-α 0.1PT=PT<0.2PT 0.1PT>PT 
Adipocyte plasma membrane-associated protein 0.1PT>PT<0.2PT 0.1PT=PT 
Calreticulin 0.1PT=PT<0.2PT 0.1PT=PT 
14-3-3 protein epsilon 0.1PT=PT=0.2PT 0.1PT=PT 
Leukocyte elastase inhibitor A 0.1PT=PT=0.2PT 0.1PT<PT 
Key: Significant (p<0.05) increases and decreases relative to PT are indicated by < and > symbols, 








3.5 - Discussion 
The present study was designed to test whether CPZ-induced oligodendrocytosis, when 
combined with PT-induced BBB disruption, could induce an ‘inside-out’ activation of the 
immune system causing infiltration and detection of CD4/8 immune cells into the brain 
parenchyma. The effectiveness of CPZ-feeding was confirmed by the reduced weight gain 
in these groups, the almost complete demyelination of the corpus callosum using the 
standard feeding paradigm of 0.2% CPZ for 5 weeks (Study I), and changes to the brain 
proteome (Chang et al., 2017, Franco-Pons et al., 2007, Gudi et al., 2014, Hiremath et al., 
1998). The results also demonstrated that 0.2% or 0.1% CPZ(±PT) produced comparable 
oligodendrocytosis but dose- and time-dependent demyelination and gliosis within the 
corpus callosum, indicating that 0.1% CPZ is as effective as higher doses when fed for a 
longer period of time. The presence of comparable oligodendrocytosis, but less marked 
demyelination and gliosis following 5 weeks of 0.1% CPZ-feeding, suggested a slower 
transition between oligodendrocytosis and demyelination and/or better clearance of myelin 
debris. In this transition state, limited gliosis may impede subsequent remyelination 
(Lampron et al., 2015) and induce a slow, progressive demyelination reminiscent of MS. 
CPZ-induced a dose dependent (0.2% > 0.1%) atrophy of the spleen and extending the 
CPZ-feeding resulted in time dependent atrophy in 0.1% CPZ(±PT)-fed groups as well. 
Likewise, CPZ produced a dose-dependent (0.2% > 0.1%) suppression of CD4/8 in the 
spleen. Prolonged low-dose feeding of CPZ for 12 weeks (Study II) did not cause a further 
decrease in CD4 compared to 5 weeks (Study II); however, with prolonged feeding, the 
reduction of CD8 deteriorated to levels seen at 5 weeks using the standard CPZ-feeding. 
Our results are thus consistent with a previous study where apoptosis of CD4 and CD8 
positive cells and atrophy of thymus were observed following 0.2% CPZ-feeding (Solti et 
al., 2015). In contrast, 5 weeks of 0.1% CPZ-feeding produced less CD4 and CD8 
suppression and no splenic atrophy, suggesting this lower dose may be a better model to 
examine the aetiology of MS. 
Following CPZ-feeding(±PT) in either experiment, there were no detectable CD4 or CD8 
signals in brain tissue. There are several possible reasons for this: firstly, insensitivity of 
the immunohistological or biochemical assays. This is unlikely, as WB sensitivity was 




available CD4/8 recombinant proteins, and both high protein loads (60–120 µg) and high 
antibody titres were used (Coorssen et al., 2002). Additionally, these results are consistent 
with previous studies using immunofluorescence and flow cytometry (Remington et al., 
2007, Tejedor et al., 2017) as well as BBB disruption using ethidium bromide or 
lysolecithin (Tejedor et al., 2017). Secondly, the BBB was breached during weeks 1–2 of 
CPZ-feeding, and this is a transient event (Kugler et al., 2007). However, whether 
infiltration occurred at this early time point, but resolved before the 5- or 12-week 
endpoints remains unknown. Was the lack of a detectable adaptive immune response the 
result of failure to generate an antigen? This seems unlikely, as marked gliosis, 
demyelination and oligodendrocytosis occurred. Alternatively, was there a direct effect of 
CPZ on peripheral immune function? This would be consistent with the observed 
suppression of CD4/8 signal in the spleens of CPZ-fed animals. It was recently reported 
that combining two weeks of 0.2% CPZ-feeding with an ‘immune booster’ (CFA) 
produced a secondary CD3+ (pan T-cell marker) response, a response that was not observed 
with 0.2% CPZ-feeding alone or when CPZ-feeding was continued (Caprariello et al., 
2018). Consequently, it can be expected that prolonged CPZ-feeding is unlikely to facilitate 
infiltration of immune cells into the CNS as continued feeding would result in sustained 
immune suppression (and reduction of mitochondrial ATP production) which is known to 
lead to declining health and death of mice. Likewise, extending observations beyond the 
cessation of CPZ-feeding is unlikely to reveal immune cell infiltration since cessation of 
CPZ-feeding results in spontaneous remyelination, reduction in myelin debris (a potential 
antigen), and cessation of glial activation (i.e., the antigen presenting cells) (reviewed in 
Gudi et al., 2014, Matsushima and Morell, 2001b, Sen et al., 2019b, Kipp et al., 2009, Praet 
et al., 2014). 
Notably, the prolonged CPZ-feeding preferentially suppressed CD8 signal intensity in the 
spleen, and these are the cells that predominate in human MS CNS pathology (Hauser et 
al., 1986). These observations are further supported by the large number of changes in 
spleen (n = 22) and peripheral blood mononuclear cell-derived (n = 5) proteoforms in the 
CPZ-fed animals (Partridge et al., 2016). In the spleen, the vast majority (87%) of these 
changes included membrane associated structural and metabolic proteins suggesting 




are responsible for the maturation, selection and proliferation of T-cells (Cesta, 2006, 
Pearse, 2006), key functions that are impeded by the ion dishomeostasis induced by CPZ 
(Venturini, 1973, Zatta et al., 2005, Moldovan et al., 2015, Varga et al., 2018). Such effects 
on the peripheral immune system may explain why the severity of disease and extent of 
peripheral immune involvement in EAE and Theiler’s murine encephalomyelitis were 
suppressed by CPZ (Emerson et al., 2001, Herder et al., 2012, Mana et al., 2009). Although, 
there is no evidence as to whether T-cells become functionally inactivated ('T-cell anergy'; 
Schwartz, 2003, Macián et al., 2004) due to the suppression of adaptive immune organs 
(e.g., thymus) following CPZ-feeding, there is some evidence indicating that CPZ may 
otherwise affect T-cell functions. Copper plays both direct and indirect roles (via 
interleukin-2) in the maturation and production of functional T-cells (Nelson, 2004). 
Consequently, it can be argued that CPZ, like other copper chelators (e.g., 2,3,2-
tetraamine), can reduce T-cell function (Bala and Failla, 1992, Hopkins and Failla, 1999). 
Moreover, it has been shown that when lymph node cells harvested from CPZ-fed mice are 
exposed to neuroantigens (e.g., concanavalin A and MBP) in vitro, there is reduced cellular 
proliferation. Likewise, reduced T-helper cell 1 cytokines (e.g., interferon-γ and tumor 
necrosis factor-α) and CD4 T-cell response to interleukin-17 are observed in EAE mice fed 
with CPZ (Mana et al., 2009). Together, these findings indicate that CPZ can modify the 
functional capacity of T-cells, and this may potentially affect migration into the CNS.  
The suppression of CD4/8 in the spleen indicated that CPZ has direct effects on the 
peripheral immune system that may limit the maturation and migration of adaptive immune 
cells to the CNS. Moreover, calcium/calmodulin-dependent protein kinase type II subunit-
α, a protein known to play a role in CD8 T-cell proliferation and the transition to a cytotoxic 
phenotype (Lin et al., 2005, Bui et al., 2000) decreased in abundance following CPZ-
feeding. Likewise, leukocyte elastase inhibitor A, a protein that supresses proteases 
including those released by T-cells (Weyer and Stucky, 2015), also decreased in 
abundance. These findings extend earlier proteomic analyses (Partridge et al., 2016) that 
found CPZ reduced the abundance of protein disulphide isomerase (subunits A2, A3 and 
A6) in spleen, a protein involved with folding and assembly of functional major 
histocompatibility complex class I molecules (Kang et al., 2009). In addition, the CPZ-




to the immune system as several studies have shown that mitochondrial dysfunction leads 
to the suppression of T-cell function and a compromised immune system (Desdin-Mico et 
al., 2018, Sukumar et al., 2016). Collectively, these findings indicate that CPZ has 
suppressive effects on the capacity of the peripheral immune system to launch a response, 
making it more difficult to address the ‘inside-out hypothesis’. Therefore, strategies to 
overcome peripheral immune organ suppression should be the next stage of investigation 
in evaluating the ‘inside-out’ hypothesis of MS using the CPZ model. 
While there is growing evidence that MS may initiate as a slow, low-grade primary 
oligodendrocytosis, a substantial gap still exists in our understanding of the molecular 
mechanisms underlying the fundamental susceptibility to and initiation of 
oligodendrocytosis (Partridge et al., 2015, Sen et al., 2019b, Stys, 2013, Stys et al., 2012). 
Therefore, a quantitative ‘top-down’ proteomic approach was carried out to resolve protein 
species from whole brains of the CPZ-fed(±PT) mice. To date, proteome analyses of MS 
have mainly assessed tissue from late-stage post mortem brain samples and cerebrospinal 
fluid (Newcombe et al., 2005, Menon et al., 2011) or EAE animals (Jastorff et al., 2009, 
Farias et al., 2012, Fazeli et al., 2013, Fazeli et al., 2010); these analyses provide useful 
insight into the ‘final readout’ of the disease or its autoimmune aspects (Farias et al., 2014, 
Dagley et al., 2014, Elkabes and Li, 2007) but not necessarily insight into the processes 
involved in disease aetiology and progression, including the role of oligodendrocytosis 
(Partridge et al., 2016, Partridge et al., 2015). 
Here, CPZ-mediated oligodendrocytosis and glial activation were confirmed using 
histology, and the changes in protein abundance were quantified using a high sensitivity 
‘top-down’ analysis rather than the more common ‘bottom-up’ (i.e., ‘shotgun’) analyses; 
this is critical, as the ‘top-down’ approach has the highest inherent capacity to resolve intact 
proteoforms (i.e., isoforms, splice variants, and post-translationally modified species) as 
well as provide better sequence coverage, and assessment of lower molecular weight 
species, with a high degree of consistency across technical and biological replicates 
(Coorssen and Yergey, 2015, Oliveira et al., 2014, Zhan et al., 2018). This approach thus 
detected changes in 33 proteoforms (16 metabolic, 7 synaptic, 5 structural and 5 




Furthermore, it also provided high quality confirmation of changes in the abundance of 25 
proteoforms of proteins previously related to MS or animal models of the disorder. In 
contrast to earlier work (Gat-Viks et al., 2015, Martin et al., 2018, Oveland et al., 2018, 
Partridge et al., 2016, Werner et al., 2010), this study used three technical replicates for 
each of the 5 biological replicates per experimental group, ensuring that only the most 
reproducible changes in proteoform abundance were assessed. Consequently, in contrast 
to the detection of ~700–1200 spots in previous studies (Farias et al., 2012, Fazeli et al., 
2013, Fazeli et al., 2010, Partridge et al., 2016), ~1650 protein spots per condition were 
resolved in this study. 
The most striking observation to emerge from the proteomic analysis was the large number 
of changes in metabolic proteoforms involved in glycolysis, Krebs cycle and oxidative 
phosphorylation pathways and the regulation of mitochondrial function. Bioinformatics 
platforms (DAVID, PANTHER, UniProt and STRING) further revealed the likely 
association between metabolic dysregulation and CPZ-feeding. Understanding the 
molecular pathways and potential PPI is important to understanding how dysregulation of 
biological processes may lead to a disease (Berggard et al., 2007, Dagley et al., 2014). It is 
thus notable that over 80% of proteins do not function alone but in complexes (Berggard 
et al., 2007). The data here suggested that 79% of the identified proteoforms may be 
clustered in two complexes, with 58% being metabolic in origin, which is consistent with 
previous observations (Berggard et al., 2007, Turvey et al., 2014). The strong PPI highlight 
the likely cross-talk and shared biochemical reactions among the metabolic proteoforms 
(Berggard et al., 2007). Interestingly, protein-to-protein connection analysis revealed that 
malate dehydrogenase may have 11 connections with other identified proteoforms, which 
was the highest seen, and that the ATP synthase subunit-α had the second highest with 7 
connections (Figure 6d). The central placement and increased inter-connectedness of 
malate dehydrogenase or ATP synthase subunit-α with other proteoforms implies that these 
proteoforms may be pivotal for CPZ-induced metabolic dysregulation. This explanation is 
further supported by the increased abundance of ATP synthase subunit-α and malate 
dehydrogenase (in contrast to the decreased abundance of most of the other identified 
metabolic proteoforms), perhaps as a compensatory response to the CPZ-induced 




feeding leads to the accumulation of protons in the inter-membrane space of mitochondria 
and increased generation of reactive oxygen species (Gat-Viks et al., 2015). Likewise, an 
increase in the abundance of aconitate hydratase (6 PPI connections, Figure 6d), an iron-
sulphur protein containing 4Fe-4S clusters, is likely to regulate iron-induced oxidative 
stress in the CPZ model. Disruption of iron metabolism is linked to increased oxidative 
stress and lipid peroxidation (Puntarulo, 2005); CPZ-feeding is associated with the 
dysregulation of iron (Varga et al., 2018) and thus increased oxidative stress results in 
accentuation of mitochondrial perturbations (Faizi et al., 2016). Moreover, we observed a 
synergy between CPZ-feeding(±PT) with regard to synaptic protein dynamin 1 (increased 
at 5 weeks in the Study I but decreased at 12 weeks in the Study II) suggesting that CPZ-
feeding interferes with the fission and fusion dynamics of mitochondria. The initial 
increase in dynamin 1 is consistent with mitochondrial response to metabolic stress, 
wherein the mitochondria divide, generating new functional mitochondria, and target 
damaged mitochondria for autophagy  (Youle and van der Bliek, 2012). Perturbations to 
the fission and fusion dynamics of mitochondria are consistent with the formation of mega-
mitochondria reported in the CNS, in particular in OLG (Acs and Komoly, 2012, Biancotti 
et al., 2008). The current data are consistent with previous investigations (Gat-Viks et al., 
2015, Werner et al., 2010, Partridge et al., 2016, Solti et al., 2015) corroborating the 
hypothesised link between mitochondrial dysregulation with CPZ-feeding and the 
emergence of structural and functional abnormalities that may predispose OLG to 
degeneration and death (Partridge et al., 2015). 
This susceptibility of OLG may be explained, in part, by the intense energy requirements 
associated with the production and maintenance of the expansive myelin sheath (Harris 
and Attwell, 2012, Bradl and Lassmann, 2010). The high metabolic rate of OLG means 
that the increased production of reactive oxygen (and nitrogen) species, coupled with their 
low levels of anti-oxidants (e.g., glutathione (Carvalho et al., 2014), metallothionein 
(Kang, 2006) and manganese superoxide dismutase (Pinteaux et al., 1998)) predisposes 
them to oxidative injury (McTigue and Tripathi, 2008, Lassmann and van Horssen, 2016). 
In addition, increased abundance (in Studies I and II) of the endoplasmic reticulum (ER) 
stress-related chaperone protein calreticulin may be associated with unfolded protein 




2015). This finding extends previously observed changes in ER proteins such as ribosome-
binding protein 1, endoplasmin (Partridge et al., 2016) and heat shock protein (Werner et 
al., 2010) reinforcing the role of ER stress in the CPZ-fed mice. The presence of heat shock 
protein and activating transcription factor 4 in MS (Cwiklinska et al., 2003, Menon et al., 
2011, Mycko et al., 2004) and EAE (Cwiklinska et al., 2003, Fazeli et al., 2010) indicate 
the association of protein misfolding and ER stress with OLG degeneration and 
demyelination. 
The apparent oligomerization of some proteoforms in response to CPZ-feeding(±PT) may 
be indicative of toxic protein aggregation (Michaels et al., 2015, Choi and Gandhi, 2018), 
effects that have also been observed in an EAE study (Dasgupta et al., 2013) and MS 
patients (David and Tayebi, 2014). The oligomerization of proteoforms has been 
documented in other studies, as with calreticulin and dynamin, assessed using SDS-PAGE 
or crystallographic analysis (Frohlich et al., 2013, Clinton et al., 2016, Jorgensen et al., 
2003). Likewise, the divergence of molecular weight was also observed in other proteomic 
studies of CPZ-fed mice (protein phosphatase 1G, 59.38 vs. 104.7 KDa) and MS 
cerebrospinal fluid (albumin, 67 vs. 180 KDa and alpha 1 antitrypsin, 47 vs. 100 KDa) 
(Hammack et al., 2004, Partridge et al., 2016). Indeed, changes in theoretical vs. 
experimentally observed isoelectric point have also been reported in previous studies on 
CPZ (ornithine carbamoyltransferase, 8.81 vs. 6.9 and ribosome-binding protein 1, 9.35 
vs. 5.0) (Partridge et al., 2016), EAE (septin-8, 5.7 vs. 6.4 and cytochrome c oxidase, 9.2 
vs. 5.8) (Fazeli et al., 2013) and MS (Ig kappa chain NIG 93 precursor, 8.1 vs. 6.5 and 
albumin, 5.5 vs. 9) (Lehmensiek et al., 2007, Hammack et al., 2004). Naturally, none of 
this key data, upon which to better design future studies to identify critical proteoforms 
(rather than just amino acid sequences), would be routinely available using any other 
current approach. 
Within the demyelinated regions, the hypertrophy of astrocytes and microglia, 
compounded by increased microglia numbers, may intensify the local energy imbalance 
and further compromise the function of OLG. Moreover, hypertrophied microglia and 
astrocytes may diminish the supportive roles played by glia at synapses leading to a pre-




2016, Matute et al., 2002)—a disturbance further implicated by changes in other synaptic 
proteoforms identified in this study. 
The abundance of synaptic-regulatory proteoforms was either decreased (rab GDP 
dissociation inhibitor-α/β and vesicle-fusing ATPase), elevated (charged multivesicular 
body protein) or displayed opposing changes (syntaxin-binding protein 1) across the two 
time points—changes in synaptic function that may contribute to alteration of mood or 
behaviour in humans or animal models (Hanin, 1978, Dutta et al., 2011, Dutta et al., 2013). 
Likewise, the changes of abundance of proteins such as calcineurin, calbindin 2 and 
parvalbumin-α, involved in neurotransmitter release, has also been reported in EAE (Fazeli 
et al., 2013). Although CPZ-feeding induce a wide range of behavioural deficits including 
motor, anxiety and cognition (reviewed by Sen et al., 2019b); the present proteome analysis 
did not seek correlation with behavioural phenotypes, other studies have argued that CPZ-
induced alteration of proteoforms involved in neurotransmitter release can result in 
cognitive decline (Dutta et al., 2013) or increased climbing, rearing and ambulatory 
behaviours (Chang et al., 2017, Franco-Pons et al., 2007, Werner et al., 2010). This study 
also revealed a marked change in neuronal and glial structural proteoforms, including Gfap, 
neurofilament light polypeptide, actin-related protein 2/3 complex subunit 5, and septins-
2 and -5, at both time points, indicating axonal and glial remodelling. Consistent with the 
capacity for CPZ to induce the hypertrophy of astrocytes and increase microglia in the 
innate immune system (Figure 2a; Supplementary Figures S1–3), a marked increase in 
proteoforms involved in structural (Gfap), signalling, and inflammatory pathways were 
observed. 
For some proteoforms, breaching the BBB negated the effects of 5 weeks of CPZ-feeding 
(e.g., septin-5, creatine kinase U-type and 14-3-3 protein epsilon). The effects of PT alone, 
or in combination with CPZ, indicate that PT did have an effect on the brain proteome, 
likely, in part at least, by altering the capacity of the BBB to regulate access to the CNS 
(Schellenberg et al., 2012, Kugler et al., 2007, Mohajeri et al., 2015). This is the first study 
to document the effects of giving PT alone on the CD4/8+ cell migration and the whole 
brain proteome. In EAE, when PT is given together with adjuvant (CFA) and antigen 




inflammation and demyelination occurs (Bennett et al., 2010). In addition, increased rates 
of relapsing-remitting episodes (Mohajeri et al., 2015), increased infiltration of serum 
albumin in the spinal cord (Farias et al., 2014) and suppression of the anti-inflammatory 
interleukin-10 (Arimoto et al., 2000) are observed. However, the extent to which these 
changes are attributable to PT alone, or the combined treatments used to induce EAE, 
remains un-documented. However, other studies have shown that PT alone evokes changes 
in BBB function leading to increased protein infiltration into the brain  (~15 days; Amiel, 
1976), or disruption of G-protein function  (~40 days; Shah et al., 1997) following PT 
administration. In the present study, repeated injections of PT during the second and third 
weeks of CPZ-feeding resulted in proteoform changes after 5 weeks (Study I) or 12 weeks 
(Study II) indicating that PT injections alone have long-term effects at least on the brain 
proteome. Moreover, the proteomic analysis highlighted proteoform differences between 
the CPZ vs. EAE models; specifically, CPZ-feeding resulted in increased guanine 
nucleotide-binding protein G(o) subunit-α, glutamate dehydrogenase 1 and malate 
dehydrogenase, which decrease in EAE (Linker et al., 2009, Farias et al., 2012, Fazeli et 
al., 2010), perhaps reflecting the different underlying aetiologies (potentially including 
changes in specific proteoforms). Whether these opposing changes result specifically from 
the use of peripherally administered exogenous myelin antigens (e.g., MBP, PLP and 
MOG) in EAE or endogenously generated antigens (i.e., myelin debris) in the brain of 
CPZ-fed mice remains unclear but would seem likely. 
Despite our rigorous efforts to minimize the experimental variables, we acknowledge 
certain inherent limitations in the analytical approach. This study relied on only two time 
points (i.e., 5 and 12 weeks) of CPZ-feeding(±PT), which did not allow us to determine if 
or when the identified proteoforms returned to baseline nor to correlate proteome changes 
with the initiation of oligodendrocytosis, demyelination and gliosis. Moreover, the sub-
femtomole in-gel detection sensitivity may well have missed significant changes in very 
low abundance species, although these remain a substantial issue with all available 
analytical approaches if high quality final identifications are a serious expectation (Noaman 
et al., 2017). Furthermore, reliance on existing databases that address only amino acid 
sequences, as well as an apparent developing reliance in the field for online bioinformatics 




(Armirotti and Damonte, 2010, Kachuk and Doucette, 2018, Perkel, 2012), tends to further 
emphasize the fundamental importance of developing even more sensitive analytical 
approaches to routinely quantifying and fully characterizing proteoforms in order to 
provide the most direct understanding of the molecular mechanism underlying human 
diseases like MS. 
 
3.6 - Conclusions 
This study confirmed that CPZ-feeding(±PT) in mice induced dose- and time-dependent 
oligodendrocytosis, demyelination and gliosis, but was not associated with any detectable 
invasion of peripheral adaptive (CD4/8) immune cells into the CNS. In the periphery, CPZ-
feeding induced a dose-dependent suppression of splenic CD4/8 and organ mass, 
suggesting that this peripheral action of CPZ was a major impediment to studying the role 
of the peripheral immune system following demyelination and disruption of the BBB. 
Notably, oligodendrocytosis, demyelination and gliosis with the low dose of CPZ for 5 
weeks (Study I) resulted in minimal splenic atrophy and less severe adaptive immune 
system suppression, indicating that this might be a better model to test the ‘inside-out’ 
theory of MS. Moreover, using a highly sensitive ‘top-down’ proteomic approach, changes 
in 33 brain proteoforms were identified in the CPZ-fed mice, the majority of which were 
found to be associated with mitochondrial function. This strongly suggests that 
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4.1 - Abstract  
Cuprizone (CPZ)-feeding in mice induces atrophy of peripheral immune organs (thymus 
and spleen) and suppresses T-cell levels, thereby limiting its use as a model for studying 
the effects of the immune system in demyelinating diseases such as Multiple Sclerosis 
(MS). To investigate whether castration (Cx) can protect the peripheral immune organs 
from CPZ-induced atrophy and enable T-cell recruitment into the central nervous system 
(CNS) following breach of the blood brain barrier (BBB), three related studies were carried 
out. In Study III, Cx prevented the dose-dependent reductions (0.1% < 0.2% CPZ) in 
thymic and splenic weight, size of thymic medulla and splenic white pulp, and CD4 and 
CD8 (CD4/8) levels remained comparable to gonadally intact (Gi) control males. 
Importantly, 0.1% and 0.2% CPZ were equipotent at inducing central demyelination and 
glial activation. In Study IV, combining Cx with 0.1% CPZ-feeding and BBB disruption 
with pertussis toxin (PT) enhanced CD8+ T-cell recruitment into the CNS. The increased 
CD8+ T-cell level observed in the parenchyma of the cerebrum, cerebellum, brainstem and 
spinal cord were confirmed by flow cytometry and western blot analyses of CNS tissue. In 
Study V, PT+0.1% CPZ-feeding to Gi female mice resulted in similar effects on the 
peripheral immune organs, CNS demyelination and gliosis comparable to Gi males, 




in Study IV. The combination of Cx+0.1% CPZ-feeding+PT indicates that CPZ-induced 
demyelination can trigger an ‘inside-out’ immune response when the peripheral immune 
system is spared, and may provide a better model to study the initiating events in 
demyelinating conditions such as MS. 
  
Key words: castration, gonadally intact, demyelination, gliosis, inside-out, peripheral 
immune organs, atrophy. 
 
4.2 - Introduction 
Multiple Sclerosis (MS) is a heterogeneous, inflammatory demyelinating disease of the 
human central nervous system (CNS) for which the early initiating events and thus 
underlying aetiology remain unclear (Stys et al., 2012; Stys, 2013; Partridge et al., 2015). 
Currently, there are no effective treatments to prevent disease initiation and progression 
(Sriram and Steiner, 2005; Vargas and Tyor, 2017). Several animal models such as 
experimental autoimmune encephalomyelitis (EAE; Glatigny and Bettelli, 2018), Theiler’s 
murine encephalomyelitis virus (Carrillo-Salinas et al., 2017), and the diphtheria toxin 
model (Traka et al., 2016) mimic various clinical and pathological features of the disease 
but no single model replicates the full complexity of disease initiation and progression. 
Nonetheless, the cuprizone (CPZ) model possesses many key characteristics of MS 
including demyelination and gliosis (reviewed in Sen et al., 2019b). According to these 
pathological features, the CPZ model was selected as the most appropriate tool to test the 
‘inside-out’ theory of disease initiation (Caprariello et al., 2018). According to this theory, 
the initiating event in MS is an early, slow degeneration of myelin, which causes the release 
of potential myelin antigens (as debris) that then activate microglia and macrophages in the 
presence of proinflammatory mediators. Consequently, myelin antigen presentation by 
antigen presenting cells attracts peripheral T- and B-cells into the CNS, triggering a 
secondary inflammatory reaction that ultimately leads to the progressive autoimmune 
response characterized clinically (Stys et al., 2012; Stys, 2013).  
While there have been numerous reports of CPZ being used to study demyelination, these 
have not established the involvement of peripheral T-cells at the sites of CPZ-induced 
demyelination in the CNS (Remington et al., 2007; Partridge et al., 2016; Traka et al., 2016; 




of the BBB, T-cells have no access to the CNS (Remington et al., 2007; Skripuletz et al., 
2011; Tejedor et al., 2017). However, even when the BBB was breached using pertussis 
toxin (PT), CPZ evoked marked CNS demyelination, gliosis and changes in the abundance 
of proteoforms involved in metabolism, immune and synaptic functions, without detectable 
T-cell infiltration (Sen et al., 2019a). Studies have indicated  that the apparent failure to 
trigger a T-cell-mediated CNS immune response is due to CPZ-induced atrophy of the 
thymus (the organ responsible for T-cell maturation and differentiation) and spleen (the 
organ of T and B lymphocyte production) (Solti et al., 2015; Martin et al., 2018; Sui et al., 
2018; Sen et al., 2019a). Two additional effects of CPZ on the integrity and function of the 
peripheral immune system include an increase in the abundance of splenic arginase-I (a 
protein expressed by myeloid-derived suppressor cells in spleen) and a decreased 
abundance of protein disulphide isomerise (a protein required for assembly of the major 
histocompatibility complex-I) (Partridge et al., 2016). A change in the abundence of these 
proteins results in suppressed T-cell function (Kang et al., 2009). Likewise, proteoforms of 
calcium/calmodulin-dependent protein kinase type II subunit-α and leukocyte elastase 
inhibitor A, involved in T-cell functions, decreased in abundance following CPZ-feeding 
(Sen et al., 2019a). Moreover, marked changes in the number of mitochondrial proteoforms 
are suggested to suppress T-cell function (Sen et al., 2019a). Furthermore, a significant 
reduction in thymic and splenic T-cell numbers as well as thymocyte apoptosis was 
observed after 1-2 weeks of CPZ-feeding (Solti et al., 2015; Martin et al., 2018). 
Collectively, these studies indicate that the absence of adaptive immune cell involvement 
in the CNS of CPZ-fed mice is not only due to the intact BBB but is also due to suppression 
of the adaptive immune system. However, when the BBB was disrupted by PT and the 
peripheral immune system ‘boosted’ via injection of Complete Freund’s Adjuvant (CFA), 
an increased pan T-cell marker (CD3+) response was observed in the CNS of CPZ-fed mice 
(Caprariello et al., 2018).  
Circulating T-cell numbers are maintained by the thymus gland through various processes 
including maturation, selection, differentiation and the release of mature T-cells into the 
blood. During puberty, in both humans and animals, the thymii become atrophied and 
inactivated (physiological thymic involution) when circulating androgen concentrations 




administration (Oner and Ozan, 2002) or CPZ-feeding  produced similar effects to natural 
androgen-induced physiological thymic involution, including thymic atrophy, with the 
remaining tissue displaying enlarged and degraded mitochondria, lipid droplets and 
enlarged lysosomes (Solti et al., 2015). Androgen deprivation following castration (Cx) 
increased T-cell levels, thymic function (maturation and differentiation of T-cells) in young 
and aged mice (Roden et al., 2004; Sheean et al., 2015), and splenic function (T- and B-
cells production) in adult mice (Roden et al., 2004). Likewise, Cx increased thymic mass 
(hypertrophy) and resulted in complete restoration of thymus structure (both lymphocytic 
and epithelial) and function in the primary peripheral immune organs (thymus and bone 
marrow), including associated T-cell levels (Sutherland et al., 2005). However, no study 
has investigated whether Cx-induced preservation of the thymic and splenic size and 
function can surmount the suppressive effects of CPZ on the peripheral immune system 
(i.e. maintain structure and function). Furthermore, no study has tested whether the effect 
of BBB disruption during CPZ-feeding in female mice, which have naturally low 
testosterone levels, can lead to T-cell infiltration into the CNS. This is important as MS is 
seen ~2-3 times more frequently in females than males (Ahlgren et al., 2011; Harbo et al., 
2013).  
The current work tested the hypothesis that Cx protects against the negative effects of CPZ-
feeding on thymus and spleen and thus enables T-cell recruitment into the CNS following 
disruption of the BBB by PT. To investigate this hypothesis, three inter-related studies 
were carried out using CPZ-feeding in male and female mice. In Study III, surgical Cx was 
used to protect the adaptive immune system against CPZ effects. In Study IV, Cx was 
combined with 0.1% CPZ-feeding and BBB disruption to test whether the CPZ-induced 
demyelination initiated an ‘inside-out’ T-cell-mediated response in the CNS. In Study V, 
gonadally intact (Gi) female mice were fed 0.1% CPZ and the BBB disrupted to test 
whether females could mount a T-cell response in the CNS, as seen in Study IV. The results 
suggest a new mouse model for studying the initiating events of MS and further testing the 






4.3 - Materials and methods 
4.3.1 - Animals and monitoring 
Weaned (three-week-old) male and/or female C57BL/6 mice (n=187) were purchased from 
the Animal Resources Centre, Murdoch, WA, Australia (www.arc.wa.gov.au). Mice were 
acclimatized for one week prior to each study and housed (5 animals/ventilated GM500 
cage, Tecniplast, Buguggiate, VA, Italy) in a controlled environment (12-hours light/dark 
cycle, 50-60% humidity and 21-23°C room temperature, RT). Standard rodent powder 
chow (Gordon's Specialty Stockfeeds, Yanderra, NSW, Australia) and water were 
available ad-libitum. Mice were weighed individually at the beginning of the studies, every 
third day, and prior to sacrifice. Research and animal care procedures were approved by 
the Western Sydney University animal ethics committee (A11938) in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes as laid 
out by the National Health and Medical Research Council of Australia.  
 
4.3.2 - Bilateral orchiectomy (castration, Cx) 
Adolescent (four-week old) mice (n=77) were surgically castrated under deep anaesthesia 
using isoflurane (Cenvet, Blacktown, NSW, Australia) 2-3% in 100% oxygen. Mice 
underwent orchiectomy at this specific age to precede the onset of normal age-related 
thymic atrophy. The ventral midline of the scrotum was incised (~1 cm) and the tunica 
exposed. The vas deferens and spermatic artery of each testis were ligated with absorbable 
polyglycan sutures and the testicles were excised. Then the incision was closed with silk 
thread (1 stitch) and Michel clips (Fine Science Tools, North Vancouver, BC, Canada). 
Subcutaneous analgesia (Meloxicam 3 mg/kg, Randdolab, NSW, Australia) was injected 
twice (at the end of surgery and 12 hours later) and mice were kept under a heat lamp 
(~37oC) until awake and mobile. All mice (Cx and Gi) were inspected daily to identify any 
abnormal changes in gait, movement, posture, and skin; no abnormalities were observed. 
 
4.3.3 - Cuprizone administration 
0.1% or 0.2% CPZ (w/w, [Bis(cyclohexanone)oxaldihydrazone], Sigma-Aldrich, St. 




demyelination and gliosis (Figure 4, Study III panel) but less thymic and splenic atrophy 
than 0.2% CPZ (Figure 1, Study III panel), 0.1% CPZ was used in studies III and IV. CPZ 
was mixed with powdered chow to induce demyelination as shown previously (Sen et al., 
2019a). Animals were fed either 0.1% or 0.2% CPZ for two weeks. Chow was prepared 
daily with and without CPZ. 
 
4.3.4 - Pertussis toxin injection 
In Studies IV and V, intraperitoneal injections of PT (Sigma-Aldrich) were used to disrupt 
the BBB as described previously (Sen et al., 2019a). PT (400 ng/mouse, Sigma-Aldrich) 
was injected on days 5, 7, and 9 of CPZ-feeding in Studies IV and V.  
 
4.3.5 - Experimental groups 
In Study III, male mice were randomly assigned to one of six groups (n=11/group): controls 
(Ctrl), 0.1% CPZ and 0.2% CPZ (all Gi), Cx, Cx+0.1% CPZ and Cx+0.2% CPZ. In Study 
IV, male mice were randomly assigned into one of 7 groups: Ctrl, PT, 0.1% CPZ (all Gi) 
and Cx, Cx+PT, Cx+0.1% CPZ and Cx+0.1% CPZ+PT (n=11/group). In Study V, Gi 
female mice (n=11/group) were randomly assigned to one of four experimental groups: 
Ctrl, PT, 0.1% CPZ and 0.1% CPZ+PT. Mice were assigned to each analysis as follows: 3 
animals/group for western blot analysis, 3 animals/group for paraffin embedded tissue 
staining, 5 animals/group for free floating tissue staining.  
 
4.3.6 - Western blot  
Western blot was carried out as previously described (Sen et al., 2019a). Briefly, mice (n=3 
animals/group) were euthanised and immediately thereafter brains, spinal cords, thymii and 
spleens were harvested, washed thoroughly with ice cold 0.01 M phosphate-buffered saline 
(PBS, Sigma-Aldrich) containing a protease inhibitor cocktail (4 µM staurosporine, 1 mM 
α-napthyl phosphate and 1 mM sodium orthovanadate) to prevent protein degradation 
during sample preparation and then snap frozen in liquid nitrogen. Frozen samples were 
pulverised, solubilized (~1 µl/1 µg tissue) in pre-chilled lysis buffer (25mM Tris, 1 mM 




4°C, for 1 hour. Total protein in the supernatant was quantified in each sample using the 
EZQ protein quantitation kit (Life Technologies, Eugene, OR, USA) with bovine serum 
albumin (Ameresco, Solon, OH, USA) as a calibration standard (Butt and Coorssen, 2005; 
Churchward et al., 2005). Thymus, spleen, brain, spinal cord and standard purified CD4/8 
recombinant proteins (Sino Biological, Wayne, PA, USA) were resolved by 10% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 100 V for 2 hours at 
4°C) and then transferred onto polyvinylidene difluoride membrane (PVDF, 0.22 µM pore 
size, Bio-Rad, Hercules, CA, USA) for 2 hours at 4°C; transfer efficiency,  determined as 
previously described (Sen et al., 2019a), was 95.6±1.7% (Supplementary Figure 1a,b). The 
PVDF blots were incubated at RT in blocking solution (5% skimmed milk (Coles, 
Hawthorn East, VIC, Australia), in 0.05% Tris buffered saline-Tween-20, TBST 
(Ameresco) and 1% polyvinylpyrrolidone (Sigma-Aldrich). Membranes were then probed 
with primary antibodies (Abs) to detect the signal of T-cell subtypes according to their 
cluster of differentiation (CD) - either anti-CD4 (1:500, Abcam, Cambridge, UK) or anti-
CD8 - (1:75, Santa-Cruz Biotechnology, Dallas, TX, USA) for 1 hour at RT. In the next 
step, each blot was incubated with a horseradish peroxidase-conjugated (HRP) compatible 
secondary antibody (CD4 and CD8 blots were incubated with goat anti-rabbit 1:2000 and 
mouse anti-mouse, 1:500, respectively) for 1 hour at RT. Protein signals were visualized 
using an enhanced chemiluminescence detection reagent (1 mL/10 cm2 for 1 minute, 
Luminata Crescendo Western HRP Substrate, Merck-Millipore, Burlington, MA, USA) 
and scanned using an ImageQuantTM FUJI LAS-4000 (GE Healthcare, Chicago, IL, USA). 
The intensity of each protein band was measured using ImageJ software 
(https://imagej.nih.gov/ij/) to calculate the arbitrary value of each single band and the local 
background was subtracted from these values. The intensity of each band (n=3 
bands/mouse, n=3 mice/group) was expressed as a raw value and presented relative to the 
values obtained from Ctrl mice. The sensitivity of the Abs used in western blot analyses 
were confirmed by comparing the molecular weight and band size of the signals obtained 
from brain, splenic and thymic samples to the signals of the standard purified CD4 or CD8 






4.3.7 - Flow cytometry analysis 
T-cell levels in Study IV were also analysed using flow cytometry of thymic, splenic and 
CNS tissue (n=3 mice/group) to further confirm the western blot and 
immunohistochemistry results. A standardised application protocol for flow cytometric 
analysis of T-cell subsets (Miltenyi Biotec, www.miltenyibiotec.com) was applied to 
prepare a cell suspension suitable for single cell detection. Briefly, following perfusion 
with PBS, each organ was placed in a Petri dish and covered with 5 mL of freshly prepared 
cold (~5°C) PEB buffer (0.5% bovine serum albumin, and 2 mM EDTA dissolved in 0.01 
M PBS) and then organs were subjected to mechanical dissociation to obtain a cell 
suspension. A nylon mesh strainer (70 µm) was used to remove tissue debris and the cell 
suspension was centrifuged (300 g, 10 min, 4°C). Pellets were resuspended in PEB buffer, 
centrifuged (300 g, 10 min, 4°C), and washed with 2 mL 0.01 M PBS before resuspending 
cells in 1mL of 0.01 M PBS. Cells (5 µl) were stained with Trypan Blue (Life 
Technologies) and counted (Countess automated cell counter, Invitrogen). Each sample 
was divided into three aliquots: unstained aliquot (negative control) and stained aliquots 
(CD4 and 8). Cells were stained (~1x105 cells/mL) separately with either fluorochrome 
conjugated FITC anti-mouse CD4 or PE/Cy7 anti-mouse CD8a antibodies (1:50 dilution, 
BioLegend, San Diego, CA, USA) for 1 hour in the dark at RT while shaking. After adding 
2 mL of 0.01 M PBS and centrifugation (300 g, 10 min, 4°C) the pellet was resuspended 
in 100 µl of 0.01 M PBS and analysed using a MACSQuantⓇ Flow Cytometer (Bergisch 
Gladbach, NRW, Germany). A total of 20,000 events were analysed for each sample. The 
lymphocyte gate was defined by forward and side scatters and the CD4+ and CD8+ T-
lymphocytes gates were defined by FITC and PE channels, respectively. Data were 
analysed on FlowJo software (version 10, LLC, Ashland, OR, USA) and presented as the 
absolute number of dot blots/quadrant 1(Q1) or 3 (Q3) for CD4 and CD8 T-cell 








4.3.8 - Histology and immunohistochemistry  
4.3.8.1 - Tissue preparation 
Mice (n=5/group in each study) were deeply anaesthetized with isoflurane (2-3% in 100% 
oxygen) and perfused transcardially with cold 0.9% saline followed by 4% 
paraformaldehyde (in 0.1 M phosphate buffer, Sigma-Aldrich). Samples (CNS, thymii and 
spleens) were collected from the different groups and postfixed using 4% 
paraformaldehyde at 4°C for three days, then kept in 0.02% sodium azide (prepared in 0.01 
M PBS, Sigma-Aldrich) at 4°C until processed for staining within one month. Whole CNS 
was immersed in 30% sucrose solution for 48 hours at RT until it sank, confirming cryo-
protection. Tissue was then embedded in 4% gelatine (Chem-Supply, Gillman, SA, 
Australia) in cryomolds (Sakura, Torrance, CA, USA). Gelatine embedded tissue was then 
embedded in Tissue-Tek™ optimal cutting temperature compound (Sakura) and sectioned 
with a cryostat (Leica, Wetzlar, HE, Germany) at -20oC. Serial coronal sections of the CNS 
(40 µm) were either transferred to 6-well plates containing 0.01 M PBS (free floating for 
immunohistochemistry), or mounted onto 0.5% gelatine-coated slides for silver staining. 
Sections were placed in anti-freezing solution (glycerol, ethylene glycol and 0.01 M PBS 
at 1:1:2 by volume) at -20°C until stained (≥1 month), as described previously (Sen et al., 
2019a). To prepare tissue for haematoxylin and eosin (H&E) staining, thymii and spleens 
were postfixed in 10% formalin for three days and then dehydrated in ethanol (70%, 80%, 
95% and 100%) for 2 hours each, cleared using xylene for 2 hours and embedded in 
paraffin (SLEE medical GmbH, Mainz, Germany). Organs were placed in embedding 
cassettes (Sigma-Aldrich) and kept at 4oC to form solid paraffin blocks. Then tissue blocks 
were sectioned (10 µm) using a manual rotary microtome (Leica Microsystem, Wetzlar, 
Germany). A consecutive series of tissue sections were mounted onto glass gelatine coated 
slides and dried at RT for 1 hour. Excess paraffin wax was removed from the slides by 
heating them at 55oC for 30 minutes). 
 
4.3.8.2 - Silver myelin staining and quantification  
Staining and quantification were performed as previously described (Sen et al., 2019a). 
Briefly, slide mounted brain sections were air-dried for 48 hours at RT and then immersed 




of pyridine (VWR, Radnor, PA, USA) and acetic anhydride (Merck, Darmstadt, HE, 
Germany) followed by incubation with freshly prepared ammonical silver nitrate (Chem-
Supply) for 45 minutes for staining. Mounting medium (DPX, Merck) and cover slips 
(Knittel Glass, Braunschweig, NI, Germany) were used to cover the sections and left to dry 
for 72 hours at RT. All brain sections were imaged with bright field Olympus Carl Zeiss 
microscopy (Zeiss, Jena, TH, Germany) using the same settings (i.e. exposure time, 
magnification and illumination intensity). Images were analysed by ImageJ software as 
follows: for each section, the region of interest (midline corpus callosum, MCC) was 
contoured and the mean optical density was measured as mean grey value (i.e. summation 
of all the pixels in the region of interest divided by the number of pixels, with individual 
pixels ranging from black (0) to white (256)). The results were plotted as the reciprocal of 
the light intensity to measure the amount of myelin. The anatomical landmark was 
identified as described previously (Paxinos and Franklin, 2012; Sen et al., 2019a). 
 
4.3.8.3 - Immunofluorescence staining and quantification 
Staining and quantification were carried out as previously described (Sen et al., 2019a). In 
short, non-specific binding was blocked using 10% goat serum (Sigma-Aldrich) for 2 hours 
at RT and sections were incubated overnight at RT with primary Abs: glial fibrillary acidic 
protein (anti-Gfap-AlexaFluor 488, 1:1000, Merck-Millipore), ionized calcium-binding 
adaptor molecule 1 (rabbit anti-Iba 1, 1:1000, Wako, Japan), anti-CD4 (rabbit anti-CD4, 
1:200, Abcam), or anti-CD8 (mouse anti-CD8, 1:100, Santa-Cruz Biotechnology), then 
washed thrice with 0.01 M PBS. Sections were then incubated with secondary 
corresponding Abs (either goat anti-rabbit IgG, 1:500, Invitrogen (USA) or mouse anti-
mouse IgGκ, 1:100 (Santa-Cruz Biotechnology) for 2 hours at RT and washed 3x10 
minutes with 0.01 M PBS. Sections were counterstained with 1.5 mg/ml of nuclear counter-
stain Vectashield plus 4′,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, 
Burlingame, CA, USA) and imaged using a fluorescence Olympus Carl Zeiss microscope 
(Zeiss, Germany) using the same exposure time and magnification settings. Fluorescence 
intensity measurement of Gfap and Iba 1 stained sections was performed with ImageJ 
software as described above. Positively stained cells with Gfap and Iba 1 (and co-stained 




software (see Figure 4 and Supplementary stereology table) as described previously (Sen 
et al., 2019a). However, due to the low counts per unit area and regional heterogeneity of 
CD8+ cell distribution; these cells were counted manually across the entirety of each 
section in cerebrum, cerebellum, brainstem and spinal cord (3 animals/group, 10 
sections/brain or spinal cord, 5 sections/cerebellum or brainstem). In order to confirm that 
the CD8+ expressing cells were a distinct population (i.e. from microglia) brain and spinal 
cords sections were double labelled with CD8 and Iba 1 antibodies and co-stained with 
DAPI.  
 
4.3.8.4 - Assessment of BBB integrity  
To assess the permeability of the BBB following PT injection in Study IV, peroxidase-
based immunohistochemistry was used to visualise immunoglobulin G (IgG) in the CNS. 
In Study V, the same method was used to breach BBB and the results were consistent with 
Study IV (data not shown). Free floating coronal sections were washed as described above 
and non-specific binding and endogenous peroxidase activity were blocked  using 
peroxidase blocking solution (Dako, Carpinteria, CA, USA). Sections were then incubated 
for 1 hour at RT in biotinylated anti-mouse IgG secondary Ab (1:100 dilution, Vector 
Laboratories). Sections were then incubated with avidin-biotin–peroxidase complex (1:200 
dilution, ABC complex, Vector Laboratories) for 30 minutes at RT, and visualised using 
diaminobenzidine (DAB, Vector Laboratories) solution (0.05% DAB in 0.005% H2O2). 
All incubation and reaction steps were performed in parallel for all sections, at RT, to 
ensure that the DAB staining was comparable (i.e. equal number of sections from each 
experimental group exposed to the same batch of DAB stain and incubated for the same 
amount of time). Sections were then mounted on slides and cover-slipped using DPX 
mounting medium and left to dry overnight. Sections were imaged by bright field Olympus 
Carl Zeiss microscopy (Zeiss, Germany) and quantified using ImageJ software to measure 







4.3.8.5 - Haematoxylin and Eosin (H&E) staining 
Staining with H&E was performed in thymus and spleen tissue to assess the structural 
changes associated with CPZ-feeding. Following removal of excess paraffin from the 
tissue (see tissue preparation section), slides were rinsed in xylene for 10 minutes (to 
remove the remaining paraffin wax) and rehydrated by dipping in a series of alcohol 
washes (100%, 80%, 50% and 0%, 5 times each solution). In the next step, haematoxylin 
(4 g/L, Merck-Millipore) was used for 3 minutes to stain the sections followed by washing 
with tap water. Slides were then dipped into acid alcohol for 30 seconds to differentiate the 
cytoplasm and transferred into Scott’s Blueing solution to stain the nucleus. Then tissue 
was stained with eosin (0.5%) to counterstain acidic components of cells (e.g. cytoplasmic 
proteins) and washed with tap water followed by ascending concentrations of alcohol 
(70%, 95% and 100%) to dehydrate the tissue and xylene to clear it. Slides were covered 
with mounting medium (Merck) and sealed with cover slips (Cardiff et al., 2014). Tissue 
sections were imaged with an Olympus Carl Zeiss bright field microscopy. ImageJ 
software was used to analyse various histomorphometric measurements of the thymus and 
spleen as previously described (Tryphonas et al., 2004). Briefly, the total area (mm2) of 
each thymus section (3 mice/group, 5 sections/mouse) was contoured and measured. All 
regions of thymic medulla in each section were also contoured individually to obtain the 
area of each region; these values were summed to yield the total medullary size of each 
thymic section. The total section area was then subtracted from the medulla area to get total 
thymic cortex area. Averages of cortical and medullary values of each mouse in all groups 
were calculated. Finally, the average values of cortex were divided by average medullary 
values to obtain thymic cortex/medulla ratio. The same strategy was applied to spleen 
sections in order to measure splenic red pulp/white pulp ratio.  
 
4.3.9 - Statistical analysis and graphing 
All data were presented as mean ± standard error of the mean (SEM). Body weight data 
was analysed using the two-way analysis of variance (ANOVA). All other data were 
analysed using a one-way ANOVA and individual differences were determined using 
Newman-Keuls post hoc multiple comparison analyses. Statistically significant differences 




Statistical analyses and graphing were performed using GraphPad Prism 7.03 software 
(www.graphpad.com, San Diego, CA, USA). Figures were assembled using CorelDRAW 
graphics design software version 2019 (www.coreldraw.com, Ottawa, ON, Canada).  
 
4.4 - Results 
4.4.1 - Study III: Castration counteracts the peripheral effects of CPZ  
To quantify the impact of CPZ on the thymus and spleen, and to test whether Cx could 
protect these organs against the effects of CPZ-feeding, prepubescent male C57BL/6 mice 
(i.e. (four weeks old) were surgically castrated and subsequently fed with powdered chow 
containing 0.1% or 0.2% CPZ for two weeks, in parallel with Ctrl mice. Weight gain in all 
Cx males (Cx, Cx+0.1% CPZ and Cx+0.2% CPZ groups) was significantly reduced 
compared to Gi CPZ-fed males and Gi Ctrl during the first three days of CPZ-feeding and 
this effect continued to the end of the study. During the second week of CPZ-feeding, 
significant reductions in body weight gain were observed in the CPZ-fed animals compared 
to healthy Ctrls (Supplementary Figure S2). By the end of the experiment, the weight 
differences between Ctrl mice and those fed 0.1% or 0.2% CPZ were approximately 9% 
and 15%, respectively. This rank order was preserved when comparing Cx alone and 0.1% 
or 0.2% CPZ Cx animals, in which the weight differences were approximately 8% and 15% 
respectively. Following 2 weeks of 0.1% or 0.2% CPZ-feeding, the size (Figure 1a) and 
weight of the thymus and spleen (normalised to body weight, Figure 1b, Study III panels) 
in Gi males was reduced (p<0.05) in a dose dependent manner (thymus: 13.3±0.03% vs. 
28.4±0.03%, spleen: 27.6±0.04% vs. 42.4±0.04% for 0.1% vs. 0.2% CPZ) compared to 
their respective Ctrls. In contrast, thymic mass was increased by 69.0±4.1%, (p<0.05) 
following Cx compared to Gi Ctrls at 2 weeks and this effect remained despite CPZ-
feeding. While the splenic mass of Cx mice was not different to Gi Ctrls, Cx did prevent 











Figure 1: Effects of CPZ-feeding or castration (Cx) on thymus and spleen size and weight 
Representative examples of the gross appearance of the thymus and spleen organs (a) and 
quantification of the wet weights (b) of the different treatment groups used in the three 
different studies. In gondally intact (Gi) males and females, CPZ-feeding produced a dose-
dependent reduction in immune organ mass (p<0.05). In the Cx groups, Cx significantly 
increased thymic mass compared to Gi males and females (p<0.05) and prevented CPZ-
induced thymic and splenic atrophy (p>0.05). In Gi female mice CPZ-induced atrophy was 
indistinguishable to that observed in Gi males. Data are presented as mean (±SEM, one-
way ANOVA, n=10 thymii or spleens/group). * indicates significant difference from Ctrl 










   
   
   
   






   
   
   
   













   
   
   
   
   
   






   
   
   
   
   
   
   








                                                                            




4.4.2 - Castration restored the histological architecture of thymus and spleen 
In Gi male mice, CPZ-feeding induced dose-dependent reductions in medulla area (0.2% 
CPZ: 18.5±1.0 > 0.1% CPZ: 9.6±1.0 mm2) without any change in cortical area (Figure 2a,c 
Table 1) resulting in a dose-dependent increase in the thymic cortex/medulla ratio (0.2% 
CPZ: 1±0.03 > 0.1% CPZ: 0.7±0.04 > Ctrl: 0.5±0.03). In contrast, the thymic 
cortex/medulla ratio was unchanged by feeding 0.1% or 0.2% CPZ to Cx mice (Table 1). 
Similarly, H&E staining confirmed that feeding CPZ to Gi mice induced a dose-dependent 
(0.1% < 0.2% CPZ) reduction in splenic red pulp/white pulp ratio (Figure 2b,d lower panel; 
i.e. the white pulp size was affected by CPZ-feeding (Table 1). In contrast, CPZ-feeding 
had no effect on white pulp area following Cx, i.e. white pulp size of Cx+0.1% and 
Cx+0.2% CPZ groups were indistinguishable (p<0.05) from Gi Ctrl spleens. Taken 
together, these results showed that Cx protected mice against the deleterious effects of 
CPZ-feeding on the spleen and thymus regardless of CPZ dose.  
 
Table 1: Histomorphometric evaluation of thymii and spleens from Gi and Cx males, and 
Gi female mice, exposed to CPZ. 








Ctrl 33.8±3.3   40.1±2.6   7.7±0.9   14.5±1.4   
0.1% CPZ 32.6±3.7   18.5±1 ↓ 6.7±0.5   9.5±1.3 ↓ 
0.2% CPZ 27.1±3   9.6±1.1 ↓ 5.7±0.6   5.9±0.4 ↓ 
Cx 33.1±4.3   56.6±2.4 ↑ 8.1±0.6   15.3±1.5   
Cx+0.1% CPZ 32.2±0.8   51.7±2.5 ↑ 7.9±0.3   14.3±1.1   








Ctrl 33.8±3.3   40.14±2.57   7.7±0.9   14.5±1.5   
PT 35.0±3.9   39.37±4.23   7.0±1.1   13.9±0.6   
0.1% CPZ 32.6±3.7   18.45±0.97 ↓ 7.4±0.5   8.5±0.7 ↓ 
Cx 33.1±4.3   56.62±2.41 ↑ 8.1±0.6   15.3±1.5   
Cx+PT 31.6±4.3   44.94±4.44 ↑ 8.4±0.4   14.7±0.5   
Cx+0.1% CPZ 32.2±0.8   51.67±2.46 ↑ 7.9±0.3   14.3±1.1   







Ctrl 32.3±3.4   41.19±3.1   8.2±0.8   15.2±1   
PT 28.8±3.1   39.11±4.2   8.4±0.2   15.9±1.5   
0.1% CPZ 28.1±1.8   17.39±0.8 ↓ 7.9±0.5   10.2±1.4 ↓ 
0.1% CPZ+PT 26.8±1.5   17.29±1.1 ↓ 7.6±0.2   10.1±0.6 ↓ 
-Values are presented as mean area (mm2) ± SEM (n=3 thymii or spleens/group, 5 histological 
sections/organ). -Statistically significant changes are indicated as higher (↑) or lower (↓) relative 






Figure 2: Effects of CPZ-feeding or castration on peripheral immune organs histology 
H&E images of the thymus (a) and spleen (b), headed arrows identifying the thymic cortex 
( ), medulla ( ), splenic red pulp ( ) and white pulp ( ) regions, in the different 
groups of the three separate studies. Quantification of the mean thymic cortex/medulla (c) 
and splenic red pulp/white pulp ratios (d). Thymic cortex/medulla and splenic red 
pulp/white pulp ratios were significantly decreased by 0.1% CPZ in both Gi male and 
female mice and by 0.2% CPZ in Gi males compared to Ctrl whereas these ratios were 
unchanged in Cx groups. One-way ANOVA, n=3 thymii or spleens/group, 5 






   
   
   
   






   
   
   
   













   
   
   
   






   
   
   
   
















4.4.3 - Castration preserved CD4/8 signal in the thymus and spleen against the impact 
of CPZ  
Western blot analysis indicated a significant dose-dependent reduction (0.2% > 0.1% CPZ) 
in the signal intensity of CD4 and CD8 T-cells in both thymus and spleen of Gi CPZ males 
compared to Gi Ctrl males (Figure 3a,b). The effect of 0.1% or 0.2% CPZ on CD4 signals 
in both thymus and spleen was prevented by Cx despite feeding with CPZ. Moreover, CD8 
signal were indistinguishable from Ctrl group when Cx combined with 0.1% or 0.2% CPZ 
in spleen but only with the Cx+0.1% CPZ group in thymus. Although, the effect of CPZ 
on thymic CD8 signal in the Cx+0.2% CPZ group was ameliorated by Cx (compared with 
the Gi male at the same dose), CD8 signal was significantly (p<0.05) decreased in the 
Cx+0.2% CPZ group compared to the Ctrl group (Figure 3b). Overall, 0.2% CPZ had a 
significant (p<0.05) suppressive impact on the levels of CD4/8 in both thymus and spleen 
compared to 0.1% CPZ in Gi mice. Cx induced preservation of thymic and splenic CD4/8 





Figure 3: Effects of CPZ-feeding or castration (Cx) on CD4 and CD8 signal intensity 
in the immune organs of male and female mice 
Representative examples of western blot images of CD4 and CD8 signal intensities (a) and 
their quantification (b) in the different groups in the three separate studies. CD4/8 signal 
intensities were significantly reduced in the thymus and spleen of Gi CPZ-fed male and 
female mice, whereas CD4/8 signals were completely restored in all Cx groups in thymus 
and spleen except that CD8 signal of thymus in Cx+0.2% CPZ group was markedly 
attenuated. SDS-PAGE gels were loaded with a 20µg/well of total protein; one-way 
ANOVA, n=3 thymii or spleens/group, all samples were processed in triplicate; * indicates 
significant difference from Ctrl (p<0.05). 
 
   







4.4.4 - CPZ-induced demyelination  
Silver staining revealed that 0.1% and 0.2% CPZ-feeding induced a significant decrease in 
MCC myelin of Gi male mice compared to Gi Ctrl males (Figure 4a,b, Study III panel) and 
the extent of demyelination was indistinguishable between 0.1% or 0.2% CPZ. Cx alone, 
or when combined with 0.1% or 0.2% CPZ, did not affect the myelin staining intensity 
compared to Gi Ctrl males. Overall, 0.1% CPZ-feeding was as effective at producing 
demyelination as 0.2% CPZ in mice, with or without Cx.  
 
4.4.5 - Effects of CPZ and Cx on glial activation 
Gfap and Iba 1 staining were used to quantify astrocytes and microglia, respectively, in the 
MCC. Following CPZ-feeding in Gi males, cell density (cell/mm3) and fluorescence 
intensity of both Gfap and Iba 1 were significantly increased in a dose dependent manner 
(0.2% > 0.1% CPZ) compared to Gi Ctrl (Figure 4a,b, Study III panels, Gfap, Iba 1). 
Combining Cx with 0.1% or 0.2% CPZ-feeding did not change the cell density or the 
fluorescence intensity of either Gfap or Iba 1 staining. Both 0.1% and 0.2% CPZ-feeding 






Figure 4: Effects of CPZ-feeding or Cx on the CNS histology 
Representative silver, Gfap and Iba 1 staining images (a) and quantification (b) of silver 
staining intensity and astrocytes/microglia fluorescence intensity and cell density 
(cell/mm3) in the midline corpus callosum (MCC). 0.1% and 0.2% CPZ-feeding produced 
identical loss (p<0.05) of myelin intensity in Gi male mice. Silver intensity was unaffected 
following Cx in all castrated groups. 0.1% CPZ-feeding to Gi male and female mice 
induced comparable demyelination. Fluorescence intensity and cell density of Gfap and 
Iba 1 stained sections were significantly (p<0.05) increased in a dose dependent manner 







































































density were indistinguishable between males and females when mice were fed with 0.1% 
CPZ. One-way ANOVA, n=5 mice/group, 10 sections/brain; * indicates significant 
difference from Ctrl (p<0.05), and dashed yellow line indicates quantification area. 
  
 
4.4.6 - Study IV 
Intraperitoneal injections of PT in male mice had no synergistic effect when combined with 
0.1% CPZ in both the Gi and Cx males. As seen in Study III, CPZ-feeding resulted in 
comparable reductions in weight gain (Supplementary Figure S2, Study IV) and a reduction 
in thymic and splenic mass (Figure 1a,b, Study IV panels). Cx increased the thymic weight 
but the splenic mass remained unchanged compared to Gi Ctrl. Western blot analysis 
showed significant reductions (p<0.05) in CD4/8 signals in Gi animals fed 0.1% CPZ 
compared to Ctrl whereas in Cx groups, CD4/8 signals remained unchanged when fed 0.1% 
CPZ (Figure 3a,b, Study IV panels). Likewise, flow cytometric analysis of thymocytes and 
splenocytes showed significant decreases (p<0.05) in CD4/8 T-cell subpopulations in the 
0.1% CPZ group compared to Ctrl, whereas in the Cx groups CD4/8 T-cell subpopulations 
were significantly increased (p<0.05, Figure 5a,b). In addition, there were no changes in 
the ratio of CD4/CD8 across all groups (p>0.05, Figure 5c). Myelin, Gfap and Iba 1 
intensities in the PT group of Gi males were indistinguishable from Ctrl. PT injection did 
not change the amount of demyelination nor the extent of microglia and astrocyte activation 
when combined with Cx, 0.1% CPZ, or Cx+0.1% CPZ (Figure 4a,b, Study IV panels). The 
PT-mediated breach of the BBB was confirmed by a significant increase in the intensity of 
IgG staining in the hippocampal region of the PT injected groups (Supplementary Figure 
S3a,b). Quantification was performed in the hippocampus because the intensity of the stain 















Figure 5: Flow cytometric analysis of T-cell subpopulations (CD4+ and CD8+) in the 
immune organs of male mice  
Representative flow cytometry dot blots of thymic CD4 and CD8 T-cells (A) and the 
quantification of their cell number in thymus and spleen tissue from Study IV (B). CD4/8 
number were significantly reduced in the thymus and spleen of 0.1% CPZ-fed mice 
compared to Ctrl. Numbers of CD4/8 increased in all Cx groups compared to Ctrl and were 
unaffected by CPZ. Cell counts in the quadrant 1 (Q1) for CD4 and quadrant 3 (Q3) for 
CD8 were used to quantify cell number in each experimental group. No significant (ns, 
p>0.05) changes in the ratio of CD4/CD8 were observed in thymus and spleen (C). A one-
way ANOVA (n=3 thymii or spleens per group, 20,000 event/sample) was used to 
determine significant differences from Ctrl (* p<0.05). 
 
4.4.7 - CD8+ T-cell number increased in the CNS following PT injection in Cx-CPZ-fed 
mice  
In a previous study CD4 and/or CD8 were not detected following PT injection in the CNS 
of Gi male mice fed 0.1% CPZ (Sen et al., 2019a). In contrast, when 2 weeks of 0.1% CPZ-
feeding was combined with Cx and PT treatment (Cx+0.1% CPZ+PT, Figure 6a,b) CD8+ 
cell numbers in the CNS increased. The distribution of CD8+ T-cells in the stained slices 
was not homogeneous, with CD8+ cells appearing either as individual cells, or in small 
groups of cells distributed widely throughout the CNS (cerebrum, cerebellum, brainstem 
and spinal cord). In Gi and Cx animals, CD8+ cells were rarely encountered and their 
numbers were unaffected by CPZ-feeding (range between 0-23 cells/section) compared to 
Ctrl. When CPZ-feeding and Cx were combined with PT, the number of CD8+ cells 
increased (>2-fold) in multiple regions of the brain (whole parenchyma) and spinal cord 
(most notably in the grey matter and around the central canal, Figure 6a,b). Double 
labelling of CNS sections with CD8 and Iba 1 antibodies (and co-stained with nuclear 
DAPI staining) confirmed that CD8 and Iba 1 were expressed in distinct cell populations 
(Figure 6c).  
In addition, using the same western blot analysis of the brain and spinal cord homogenate 
samples (3 independent 60 µg sample loads per animal, 3 animals/group) we replicated the 
previous finding that neither CD4 nor CD8 signals were detected in the CNS homogenates 
of Ctrl,  0.1% CPZ and PT treated Gi males (Sen et al., 2019a). However, in the Cx+0.1% 




was not (Figure 7, Study IV). Furthermore, neither CD4 nor CD8 signals were detected in 
CNS homogenates in either Study III or Study V (Figure 7, Studies III and V).  
The increased CD8+ T-cell signal intensity (western blot) and number 
(immunohistochemistry) in the brain and spinal cord tissue of the Cx+0.1% CPZ+PT mice 
was also confirmed using flow cytometric analysis (Figure 8a,b). Moreover, CD4+ T-cells 
counts via flow cytometry did not show any changes among all groups (i.e. CD4 cell 
number in Ctrls: brain 1087±314; spinal cord 834±176). The ratio of CD4/CD8 was 
unchanged in all groups compared to Ctrl except in the Cx+0.1% CPZ+PT group, in which 






Figure 6: Combined effects of CPZ-feeding and Cx with pertussis toxin (PT) on CD8+ 
T-cells in the CNS 
Representative images of CD8+ T-cells detected in the CNS tissue (a) and quantification 
(b) of CD8+ T-cell numbers in the CNS (cerebrum, cerebellum, brainstem and spinal cord). 
In Study IV, the number of CD8+ T cells was significantly (p<0.05) higher in each part of 












representative images of double labelling with CD8 and Iba 1 antibodies in the brain tissue, 
nuclear DAPI staining, and merged images confirming the identity of CD8+ T-cells. As 
indicated by white arrows, regions of the images were magnified five times and these 
appear as insets at the bottom of the image panel; one-way ANOVA, n=3 mice/group, 10 
sections/ brain or spinal cord, 5 sections/cerebellum or brainstem; * indicates significant 
difference from Ctrl (p<0.05).  
 
 
4.4.8 - Study V 
BBB disruption was applied in Study V to test whether CD8+ T-cells could be increased in 
the CNS of Gi female mice as observed in Cx+0.1% CPZ+PT treated males. Feeding 0.1% 
CPZ to Gi female mice led to reduced body weight gain (Supplementary Figure S2), severe 
thymic and splenic atrophy (Figure 1a,b) and changes in histological architecture (thymic 
cortex/medulla and splenic red pulp/white pulp ratios). These effects were 
indistinguishable from those observed in Gi males (Figure 2a,b). Notably, the reductions 
in CD4/8 were comparable to those in Gi males (Figure 3a,b). Likewise, the levels of 
demyelination, and microglia and astrocyte activation were indistinguishable from those 
observed in age (and treatment) matched Gi and Cx males (Figure 4a,b). In contrast to the 
Cx males, following 0.1% CPZ+PT, CD4/8 T-cells were not detected in CNS tissue of Gi 










Figure 7: Detection of CD4/8 signals in the CNS homogenate  
Representative images of western blot analysis of CD4 and CD8 antigen detection in the 
brain and spinal cord. No CD4 signal was detected in the CNS tissue across all groups in 
Studies III-V.  In contrast, CD8 signal band was detected only in brains and spinal cords of 
Cx+0.1% CPZ+PT mice in Study IV (red arrows). SDS-PAGE gels were loaded with 
60µg/well of total protein, all samples were processed in triplicate, and standard purified 
CD4 and CD8 protein concentrations were 5ng/well and 5µg/well, respectively. 
 
   






Figure 8: Flow cytometric analysis of T-cell subpopulations (CD4 and CD8) in the 
brain and spinal cord of male mice  
Representative CD8+ T-cells dot blots in the brain (a) and quantification (b) of CD4+ and 










in the number of CD4+ T-cell of the brain and spinal cord were observed, whereas the 
number of CD8+ T cells was significantly (p<0.05) increased only in the brains and spinal 
cord of the Cx+0.1% CPZ+PT group. Cell counts in quadrant 3 (Q3) for CD8 were used to 
quantify cell number in each experimental group. The ratio of CD4/CD8 in brain and spinal 
cord was unchanged (ns) in all groups except in the Cx+0.1% CPZ+PT group in which the 
ratio was significantly decreased in both brain and spinal cord (c). A one-way ANOVA 
(n=3 thymii or spleens per group, 20,000 event/sample) was used to determine significant 

































Figure 1: Protein transfer efficiency and protein loading 
Representative Multi Gauge line scan of the intensity (AU) of Coomassie Brilliant Blue 














gel lanes (a). Line scans for each lane are colour coded. Images of SDS-PAGE gels that 
were processed in parallel and stained with Coomassie Brilliant Blue, left image (gel 
without transfer) and right side image (gel after transfer), to quantify the efficiency of 
protein transfer from the gel onto PVDF membrane (b). Protein bands intensities were 









Figure 2: Body weight data 
Graphs (Studies III, IV and V) show the total body weight differences among the 
experimental groups used in these studies. A slow gain of body weight in 0.1% and/or 0.2% 
CPZ-fed mice compared with corresponding Cx and Ctrl groups in Studies III and IV. Cx 
delayed the thriving of mice during the first three days in studies III and IV. In the Study 
V, mice fed 0.1% CPZ showed a significantly slower weight gain compared with 
corresponding Ctrls (n=10 animals/group in study III and V, n=5 in the Study IV); 





Figure 3: Effect of PT on the permeability BBB  
Representative images showing IgG staining in the brain sections following PT injection 
(a), and quantification (b) of IgG intensity. A significant (p<0.05) increase in the IgG 
colour intensity in the hippocampus region of PT injected groups were seen in Study IV. 
This effect indicates that immunoglobulin G traversed the BBB into the brain tissue (i.e. 




4.4.10 - Supplementary stereology table 
Table 2: stereological counting of GFAP+ and Iba 1+ cells 
Study-III 
Data set (Gfap) 

























Control 10 81 75x75 150x150 40 7 26.8 109 4123 0.1 972343 372256000 1.1076E-05 
Control 10 79 75x75 150x150 40 7 26.9 111 4168.92 0.1 1159730 324724000 1.2838E-05 
Control 10 87 75x75 150x150 40 7 26.9 89 3359.37 0.09 1212300 339443000 9.8967E-06 
Control 10 77 75x75 150x150 40 7 27.6 69 2665.6 0.1 1033650 389422000 6.845E-06 
Control 10 79 75x75 150x150 40 7 27 50 1905.26 0.1 1218970 341311000 5.5822E-06 
 
0.1% CPZ 10 87 75x75 150x150 40 7 26.9 196 7476 0.07 1327330 271652000 2.7521E-05 
0.1% CPZ 10 67 75x75 150x150 40 7 27.1 101 4396.56 0.1 865477 276953000 1.5875E-05 
0.1% CPZ 10 76 75x75 150x150 40 7 25.6 138 4976.93 0.08 998146 179481000 2.773E-05 
0.1% CPZ 10 79 75x75 150x150 40 7 26.5 177 6591.62 0.08 1137820 218588000 3.0155E-05 





0.2% CPZ 10 81 75x75 150x150 40 7 25.9 247 9021.82 0.06 1135260 217873000 4.1409E-05 
0.2% CPZ 10 78 75x75 150x150 40 7 25.9 205 7459.97 0.07 1033240 289306000 2.5786E-05 
0.2% CPZ 10 80 75x75 150x150 40 7 26.5 163 6038.34 0.08 930902 360653000 1.6743E-05 
0.2% CPZ 10 76 75x75 150x150 40 7 27.1 254 9577.05 0.06 1148860 221680000 4.3202E-05 
0.2% CPZ 10 93 75x75 150x150 40 7 26.8 250 9417.73 0.06 1248840 349675000 2.6933E-05 
 
Cx 10 75 75x75 150x150 40 7 27.1 82 3133.34 0.11 1060750 297011000 1.055E-05 
Cx 10 80 75x75 150x150 40 7 27.5 99 3832.01 0.1 1242640 347940000 1.1013E-05 
Cx 10 70 75x75 150x150 40 7 27.7 107 4166.54 0.1 983482 375375000 1.11E-05 
Cx 10 91 75x75 150x150 40 7 26.2 112 4140.36 0.09 1207480 438095000 9.4508E-06 
Cx 10 87 75x75 150x150 40 7 27.1 126 4797.94 0.09 1125810 435228000 1.1024E-05 
 
Cx+0.1% CPZ 10 85 75x75 150x150 40 7 26.85 192 6297.48 0.08 1142137 219798750 2.8651E-05 
Cx+0.1% CPZ 10 85 75x75 150x150 40 7 26.3 155 5709.62 0.08 1162360 225460000 2.5324E-05 
Cx+0.1% CPZ 10 86 75x75 150x150 40 7 26.7 183 6944.35 0.07 1120650 213783000 3.2483E-05 
Cx+0.1% CPZ 10 84 75x75 150x150 40 7 26.6 249 5923.82 0.08 1186180 232130000 2.5519E-05 
Cx+0.1% CPZ 10 87 75x75 150x150 40 7 27.8 182 6612.13 0.06 1099360 207822000 3.1816E-05 
 
Cx+0.2% CPZ 10 89 75x75 150x150 40 7 35.1 280 11231.41 0.06 1221630 242056000 4.64E-05 
Cx+0.2% CPZ 10 81 75x75 150x150 40 7 26.2 238 12557.02 0.07 1231850 244917000 5.1271E-05 
Cx+0.2% CPZ 10 72 75x75 150x150 40 7 26.9 250 9438.31 0.06 989531 277069000 3.4065E-05 
Cx+0.2% CPZ 10 107 75x75 150x150 40 7 30.9 139 5518.45 0.07 1548410 193556000 2.8511E-05 
Cx+0.2% CPZ 10 89 75x75 150x150 40 7 28.6 216 8576.68 0.07 1264270 253996000 3.3767E-05 
 
Data set (Iba 1) 

























Control 10 41 50x50 200x200 40 7 27.3 62 9489.2 0.1 1140900 319451000 2.9705E-05 
Control 10 45 50x50 200x200 40 7 27.1 51 7722.12 0.1 1298010 363442000 2.1247E-05 
Control 10 40 50x50 200x200 40 7 26.7 38 5697.72 0.1 1093760 306254000 1.8605E-05 
Control 10 41 50x50 200x200 40 7 26.1 58 8554 0.1 1034290 289602000 2.9537E-05 
Control 10 46 50x50 200x200 40 7 26.4 49 7305.48 0.1 1180030 330408000 2.211E-05 
 
0.1% CPZ 10 43 50x50 200x200 40 7 28.7 128 20624.79 0.09 1214020 339927000 6.0674E-05 
0.1% CPZ 10 34 50x50 200x200 40 7 28.4 106 17001.89 0.1 1095260 306674000 5.544E-05 
0.1% CPZ 10 34 50x50 200x200 40 7 27.7 104 16269.12 0.1 1070200 299656000 5.4293E-05 
0.1% CPZ 10 44 50x50 200x200 40 7 27.2 96 14661.36 0.1 1104180 309170000 4.7422E-05 
0.1% CPZ 10 40 50x50 200x200 40 7 28.1 88 14037.8 0.1 953822 267070000 5.2562E-05 
 
0.2% CPZ 10 46 50x50 200x200 40 7 26.9 170 25675.17 0.08 1173700 328637000 7.8126E-05 
0.2% CPZ 10 40 50x50 200x200 40 7 27.1 193 29432.47 0.07 1134330 317612000 9.2668E-05 
0.2% CPZ 10 32 50x50 200x200 40 7 26.8 158 23715.43 0.08 951872 266524000 8.898E-05 
0.2% CPZ 10 45 50x50 200x200 40 7 27.2 228 34957.44 0.07 1157070 423980000 8.2451E-05 
0.2% CPZ 10 42 50x50 200x200 40 7 27.3 161 24701.88 0.08 1247510 449303000 5.4978E-05 
 
Cx 10 42 50x50 200x200 40 7 28.7 77 12375.44 0.1 1136000 318080000 3.8907E-05 
Cx 10 40 50x50 200x200 40 7 28.6 30 4791.92 0.1 1055380 295505000 1.6216E-05 
Cx 10 39 50x50 200x200 40 7 28.3 58 9165.8 0.1 1153460 322970000 2.838E-05 
Cx 10 40 50x50 200x200 40 7 28.4 60 9574.32 0.1 1120940 313863000 3.0505E-05 
Cx 10 42 50x50 200x200 40 7 28.9 62 10050.88 0.09 1161800 325304000 3.0897E-05 
 
Cx+0.1% CPZ 10 41 50x50 200x200 40 7 28 146 22939.005 0.06 1138902 318893000 7.1933E-05 
Cx+0.1% CPZ 10 38 50x50 200x200 40 7 28.1 189 29975.69 0.08 1064840 298156000 0.00010054 
Cx+0.1% CPZ 10 45 50x50 200x200 40 7 28.1 131 20561.25 0.09 1137860 318600000 6.4536E-05 
Cx+0.1% CPZ 10 41 50x50 200x200 40 7 28 140 21932.68 0.09 1330400 372512000 5.8878E-05 
Cx+0.1% CPZ 10 40 50x50 200x200 40 7 27.7 124 19286.4 0.09 1022510 286304000 6.7363E-05 
 
Cx+0.2% CPZ 10 43 50x50 200x200 40 7 28.8 221 35649.61 0.07 1358050 380254000 9.3752E-05 
Cx+0.2% CPZ 10 47 50x50 200x200 40 7 28.9 197 32136.44 0.07 1125200 315055000 0.000102 
Cx+0.2% CPZ 10 37 50x50 200x200 40 7 28.8 167 26948.59 0.08 1086460 304210000 8.8585E-05 
Cx+0.2% CPZ 10 47 50x50 200x200 40 7 28.4 187 29814.39 0.07 1241750 347690000 8.575E-05 





Data set (Gfap) 

























Control 10 81 75x75 150x150 40 7 26.8 109 4123 0.1 972343 372256000 1.1076E-05 
Control 10 79 75x75 150x150 40 7 26.9 111 4168.92 0.1 1159730 324724000 1.2838E-05 
Control 10 87 75x75 150x150 40 7 26.9 89 3359.37 0.09 1212300 339443000 9.8967E-06 
Control 10 77 75x75 150x150 40 7 27.6 69 2665.6 0.1 1033650 389422000 6.845E-06 
Control 10 79 75x75 150x150 40 7 27 50 1905.26 0.1 1218970 341311000 5.5822E-06 
 
PT 10 74 75x75 150x150 40 7 29.6 112 4157.1 0.1 9800235 375194000 1.10799E-05 
PT 10 77 75x75 150x150 40 7 27.2 102 4137 0.09 1207642 317529000 1.30287E-05 
PT 10 81 75x75 150x150 40 7 27.8 92 4999.42 0.09 1120315 341376000 1.46449E-05 
PT 10 8 75x75 150x150 40 7 27.3 59 2711.22 0.1 1094367 390458000 6.94369E-06 
PT 10 77 75x75 150x150 40 7 27.9 71 1914 0.1 1193680 339594000 5.63614E-06 
 
0.1% CPZ 10 87 75x75 150x150 40 7 26.9 196 7476 0.07 1327330 271652000 2.7521E-05 




0.1% CPZ 10 76 75x75 150x150 40 7 25.6 138 4976.93 0.08 998146 179481000 2.773E-05 
0.1% CPZ 10 79 75x75 150x150 40 7 26.5 177 6591.62 0.08 1137820 218588000 3.0155E-05 
0.1% CPZ 10 84 75x75 150x150 40 7 26.4 153 5699.47 0.08 1016990 284756000 2.0015E-05 
 
Cx 10 75 75x75 150x150 40 7 27.1 82 3133.34 0.11 1060750 297011000 1.055E-05 
Cx 10 80 75x75 150x150 40 7 27.5 99 3832.01 0.1 1242640 347940000 1.1013E-05 
Cx 10 70 75x75 150x150 40 7 27.7 107 4166.54 0.1 983482 375375000 1.11E-05 
Cx 10 91 75x75 150x150 40 7 26.2 112 4140.36 0.09 1207480 438095000 9.4508E-06 
Cx 10 87 75x75 150x150 40 7 27.1 126 4797.94 0.09 1125810 435228000 1.1024E-05 
 
Cx+PT 10 77 75x75 150x150 40 7 26.1 198 2045 0.1 1102510 302643000 6.7571E-06 
Cx+PT 10 83 75x75 150x150 40 7 25.4 216 3833.34 0.1 1217450 336933000 1.1377E-05 
Cx+PT 10 80 75x75 150x150 40 7 28.5 189 4956.25 0.09 1034427 333861000 1.4845E-05 
Cx+PT 10 78 75x75 150x150 40 7 28.7 264 4309.75 0.07 1199430 404772000 1.0647E-05 
Cx+PT 10 87 75x75 150x150 40 7 27.6 239 4525.44 0.09 1148290 467390000 9.6824E-06 
 
Cx+0.1% CPZ 10 85 75x75 150x150 40 7 26.85 192 6297.48 0.08 1142137 219798750 2.8651E-05 
Cx+0.1% CPZ 10 85 75x75 150x150 40 7 26.3 155 5709.62 0.08 1162360 225460000 2.5324E-05 
Cx+0.1% CPZ 10 86 75x75 150x150 40 7 26.7 183 6944.35 0.07 1120650 213783000 3.2483E-05 
Cx+0.1% CPZ 10 84 75x75 150x150 40 7 26.6 249 5923.82 0.08 1186180 232130000 2.5519E-05 
Cx+0.1% CPZ 10 87 75x75 150x150 40 7 27.8 182 6612.13 0.06 1099360 207822000 3.1816E-05 
 
Cx+0.1% CPZ+PT 10 89 75x75 150x150 40 7 28.2 276 6301.01 0.09 1127370 215288640 2.9268E-05 
Cx+0.1% CPZ+PT 10 83 75x75 150x150 40 7 28.1 252 4699.51 0.08 1184590 232760000 2.019E-05 
Cx+0.1% CPZ+PT 10 86 75x75 150x150 40 7 27.9 271 6701.79 0.09 1094560 209065000 3.2056E-05 
Cx+0.1% CPZ+PT 10 100 75x75 150x150 40 7 28.1 120 5899.69 0.08 1256290 238870000 2.4698E-05 
Cx+0.1% CPZ+PT 10 78 75x75 150x150 40 7 28.9 198 6592.15 0.08 11548210 207452000 3.1777E-05 
 
Data set (Iba 1) 

























Control 10 41 50x50 200x200 40 7 27.3 62 9489.2 0.1 1140900 319451000 2.9705E-05 
Control 10 45 50x50 200x200 40 7 27.1 51 7722.12 0.1 1298010 363442000 2.1247E-05 
Control 10 40 50x50 200x200 40 7 26.7 38 5697.72 0.1 1093760 306254000 1.8605E-05 
Control 10 41 50x50 200x200 40 7 26.1 58 8554 0.1 1034290 289602000 2.9537E-05 
Control 10 46 50x50 200x200 40 7 26.4 49 7305.48 0.1 1180030 330408000 2.211E-05 
 
PT 10 38 50x50 200x200 40 7 29.1 71 8463.85 0.1 1254100 323432000 2.6169E-05 
PT 10 43 50x50 200x200 40 7 27.8 58 8875.09 0.1 1198460 376296000 2.3585E-05 
PT 10 41 50x50 200x200 40 7 26.2 78 5984.02 0.1 1198470 293396000 2.0396E-05 
PT 10 39 50x50 200x200 40 7 28.1 30 8945.54 0.1 903850 308876000 2.8962E-05 
PT 10 45 50x50 200x200 40 7 27.9 32 7834.98 0.1 1256270 327698000 2.3909E-05 
 
0.1% CPZ 10 43 50x50 200x200 40 7 28.7 128 27146.23029 0.09 1214020 339927000 0.000079859 
0.1% CPZ 10 34 50x50 200x200 40 7 28.4 106 23135.89 0.1 1095260 306674000 7.54413E-05 
0.1% CPZ 10 34 50x50 200x200 40 7 27.7 104 16269.12 0.1 1070200 299656000 5.42927E-05 
0.1% CPZ 10 44 50x50 200x200 40 7 27.2 96 14661.36 0.1 1104180 309170000 4.74217E-05 
0.1% CPZ 10 40 50x50 200x200 40 7 28.1 88 14037.8 0.1 953822 267070000 5.25622E-05 
 
Cx 10 42 50x50 200x200 40 7 28.7 77 12375.44 0.1 1136000 318080000 3.89067E-05 
Cx 10 40 50x50 200x200 40 7 28.6 30 4791.92 0.1 1055380 295505000 1.6216E-05 
Cx 10 39 50x50 200x200 40 7 28.3 58 9165.8 0.1 1153460 322970000 2.83797E-05 
Cx 10 40 50x50 200x200 40 7 28.4 60 9574.32 0.1 1120940 313863000 3.05048E-05 
Cx 10 42 50x50 200x200 40 7 28.9 62 10050.88 0.09 1161800 325304000 3.08969E-05 
 
Cx+PT 10 40 50x50 200x200 40 7 28.6 167 1190.76 0.08 1153800 309345000 3.84929E-06 
Cx+PT 10 43 50x50 200x200 40 7 28.9 185 7437.83 0.09 1134330 329843000 2.25496E-05 
Cx+PT 10 41 50x50 200x200 40 7 26.4 176 9537.51 0.09 1016750 246398000 3.87077E-05 
Cx+PT 10 46 50x50 200x200 40 7 27.67 199 11651.65 0.09 1092450 427591000 2.72495E-05 
Cx+PT 10 41 50x50 200x200 40 7 28.13 189 11132.42 0.08 1193620 439834000 2.53105E-05 
 
Cx+0.1% CPZ 10 41 50x50 200x200 40 7 28 146 22939.005 0.06 1138902 318893000 7.19332E-05 
Cx+0.1% CPZ 10 38 50x50 200x200 40 7 28.1 189 29975.69 0.08 1064840 298156000 0.000100537 
Cx+0.1% CPZ 10 45 50x50 200x200 40 7 28.1 131 20561.25 0.09 1137860 318600000 6.45363E-05 
Cx+0.1% CPZ 10 41 50x50 200x200 40 7 28 140 21932.68 0.09 1330400 372512000 5.88778E-05 
Cx+0.1% CPZ 10 40 50x50 200x200 40 7 27.7 124 19286.4 0.09 1022510 286304000 6.73634E-05 
 
Cx+0.1% CPZ+PT 10 39 50x50 200x200 40 7 28.2 195 24526.231 0.08 1152750 303834000 8.07225E-05 
Cx+0.1% CPZ+PT 10 43 50x50 200x200 40 7 28.4 231 25375.37 0.07 1175380 312217000 8.12748E-05 
Cx+0.1% CPZ+PT 10 42 50x50 200x200 40 7 27.3 172 22385.72 0.08 1095180 305390000 7.33021E-05 
Cx+0.1% CPZ+PT 10 41 50x50 200x200 40 7 28.5 197 22352.46 0.09 1255390 384471000 5.81382E-05 





Data set (Gfap) 

























Control 10 77 75x75 150x150 40 7 26.8 91 4208.33 0.09 1234560 332446000 1.26587E-05 
Control 10 75 75x75 150x150 40 7 26.9 87 2661.62 0.1 1044760 373923000 7.1181E-06 




Control 10 78 75x75 150x150 40 7 27.6 71 4102.48 0.08 937195 394462000 1.04002E-05 
Control 10 73 75x75 150x150 40 7 27 62 3429.91 0.1 1174480 337591000 1.016E-05 
 
PT 10 66 75x75 150x150 40 7 29.6 105 4132.53 0.1 9837623 313374000 1.31872E-05 
PT 10 68 75x75 150x150 40 7 27.2 94 2693.72 0.08 1347527 399836000 6.73706E-06 
PT 10 74 75x75 150x150 40 7 27.8 105 1924.78 0.1 1047233 339264000 5.6734E-06 
PT 10 66 75x75 150x150 40 7 27.3 66 4207 0.1 1193374 377735000 1.11374E-05 
PT 10 78 75x75 150x150 40 7 27.9 68 4929.17 0.09 1248893 342734000 1.43819E-05 
 
0.1% CPZ 10 62 75x75 150x150 40 7 26.9 140 2450.052962 0.09 1628330 275823000 8.8827E-06 
0.1% CPZ 10 83 75x75 150x150 40 7 27.1 171 6271.82 0.1 869347 218496000 2.87045E-05 
0.1% CPZ 10 88 75x75 150x150 40 7 25.6 127 5469 0.1 998537 262856000 2.08061E-05 
0.1% CPZ 10 74 75x75 150x150 40 7 26.5 152 7465.01 0.09 1237323 273762000 2.72682E-05 
0.1% CPZ 10 82 75x75 150x150 40 7 26.4 189 3383.430886 0.1 1723992 172886000 1.95703E-05 
 
0.1% CPZ+PT 10 70 75x75 150x150 40 7 26.9 154 7065.354497 0.09 1544830 273765000 2.58081E-05 
0.1% CPZ+PT 10 70 75x75 150x150 40 7 27.1 143 4969.670283 0.1 8245533 243775000 2.03863E-05 
0.1% CPZ+PT 10 73 75x75 150x150 40 7 25.6 151 5939.81 0.1 1071746 283762000 2.09324E-05 
0.1% CPZ+PT 10 76 75x75 150x150 40 7 26.5 192 7829.22 0.09 1387230 277693000 2.81938E-05 
0.1% CPZ+PT 10 68 75x75 150x150 40 7 26.4 138 4898.74 0.1 1208360 172749000 2.83576E-05 
 
Data set (Iba 1) 

























Control 10 55 50x50 200x200 40 7 27.5 73 649.7284838 0.1 1061260 285482000 2.2759E-06 
Control 10 48 50x50 200x200 40 7 28.3 54 9519.41 0.08 1173940 335185000 2.84005E-05 
Control 10 51 50x50 200x200 40 7 27.2 66 7475.71 0.1 1739030 315393000 2.37028E-05 
Control 10 62 50x50 200x200 40 7 26.7 47 5651.49 0.09 1084630 327548000 1.72539E-05 
Control 10 41 50x50 200x200 40 7 28.5 64 7842.55 0.1 1378240 335275000 2.33914E-05 
 
PT 10 44 50x50 200x200 40 7 28.5 62 1862.75743 0.1 1277260 325526000 5.7223E-06 
PT 10 42 50x50 200x200 40 7 27.4 67 8935.17 0.1 1037860 304627000 2.93315E-05 
PT 10 52 50x50 200x200 40 7 25.4 64 5972.43 0.09 1283470 325916000 1.83251E-05 
PT 10 47 50x50 200x200 40 7 29.7 57 12156.74944 0.1 1001820 336118000 3.61681E-05 
PT 10 54 50x50 200x200 40 7 28.2 44 3265.900565 0.1 1117270 348255000 9.3779E-06 
 
0.1% CPZ 10 41 50x50 200x200 40 7 29.1 98 22252.40566 0.1 1144520 304373000 0.000073109 
0.1% CPZ 10 52 50x50 200x200 40 7 28.5 119 15998.97144 0.1 1074560 326228000 4.90423E-05 
0.1% CPZ 10 42 50x50 200x200 40 7 28.2 93 15446 0.09 1257200 282496000 5.46769E-05 
0.1% CPZ 10 39 50x50 200x200 40 7 28.6 87 16115.17 0.1 1047210 313740000 5.13647E-05 
0.1% CPZ 10 46 50x50 200x200 40 7 28.3 96 15817.69 0.09 1054727 305740000 5.17358E-05 
 
0.1% CPZ+PT 10 39 50x50 200x200 40 7 25.6 87 26114.0464 0.1 1214550 308345000 0.000114691 
0.1% CPZ+PT 10 44 50x50 200x200 40 7 27.3 79 24634.36 0.09 1195370 307748000 8.00472E-05 
0.1% CPZ+PT 10 53 50x50 200x200 40 7 27.5 93 35364.47 0.1 1153840 319922000 8.16263E-05 
0.1% CPZ+PT 10 38 50x50 200x200 40 7 27.8 123 14643.33 0.08 1583480 303486000 4.82504E-05 







4.5 - Discussion 
To better understand why T-cells have been so infrequently found at sites of demyelination 
in the CPZ animal model, the impact of CPZ-feeding on the peripheral immune organs that 
are responsible for the maturation, differentiation and production T-cells, namely the 
thymus and spleen, was assessed (Cesta, 2006; Pearse, 2006). While previous studies have 
shown CPZ-induced thymic and splenic atrophy, they did not attempt to alleviate these 
effects (Solti et al., 2015; Martin et al., 2018; Sui et al., 2018; Sen et al., 2019a). The 
morphological and histopathological changes to the thymus following CPZ-feeding 
observed here and in other studies (Solti et al., 2015), are remarkably similar to those 
observed and attributed to androgen-dependent thymic involution that can be reversed by 
androgen depletion (Roden et al., 2004; Tang et al., 2012). Consistent with this observation, 
Study III demonstrated that Cx reversed the 0.1% or 0.2% CPZ-induced atrophy of the 
thymus and spleen and preserved CD4/8 signal intensity in both immune organs. In Study 
IV, Cx, when combined with two weeks of CPZ-feeding and disruption of the BBB (using 
PT), resulted in demyelination, gliosis and CD8+ T-cell infiltration in the cerebrum, 
cerebellum, brainstem and spinal cord. In female mice (Study V), combining CPZ-feeding 
with BBB disruption resulted in CNS demyelination and gliosis, but no CD8+ T-cell 
infiltration into the brain or spinal cord. Taken together, these results indicate that CPZ-
induced demyelination in the CNS can trigger a CD8+ T-cell-mediated central response 
when the peripheral immune system is preserved. 
As previously documented, CPZ-feeding led to a significant reduction in weight gain 
(Franco-Pons et al., 2007; Torkildsen et al., 2009; Ye et al., 2013; Chang et al., 2017; Sen 
et al., 2019a) and a reduction in thymic and splenic weights (Solti et al., 2015; Martin et 
al., 2018; Sui et al., 2018; Sen et al., 2019a). Although, Cx was timed to precede the onset 
of normal age-related thymic atrophy (Sheean et al., 2015), Cx did not prevent the CPZ-
induced suppression of total body weight gain. However, Cx did counteract the CPZ-
induced suppression of thymus size and weight, spleen weights, and changes in the thymic 
medulla and splenic white pulp (structures responsible for T-cell development and 
production). Furthermore, western blot analysis confirmed that Cx countered all CPZ-




protective effects of Cx, the direct effects of CPZ-feeding on the thymus and spleen provide 
a plausible explanation as to why prior studies did not show the involvement of T-cells in 
the CNS of CPZ-fed mice (Remington et al., 2007; Tejedor et al., 2017; Sen et al., 2019a). 
Likewise, the demonstration that CPZ ameliorates and/or prevents the clinical and 
pathological features of EAE and Theiler’s virus encephalomyelitis (Mana et al., 2009; 
Herder et al., 2012), is consistent with CPZ suppressing peripheral immune function and 
hence improving both clinical and pathological features driven by T-cells. Based on this, 
and prior work (Solti et al., 2015; Martin et al., 2018; Sui et al., 2018; Sen et al., 2019a), it 
is clear that suppressive effects of CPZ on the thymus and spleen, and thus T-cells (CD4+ 
and CD8+ lymphocytes), are not conducive to study effects mediated by peripheral immune 
cells unless strategies to protect and/or boost the peripheral immune system are employed.   
Broadly speaking, the toxic effects of CPZ have been attributed to copper chelation that 
interferes with cellular and mitochondrial metabolism and results in the formation of mega 
or enlarged-mitochondria in the liver and thymus of mice (Suzuki, 1969; Hoppel and 
Tandler, 1973; Solti et al., 2015). Likewise, in the mitochondria of oligodendrocytes, 
increased reactive oxygen species and decreased activity of respiratory chain complexes 
resulted from CPZ-feeding (Gudi et al., 2014; Faizi et al., 2016). Additionally, in atrophied 
thymii, enlarged mitochondria, myelin bodies, enlarged lysosomes and lipid droplets were 
observed following CPZ-feeding (Solti et al., 2015). The enlarged lysosomes are the result 
of increased membrane permeability, and the release of lysosomal proteases activates 
caspases, ultimately leading to thymocyte apoptosis (Zhang et al., 2009; Veto et al., 2010).   
T-helper (CD4+) cells require copper to transcribe interleukin-2 (Hopkins and Failla, 
1999)-a process that may be suppressed due to the copper chelating action of CPZ 
(Emerson et al., 2001). These effects of CPZ on mitochondrial function and thymocyte 
apoptosis may explain why western blot and flow cytometry analyses of the thymii from 
CPZ-fed Gi mice identified a reduction in CD4/8 T-cell levels whereas Cx counteracted 
this effect, at least in-part due to the hypertrophy resulting from the ablation of androgens. 
Supporting this, it has been suggested that androgen depletion may be involved in the 




The suppressive effects of androgens on the structure and function of the thymus have been 
extensively investigated. The most prominent effects are mitochondrial dysfunction-
induced thymocyte apoptosis and thymic atrophy, which result in a subsequent reduction 
of circulating T-cells (Olsen et al., 1994; Olsen et al., 1998; Veto et al., 2010). However, 
Cx countered these effects. The preservation of thymic CD4/8 signal intensity in Cx groups, 
in the presence of CPZ, may not be limited to the effects of Cx on developing thymic 
cortical and medullary cells, but include effects on bone marrow-derived stem cells. Cx 
increased the number of thymocyte precursor cells in the bone marrow and enhanced their 
differentiation into mature thymocytes in the thymus, leading to thymic regeneration 
(Sutherland et al., 2005). These effects of Cx are consistent with other findings in young 
and aged animals in which orchiectomy induces rapid restoration of thymopoiesis, a 
significant increase in the proliferation of immature thymocytes, and a reduction in 
apoptosis (Olsen et al., 1994; Roden et al., 2004; Page et al., 2006; Sheean et al., 2015). In 
the current work, combining a 0.1% CPZ with Cx meant that the suppressive effects of 
CPZ on the peripheral immune system were counter-balanced by ablating the normal 
androgen-mediated involution of the thymus, thereby preserving peripheral immune 
function.   
Immature T-cells are selected in the thymic tissue according to their specificity to T-cell 
receptors (e.g. CD4+, CD8+ and forkhead P3+ regulatory T-cells), to develop functional and 
self-tolerant T-cell repertoires (positive selection), and induce a central tolerance to 
eliminate of autoreactive T-cells (negative selection). The maturation of thymocytes occurs 
in the thymic cortex, whereas the differentiation and negative selection of T-cells occurs 
in the thymic medulla (Klein et al., 2014; Kurd and Robey, 2016). This suggests that the 
CPZ-mediated effects in the medulla (i.e. on maturation, differentiation and selection of T 
lymphocytes) might decrease the capacity of the thymus to support a T-cell-mediated 
immune response in the CNS. In contrast, in the Cx-CPZ-fed animals, the increased thymic 
mass, particularly in the medulla, is still capable of initiating/sustaining a T-cell response 
through maturation, differentiation and selection processes.  
The central role of androgen-mediated thymic atrophy has been suggested on the basis of 




2000) and developing thymocytes (Viselli et al., 1995) that are stimulated by circulating 
androgens, thus resulting in thymic atrophy (Olsen et al., 2001). CD4 and CD8 T-cells are 
the major cell subsets that express androgen receptors (Sutherland et al., 2005), and are the 
major cell subsets that are reduced by CPZ-feeding. Therefore, the combined effects of 
androgen dependent involution and CPZ-feeding in the Gi male mice resulted in reduction 
in thymic mass and function, whereas in CPZ-fed Cx mice, thymic mass (and CD4+ and 
CD8+ thymocytes) are preserved.  
As in the thymus, CPZ-feeding reduced splenic wet weight, the size of its white pulp (a 
site of B and T-cell production) and CD4/8  T-cell levels, effects that have been attributed 
to CPZ-induced mitochondrial dysfunction and oxidative stress (Martin et al., 2018). 
Furthermore, a highly sensitive top-down proteomic analysis of spleens from CPZ-fed Gi 
male mice identified a significant increase in arginase-I abundance as well as decreased 
levels of protein disulphide isomerase (Partridge et al., 2016). The increased level of 
arginase-I, expressed by myeloid-derived suppressor cells, may have contributed to the 
decreased T-cell levels in the CPZ-fed mice. Furthermore, protein disulphide isomerase is 
required for the appropriate assembly of major histocompatibility complex-I (Kang et al., 
2009). A reduction in major histocompatibility complex-I molecules and consequent 
reduction in antigen presentation will impair cytotoxic T-cell (CD8+) activity and thus limit 
subsequent T-cell activation and clonal expansion, thereby providing another mechanism 
by which T-cell activity in CPZ-fed mice was compromised. Following orchiectomy, 
spleens were enlarged with increased white pulp areas, an effect attributed to mitotic 
expansion of splenic lymphoid cells capable of responding to immune stimuli (Dean et al., 
1984). This increased mitotic division of splenic lymphoid cells in Cx groups may 
compensate for the loss of mass and cell number induced by CPZ-feeding.  
In Studies III and IV, two weeks of CPZ-feeding led to extensive demyelination that was 
unaffected by androgen ablation in Cx mice. However, it has been shown that androgen 
depletion by Cx increased the severity of demyelination after 5 weeks of CPZ-feeding 
(Patel et al., 2013). The authors attributed this to the lack of protective androgen effects in 
the CNS following Cx. This suggests that at this early time point (i.e. two weeks of CPZ-




Androgens work as trophic factors to maintain the development and the plasticity of 
neuronal tissue regulate glial cell activity, and enhance myelination (Melcangi et al., 2001; 
Garcia-Segura and Melcangi, 2006). These protective effects of androgens are sustained 
by androgen receptors that are found on all cells types in the CNS including astrocytes, 
microglia, oligodendrocytes and neurons (Jung-Testas and Baulieu, 1998; Garcia-Ovejero 
et al., 2002). In contrast, others have argued that testosterone administration increases 
oligodendrocytosis by amplifying the toxic damage through α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA)/Kainate receptor activation (Marin-Husstege et al., 
2004; Cerghet et al., 2006). Other studies have shown that as little as two week of CPZ-
feeding can induce significant demyelination in the mouse CNS (Pfeifenbring et al., 2015; 
Caprariello et al., 2018). In the current work, short term (2 week) feeding of 0.1% CPZ 
produced comparable demyelination and gliosis to the standard 0.2% CPZ dose; yet 0.1% 
CPZ has more limited effect on the peripheral immune structures. These findings are 
consistent with previous data showing that 0.1% CPZ-feeding was as effective at producing 
demyelination as 0.2% CPZ but with less impact on the spleen (Sen et al., 2019a). 
Having demonstrated that Cx did not enhance CPZ-induced demyelination and gliosis, yet 
protected against the suppression of peripheral immune organs, Study IV showed that 
combining Cx and CPZ-feeding with disruption of the BBB resulted in a CD8+ T-cell 
immune response in the CNS. The disruption of the BBB was confirmed in Studies IV and 
V by an increased presence of IgG in the brain parenchyma following PT injection. It has 
been argued that the disruption of the BBB increases the possibility of adaptive immune 
cells traversing the barrier leading to activation and recruitment of T-cells due to myelin 
antigen presentation by microglia following oligodendrocytosis and the degeneration of 
myelin induced by CPZ (Caprariello et al., 2018). Disruption of the BBB alone, even when 
combined with either CPZ-feeding or castration, was not sufficient to initiate a CD8+ T-
cell mediated response in the CNS. This means that the release of myelin antigens 
following CPZ-feeding is the key step to induce a peripheral immune response and 
provides strong evidence for the inside-out theory of MS disease initiation (Stys et al., 
2012; Stys, 2013). The increase in the number of CD8+ T-cells observed in the CNS using 
immunohistochemistry was further confirmed by flow cytometric analysis of brain and 




western blot analysis when Cx was combined with 0.1% CPZ and PT. This preferential 
increase in CD8 levels was not observed in previous CPZ-feeding studies that did not 
include strategies to protect the peripheral immune system (Remington et al., 2007; 
Partridge et al., 2016; Traka et al., 2016; Tejedor et al., 2017; Sen et al., 2019a) or which 
the focus of analysis was on a pan T-cell maker (CD3) (Caprariello et al., 2018). While it 
has been argued that “cellular sources of CD8 were reactive macrophages/microglia” 
(Zhang et al., 2006), here, double labelling of brain and spinal cord sections with Iba 1 and 
CD8 showed distinct microglia and CD8 cell populations. Notably, as observed in human 
MS lesions (del Pilar Martin et al., 2008), most of the CD8+ T-cells were observed in the 
CNS parenchyma surrounding the blood capillaries, suggesting recent infiltration of these 
cells into the CNS tissue. Previous studies showed that Cx significantly increases peripheral 
CD8+ T-cell numbers and function in humans and mice (Page et al., 2006; Tang et al., 
2012). The exact mechanism of CD8 T-cell infiltration was not examined in this study, but 
seems most likely to have occurred following BBB disruption with subsequent expansion 
in response to the CPZ-induced demyelination, consistent with the inside-out theory of MS 
(Stys et al., 2012; Stys, 2013). 
Indeed, the process of infiltration may have been facilitated by the activation of innate 
immune cells (microglia and astrocytes), their presentation of myelin antigens and the 
release of tumour necrosis factor-γ and reactive oxygen species (Bonetto et al., 2017), that 
are known to increase the permeability of the BBB and attract CD8+ T-cell (Suidan et al., 
2006). Notably, the predominance of CD8+ T-cell in the CNS of mice (Study IV) resembles 
that seen at MS lesion sites where the key steps include recruitment and clonal expansion 
(Hauser et al., 1986; Friese and Fugger, 2005), with CD8+ outnumbering CD4+ T-cells by 
3-10 fold (Booss et al., 1983; Babbe et al., 2000). In contrast, CD4+ and CD8+ T-cell levels 
in the blood of MS patients are comparable to those observed in healthy individuals 
(Waschbisch et al., 2014), suggesting that the initiation of immune involvement in MS 
patients is a result of CD8+ T-cell expansion at the site of the lesion (Crawford et al., 2004). 
The inability to detect the CD4 antigen by western blot in the CNS did not appear to be 
due to failure of the techniques used as CD4 antigens were readily identified in the spleen, 




standard (Sen et al., 2019a). Notably, the specificity of the CD4 antibody has been 
confirmed by others (Forlani et al., 2019; Zhao et al., 2019), and has been used to detect 
CD4+ cells in the spinal cord of EAE animals (Sen et al., 2019a). In addition to the copper 
chelating actions of CPZ causing apoptosis of T-helper cells, the lack of CD4 detection in 
the CNS may, at least in part, be due to a PT-mediated inhibition of CD4 chemokine 
receptors (Gi protein-coupled receptors), which play a key role in migration and 
extravasation of CD4+ T cell into target tissues (Su et al., 2001; Alt et al., 2002). 
Conversely, a PT-mediated inhibition of chemokine receptors that protect against apoptotic 
signalling in CD4+ T-cells may also contribute to the absence of CD4+ T-cells (Vlahakis et 
al., 2002; Rot and von Andrian, 2004). Although EAE (a widely used animal model of MS) 
has provided important insights into how CD4+ T-cell responds to peripherally injected 
myelin antigens (Steinman and Shoenfeld, 2014), it does not address the role of central 
(e.g. inside-out), triggers of immune responses (Caprariello et al., 2018). Therefore, the 
EAE model does not replicate the same circumstances of disease initiation as seen in 
humans: namely, a response to a slow, long-term endogenous demyelination in the CNS, a 
predominance of brain and spinal cord pathology (vs predominance of spinal cord 
pathology), and CD8 (vs. CD4) mediated T-cell involvement (Wiendl and Hohlfeld, 2002). 
In contrast, here, Study IV resulted in a pathological pattern that included focal 
demyelination inside the CNS and a subsequent outside infiltration of CD8+ T-cell into the 
CNS, closely resembling the pattern observed in type III MS lesion in humans that is 
characterized by severe oligodendrocytosis and T-cell infiltration (presence of T-
lymphocytes, macrophages and  large numbers of oligodendrocytes loss; Lucchinetti et al., 
2000).     
The hypothesis underlying Study V was that combining CPZ-feeding with BBB disruption 
in females that have naturally lower testosterone levels, would result in CD8+ T-cell 
infiltration into the CNS similar to that seen in Cx males (Study IV). However, the 
preservation of thymic and splenic mass (and their associated CD4+ and CD8+ thymocytes) 
seen in Cx males was not reproduced in Gi females. This indicates that the preservation of 
immunological function observed following Cx in males cannot be solely ascribed to the 
loss of androgen production, but may be attributed to other gonadal hormones shared by 




production offers some protection against the development of immunological disorders in 
males, such as MS, an effect that may explain why the disease occurs more frequently (2-
3-fold) in females (Compston and Coles, 2008; Orton et al., 2010; Wallin et al., 2012). The 
high incidence of the disease in females has been ascribed to the rapid response of their 
immune system to any immunological stimulus such as vaccination because the 
concentrations of serum immunoglobulin are higher than in males (Azar et al., 2017; Trend 
et al., 2018). Aspinall and Andrew reported that age-related involution of thymus (thymic 
atrophy) occurred earlier in Gi male mice than in females due to the effects of androgens. 
Consequently, the numbers of CD4+ and CD8+ thymocytes were reduced prior to positive 
selection (Aspinall and Andrew, 2001). Additionally, CPZ-feeding to female mice induced 
a 2-3-fold reduction in the weights of their uterus and ovaries compared to Ctrls (Taylor et 
al., 2010). This means that androgens in normal female mice have a slower effect on age-
related thymus atrophy than in males. In addition, CPZ-feeding effects on the uterus and 
ovaries may reduce the levels of circulating androgens in females, thereby somewhat 
alleviating their effects on peripheral immune organs.  
In Study V, it was found that feeding CPZ to prepubescent female mice induced similar 
effects on the CNS (demyelination and gliosis) and peripheral immune organs as seen in 
males, consistent with previous studies (Taylor et al., 2010; Martin et al., 2018). This 
indicates that there are no sex differences with regard to the deleterious effects of CPZ-
feeding in juvenile or adult mice.  
Overall, this work has addressed two important questions relevant to the aetiology of MS. 
First, could demyelination and activation of innate immunity trigger an autoimmune 
response similar to that seen in MS? Second, might MS primarily be initiated by 
demyelination that then triggers peripheral T-cell recruitment to the CNS lesions? 
Concerning the first question, the data indicate that the peripheral actions of CPZ are an 
impediment to studying the role of the peripheral immune system in response to central 
demyelination, despite damage to the CNS that is quite reminiscent of MS. With regard to 
the second question, the data confirm that, subsequent to CPZ-induced demyelination, 
CD8+ T-cells are recruited to the CNS following disruption of the BBB when the peripheral 




following CPZ-feeding and BBB disruption (with PT), when combined with strategies that 
protect or ‘boost’ the peripheral immune system, i.e. peripheral CFA injections 
(Caprariello et al., 2018), provides further support for an ‘inside-out’ initiation of MS.  
Despite using multiple techniques (organ weight, western blot analysis, 
immunohistochemistry and flow cytometry) to confirm the interaction (and its reversal by 
Cx) between CPZ-feeding, peripheral immune structures and CD4/8 T-cell recruitment to 
the CNS, future activation and proliferation assays are required to determine the impact of 
individual or combined (Cx+0.1% CPZ+PT) treatments on T-cell function and their 
capacity to traverse the BBB. This need for detailed functional studies is reinforced by 
other work showing that use of CFA injection to ‘boost’ the peripheral immune system 
resulted in an enhanced infiltration of cells expressing the pan T-cell marker CD3 following 
CPZ-induced demyelination (Caprariello et al., 2018).    
 
4.6 - Conclusions 
The findings fully establish that feeding juvenile male mice with 0.1% or 0.2% CPZ for 
two weeks produced equivalent levels of demyelination and gliosis in the corpus callosum. 
However, 0.1% CPZ-induced less thymic and splenic atrophy, histopathology and a more 
modest effect on T-cell levels than the standard CPZ dose (0.2%). Moreover, the 
suppression of peripheral immune structures by CPZ explains why the recruitment of 
peripheral immune cells into the CNS has not been reported in previous studies. Castration 
protected against CPZ-induced thymic and splenic atrophy and thus the loss of CD4/8 T-
cells. Furthermore, the addition of PT to castrated CPZ-fed mice resulted in CD8+ T 
lymphocyte infiltration into CNS parenchyma, providing strong supporting evidence for 
the ‘inside-out’ hypothesis in the aetiology of MS. Demonstration of CD8+ T-cell 
recruitment into the CNS of CPZ-fed mice, albeit castrated male mice, provides a potential 
new variant of the CPZ model with which to explore the early events involved in CNS 
demyelinating diseases like MS and thus move beyond the focus on glia responses and pan 
T-cell markers in the literature. However, while 0.1% CPZ-feeding in Gi female mice 
induced peripheral immune organ atrophy, T-cell signal suppression, and CNS 




T-cell infiltration into the CNS, indicating that testosterone levels alone are not responsible 



























5 - General discussion, conclusions and future directions 
 
5.1 - General discussion 
5.1.1- Beyond BBB integrity: T-cell suppression in the periphery limits their recruitment 
into the CNS  
MS lesions (pattern III and IV) and the CPZ model share many pathological changes 
including oligodendrocytosis, demyelination and glial activation (Acs and Kalman, 2012, 
Kipp et al., 2009, Kipp et al., 2017). Therefore, CPZ-induced demyelination in mice was 
chosen as a fundamental tool in this thesis to develop a new animal model for MS, based 
on testing the inside-out theory of disease initiation (Caprariello et al., 2018). However, the 
CPZ model classically lacks T-cell involvement in CNS lesions, which has been the focus 
of extensive research in MS (Remington et al., 2007, Tejedor et al., 2017, Traka et al., 
2016). This lack of T-cell involvement has, at least in part, been attributed to the integrity 
of the BBB during and following CPZ-feeding (Remington et al., 2007, Tejedor et al., 
2017). Thus, in Study I of this thesis, the BBB disruption by multiple intraperitoneal 
injections of PT was the first modification of the CPZ model in adult C57BL/6 mice fed 
with 0.1% and 0.2% CPZ for 5 weeks. The study aimed to initiate an adaptive immune 
response (T-cell-driven inflammation) to the CPZ-induced demyelinating lesions within 
the CNS. Although extensive oligodenrocytosis, demyelination and gliosis were observed 
in this study, T-cell involvement was not evident. In Study II, the hypothesis that induction 
of a slow progressive oligodendrocytosis, comparable to that proposed to underlie the 
inside-out mechanism of MS initiation, would trigger a T-cell-mediated immune response 
in the CNS was tested. In this study, feeding a low dose of CPZ (0.1%) for 12 weeks was 
combined with disruption of the BBB, in order to induce a slow progression of 
oligodendrocytosis that would provide a stimulus (i.e., the formation of myelin debris and 
presentation of myelin antigens) capable of recruiting T-cells into the CNS of mice. This 
extended period (12 week) of 0.1% CPZ-feeding induced oligodendrocytosis, gliosis and 
demyelination that were indistinguishable from those seen in the short (5 weeks) period 
following 0.2% CPZ-feeding. Notably, the use of WB analysis indicated that splenic T-cell 




feeding in Studies I and II. In addition, CD4/8 were not detected in the CNS by either WB 
or immunohistochemistry.  
Top-down proteomic analysis (2DE/LC/MS/MS) in both studies revealed a reduced 
abundance of two proteins responsible for suppression of T-cell functions, namely 
calcium/calmodulin-dependent protein kinase II alpha (Camk 2a) and leukocyte elastase 
inhibitor type A (Serpinb1a). Camk 2a is an essential protein that is required in the process 
of proliferation and differentiation of cytotoxic (CD8+) T-cells (Lin et al., 2005, Bui et al., 
2000). Serpinb 1 inhibits serine proteases released by T-cells thereby suppressing their 
actions in the induction and maintenance of inflammation within the CNS (Weyer and 
Stucky, 2015). In addition, Partridge and colleagues (Partridge et al., 2016) proposed that 
CPZ-feeding induced suppression of T-cells function in spleen, based on proteomic 
analysis of the splenic tissue. They detected an increase in the abundance of splenic 
arginase-I (a protein expressed by myeloid-derived suppressor cells in spleen) and a 
decreased abundance of protein disulphide isomerise (a protein required for assembly of 
the major histocompatibility complex-I, MHC-I). It was previously reported that the 
change in the abundence of these proteins resulted in a suppressed T-cell function (Kang 
et al., 2009). 
In addition to these findings, it was shown that combining CPZ with EAE, or Theiler’s 
virus encephalomyelitis, ameliorates and/or prevents the development of the T-cell-
mediated immune conditions, indicating that the immune system was suppressed by CPZ-
feeding (Herder et al., 2012, Mana et al., 2009). Other studies demonstrated that CPZ-
feeding causes negative impacts on the peripheral immune organs including thymic atrophy 
that was attributed to CPZ-induced thymocyte (CD4+ and CD8+) apoptosis (Solti et al., 
2015) and splenic atrophy (Martin et al., 2018, Sui et al., 2018). Based on these 
observations, it is now clear that the deleterious action of CPZ-feeding in mice is not 
limited to CNS demyelination and gliosis, but it also affects the peripheral immune organs, 






5.1.2 - Metabolic perturbations and oxidative stress underlie oligodendrocytosis in the 
CPZ model  
In the first and second studies, 33 proteoforms were identified using a highly sensitive top-
down proteomic analysis (see method section). This analytical approach is well-established 
and enables separation of whole proteomes in the test samples with high consistency and 
reproducibility across biological (n=5 animals/group) and technical (n=3 gels/fraction) 
replicates (Partridge et al., 2016, Wright et al., 2014a, Oliveira et al., 2014, Coorssen and 
Yergey, 2015). Following protein identifications, the detailed literature investigation 
indicated that 25/33 proteoforms were previously identified in relation to CPZ, EAE and 
MS research, whereas the remaining 8 proteoforms were not previously reported. The 
bioinformatic analysis revealed that the vast majority of these 33 proteoforms are involved 
in cellular metabolic disturbances and energy failure, thereby providing further proof 
implicating the mitochondrial dysfunction following CPZ-feeding. 
In normal CNS tissue, mature OLG contain a large number of functional mitochondria to 
meet the energy demands of axonal myelination (Harris and Attwell, 2012). This process 
includes expanding the surface area of OLG, approximately 6500-fold, to form their 
myelinating processes (McLaurin and Yong, 1995, McTigue and Tripathi, 2008, Freeman 
and Rowitch, 2013). These OLG processes extend to cover a wide area of up to 50×103 
μm2 around the axons (Butt et al., 1995, Pfeiffer et al., 1993). During this process, the high 
energy demands and increased production of reactive oxygen and nitrogen species lead to 
oxidative stress and cellular injury (McTigue and Tripathi, 2008). Within OLG, the 
oxidative stress on the mitochondria and endoplasmic reticulum leads to protein unfolding 
and OLG degeneration (Huang et al., 2014). However, the limited storage of antioxidants 
such as superoxide dismutase (Pinteaux et al 1998) and glutathione in the OLG reduce the 
damage induced by oxidative stress (Carvalho et al., 2014, Ferreira et al., 2013).  
OLG degeneration in the CPZ model was attributed to energy failure resulting from 
mitochondrial dysfunction (McTigue and Tripathi, 2008, Mronga et al., 2004). Supporting 
this, the early effects of CPZ-feeding are the formation mega-mitochondria in the liver and 
OLG as well as enlarged mitochondria in the thymus, indicating that CPZ toxicity occurs 




apoptosis (Matsushima and Morell, 2001a, Ludwin, 1978, Solti et al., 2015). The proteomic 
analyses in Studies I and II revealed an increased abundance of calreticulin, a change that 
correlates with oxidative damage in the endoplasmic reticulum, and may also increase 
levels of unfolded proteins during CPZ-feeding (Ni Fhlathartaigh et al., 2013, Lee et al., 
2007). Moreover, activation and proliferation of astrocytes and microglia at the sites of 
CPZ-induced demyelination lesions increase the energy demands thereby contributing to 
the oxidative stress imposed on the OLG (Thorburne and Juurlink, 1996). These 
observations indicated that CPZ-induced mitochondrial dysfunction and endoplasmic 
reticulum oxidative stress exacerbate OLG degeneration and subsequent myelin loss. 
 
5.1.3 - T-cell involvement in the CPZ model is limited unless strategies to protect the 
peripheral immune system are employed   
Based on the results of studies I and II it was evident that CPZ-feeding produced 
suppression of T-cells in the periphery. Consequently, Studies III-V were designed to test 
whether protection, and/or boosting, of the peripheral immune system during CPZ-feeding 
would increase peripheral T-cell levels and reveal a central T-cell response. Intriguingly, a 
broader review of the literature revealed that administration of testosterone (Oner and 
Ozan, 2002) induces similar effects on the primary peripheral immune organ (thymus) to 
those seen in animals fed CPZ (Solti et al., 2015). These effects include thymic atrophy, in 
which the apoptotic thymocytes displayed enlarged and degraded mitochondria, increased 
lipid droplets, and enlarged lysosomes associated with reduced T-cell levels. Conversely, 
testosterone ablation by orchiectomy or chemical castration, increased the size and function 
of the thymus (Sheean et al., 2015, Roden et al., 2004) and spleen (Roden et al., 2004). 
Furthermore, castration reversed the age dependent thymic involution, in effect restoring 
normal histological structure while enhancing the function of both thymus and bone 
marrow, and their associated T-cell levels (Sutherland et al., 2005). Based on these 
observations, surgical Cx was used to increase the size of the thymii and spleens and to 
boost their immune functions so as to offer protection against the negative effects of CPZ-
feeding. In the Gi male mice, CPZ-induced a dose dependent (0.1% < 0.2% CPZ) reduction 
of thymic and splenic weight and their associated CD4/8 signals, whereas Cx preserved 




when combined with 0.1% CPZ-feeding, was not sufficient to induce T-cell infiltration into 
the CNS. Notably, the 0.1% CPZ dose was as effective as 0.2% CPZ in terms of 
demyelination and gliosis, yet 0.1% CPZ produced less suppression of the peripheral 
immune organs. This indicated that Cx is a potent method to counteract the peripheral 
effects of CPZ (atrophy) on the thymus and spleen.  
The central and peripheral toxic effects of CPZ have been attributed to copper chelation 
that interferes with cellular metabolic process (Acs et al., 2013, Pasquini et al., 2007, Acs 
and Komoly, 2012, Solti et al., 2015). For example, copper is a key factor in IL-2 
transcription in CD4+ T-cells (Hopkins and Failla, 1999). This process may thus be 
suppressed due to copper chelating during CPZ-feeding (Emerson et al., 2001) and may 
underpin the reduction in peripheral (thymic and splenic) CD4 signal.  
The mitochondrial dysfunction that leads to thymocyte apoptosis may explain the 
decreased levels of thymic CD4/8 seen in Gi male mice following CPZ-feeding. The 
reduction in the circulating T-cell levels in Gi mice may result from the effects of 
testosterone (Veto et al., 2010, Olsen et al., 1994, Olsen et al., 1998) and CPZ-feeding on 
the mitochondrial function that leads to thymocyte (CD4+ and CD8+) apoptosis and thymic 
atrophy (Solti et al., 2015). Cx induced testosterone ablation preserved thymic CD4/8 levels 
presumably through its regenerative effects on CD4+ and CD8+ thymocytes. Supporting 
this, previous reports have shown that androgen depletion reduced mitochondrial 
dysfunctions and eliminated the subsequent oxidative stress in the thymus (Liu et al., 2019). 
In addition, Cx-induced androgen deprivation stimulates stem cell proliferation in the bone 
marrow and enhances their differentiation into mature thymocytes and thus the 
regeneration of thymic tissue (Sutherland et al., 2005, Olsen et al., 1994, Roden et al., 2004, 
Page et al., 2006, Sheean et al., 2015). Together, the suppressive effects of CPZ-feeding on 
the peripheral immune system were countered by preventing the normal thymic involution 
via Cx, leading to a complete preservation of peripheral immune function.   
 
5.1.4 - The intact BBB prevents T-cell recruitment to the demyelinated CNS lesions  
Over the course of the experimental work and incremental modifications of the CPZ mouse 




involvement despite clear CNS pathology. However, during the course of these studies, it 
was shown that after two weeks of CPZ-feeding, combining a ‘boosting’ of the peripheral 
immune system (by peripheral injection of CFA) and disruption of the BBB by PT resulted 
in detectable CD3+ T-cells in the CNS (Caprariello et al., 2018). Furthermore, the authors 
demonstrated that continued CPZ-feeding limited T-cell recruitment into the CNS. In this 
thesis, an alternative peripheral immune ‘boosting’ strategy was employed. In Study III, 
Cx was shown to increase thymic weight and preserve splenic mass as well as their CD4/8 
levels, and when combined with 0.1% CPZ feeding produced comparable demyelination 
and gliosis in the CNS, but without central T-cell involvement.  Consequently in Study IV, 
0.1% CPZ-feeding was combined with castration and PT injection. The preservation of the 
peripheral immune structures combined with breach of the BBB in CPZ-fed mice resulted 
in increased recruitment of CD8+ T-cells into the cerebrum, cerebellum, brainstem and 
spinal cord – a finding confirmed by WB analysis and at the single cell level using 
immunohistochemistry. Furthermore, the effect of PT-mediated breach of the BBB was 
confirmed by increased levels of IgG within the brain parenchyma. This increase in IgG 
intensity indicates that IgG movement across the BBB from the blood to the neural tissues 
was increased following PT injections (Yin et al., 2010, Wunder et al., 2012).  In contrast 
to Studies I and II (5 and 12 weeks of CPZ feeding), low numbers of CD8+ T-cells were 
seen in control, Cx or PT alone (Study IV) that were increased following CPZ-feeding 
(Cx+0.1% CPZ+PT). Notably, when CD8+ T-cells were found, they appeared as either 
individual cells or small groups surrounding the blood capillaries in the CNS tissue, 
indicating a recent infiltration of these cells into the CNS parenchyma - a pattern of CD8+ 
T-cell infiltration similar to that observed in active MS lesions (del Pilar Martin et al., 
2008).   
It has been reported that Cx increased the levels of circulating CD8+ T-cell in humans and 
mice (Page et al., 2006, Tang et al., 2012). The current study did not investigate the 
mechanisms that facilitated CD8+ T-cell infiltration into the CNS tissue. However, it would 
seem most likely that BBB disruption enhanced CD8+ T-cell availability and infiltration 
following preservation of the peripheral immune system by Cx and that together with CPZ-
induced demyelination, this resembles the conditions described by the ‘inside-out’ theory 




that glial activation (astrocytes and microglia) and myelin antigen presentation as well as 
the release of proinflammatory molecules attracted T-cells to the demyelinating lesions 
(Bonetto et al., 2017). The release of proinflammatory molecules was also found to increase 
the permeability of the BBB and facilitate T-cell infiltration (Suidan et al., 2006). It was 
also suggested that the increased CD8+ T-cells in the CNS of MS patients is a result of the 
infiltration of these cells from the periphery in addition to local clonal expansion within 
the CNS (Crawford et al., 2004). The predominance of CD8+ T-cells in the current study 
was consistent with that seen in MS lesions, in which the CD8+ T-cell numbers were higher 
than CD4+ by 3-10 fold (Friese and Fugger, 2005, Hauser et al., 1986). The pathological 
changes seen in this modified CPZ model, including demyelination, gliosis and increased 
CD8+ T-cell levels in the CNS, closely resemble the proposed inside-out initiation of MS. 
This is in direct contrast to the EAE model in which the pathology involves CD4+ T-cells 
and the majority of lesions occur in the spinal cord (Steinman and Shoenfeld, 2014). In 
addition, EAE is built on peripheral induction following exposure to exogenous antigens 
(outside-in) and thus ignores the likely central, upstream (inside-out) inflammatory triggers 
that are generated in the CNS (Caprariello et al., 2018). Altogether, these findings provide 
evidence that a central stimulus (demyelination), following boosting the peripheral immune 
system, can induce a CD8+ T-cell-mediated immune response in the CNS.   
 
5.1.5 - Castration affects more than androgens: PT injection in CPZ-fed female mice did 
not enhance CD8+ T-cell recruitment into the CNS  
Following successful detection of CD8+ T-cells in Cx male mice, Study V tested whether 
BBB disruption when combined with CPZ-feeding of female mice also resulted in T-cell 
infiltration into the CNS. This approach was devised based the observed effects of Cx 
(Study IV) and human epidemiology that shows a 2-3 fold increase in the incidence of MS 
in women (i.e. with naturally low levels of testosterone) and the gender based variances in 
disease severity (Ahlgren et al., 2011, Harbo et al., 2013). Study V revealed that 
demyelination, gliosis and atrophy of the immune organs (and their associated CD4/8 
lymphocytes) in CPZ-fed Gi females were indistinguishable from those seen in Gi males, 
indicating that the preservation of peripheral immune organ function observed following 




gonadal hormones, such as activin and inhibin, that are shared by males and females 
(Licona et al., 2006).  
While correlations between age, gender and hormone levels do not provide proof of 
causality, they do provide an interesting insight into some differences observed between 
males and females at a population level. For example, acute androgen-driven thymic 
atrophy starts at puberty in both men and women, with this thymic involution occurring 
earlier in men (25-29 years) than women (30-34 years) (Zabrodin 2002; Zabrodin 2003) 
indicating that women exhibit a prolonged heightened thymic function. MS occurs most 
often in younger people, usually aged between 20-30 years (Marrie et al., 2010, Ochi, 
2017). If we accept the postulate that disease onset starts during the second decade of life 
before the detection of early clinical signs (Waldman et al., 2014) and that disease onset is 
modulated by androgen-induced thymic atrophy, then prevalence and timing of clinical 
signs should be related to the onset of androgenesis. As the clinical symptoms of MS 
emerge during 20-30 years of age, this would be approximately 10 years after the onset of 
puberty and the consequent gender based thymic atrophy that occurs sooner in men (from 
25-29 years), in which elevated testosterone levels decrease T-cell production (Zabrodin 
2002, Zabrodin 2003), relative to women (30-34 years). This may thus yield a prolonged 
period in women during which enhanced thymic function predisposes them to the more 
rapidly progressing autoimmune elements of MS, and thereby increasing their relative 
representation in terms of autoimmune diseases overall.  This indicates that testosterone 
may have a protective role in men by reducing T-cell levels and consequently their immune 
response against myelin antigens, whereas in women the delayed severity of thymic 
involution starts from 30-34 years (Zabrodin 2002; Zabrodin 2003).  These gender 
differences in thymic involution may thus contribute to the higher incidence of the disease 
in women than in men (Ahlgren et al., 2011, Harbo et al., 2013). 
In terms of modelling these interactions in mice, C57BL/6 male mice show a dramatic 
decrease in the parenchyma of the thymus that starts at ~5-weeks of age (Gray et al., 2006, 
Gui et al., 2012), whereas in the same strain, females display a thymic atrophy that starts 
at ~7-weeks (Dominguez-Gerpe and Rey-Mendez, 2003, Gui et al., 2011). Consistent with 




thymocytes compared to age matched females (Aspinall and Andrew, 2001, Dominguez-
Gerpe and Rey-Mendez, 2003). These observations indicate that the timing of 
physiological androgen-dependent (age related) thymic involution in male and female mice 
is very similar to the timing of thymic involution in human (i.e. female mice experience a 
slower effect on androgen-driven thymic atrophy than do males). 
The results in female mice (Study V) were thus consistent with the prior demonstration that 
CPZ induced a similar extent of demyelination and gliosis in both male and female mice 
(Taylor et al., 2010). Furthermore, the effects of CPZ on the peripheral immune system in 
female mice prevailed over any age-related delay in thymic atrophy. Whilst the aim of 
Study IV in female mice was to test whether PT injection could lead to T-cell infiltration 
into their CNS, these cells were not detected in the CNS tissue homogenate using our 
sensitive WB method.  Furthermore, a few scattered CD8+ T-cells were found in the 
immunostained CNS sections of all the test groups but without significant differences. 
Although thymic (Solti et al., 2015) and splenic (Martin et al., 2018, Sui et al., 2018) 
atrophy and peripheral T-cell suppression are known effects of CPZ in male mice, the 
results of this study revealed, for the first time, the impact of CPZ feeding plus PT injection 
on the thymus and spleen in C57BL/6 female mice. Together, CPZ-feeding and/or PT in 
female mice induced similar effects in the CNS and peripheral immune organs to those 






5.2 - Summary and Conclusions 
• In adult mice, 5 weeks of 0.2% CPZ-feeding (Study I) produced comparable 
oligodendrocytososis, demyelination and gliosis to that observed following 12 weeks of 
0.1% CPZ-feeding (Study II).  
  
• In adult mice, combining 5 or 12 weeks of CPZ-feeding with disruption of the BBB: 
 
o Induced proteoform alterations in the brain related to mitochondrial and 
endoplasmic reticulum dysfunction. 
o Induced splenic atrophy and reduce T-cell levels.   
o Was not associated with T-cell infiltration into the CNS.  
 
These finding suggest that the CPZ-induced suppression of T-cells in the spleen is the 
reason behind the limited capacity of peripheral T-cells to infiltrate into the brain and 
recognise endogenous myelin antigens. 
 
• In the prepubescent male mice, feeding 0.1% or 0.2% CPZ for two weeks produced: 
 
o Comparable demyelination and gliosis in the midline corpus callosum.  
o Dose dependent (0.2% > 0.1% CPZ) reductions in the weight of the thymus (and 
spleen) and their associated CD4/8 signal intensities. 
o Castration had no effect on the demyelination and gliosis but did reverse the CPZ-
induced thymic and splenic atrophy. 
o No detectable CD4/8 cells in the CNS. 
 
As combining 0.1% CPZ with castration preserved the spleen and thymus, but failed to 
reveal detectable CD4/8 in the CNS, it was concluded that the lack of T-cell infiltration 
was attributed to an intact BBB.  
 
• When castration was combined with 0.1% CPZ-feeding and disruption of the BBB 
increased CD8+ T-cell infiltration was observed in the CNS. 
The short (2-week) period of low dose of CPZ (0.1%) feeding to prepubescent mice 




antigen presentation with the release of proinflammatory molecules that enhanced CD8+ 
T-cell recruitment thereby initiating an “inside” (demyelination) “out” (CD8+ T-cell 
mediated) immune response. 
• In female mice (gonadally intact), 0.1% CPZ-induced thymic and splenic atrophy, 
demyelination and gliosis comparable to that seen in intact males.  
These data suggest that factors other than androgen production contribute to the age-






5.3 - Future directions 
The experimental work in this thesis was designed to address the limitations of the CPZ 
model (i.e. the intact BBB and suppression of the peripheral immune system), in order to 
develop an animal model that more closely resembles the aetiology of MS (i.e. to test the 
inside-out versus outside-in theories of disease initiation). In this thesis, the incremental 
modifications of the CPZ model have confirmed the causes (thymic/splenic atrophy) for 
the absence of T-cells in the CNS and demonstrated that this could be ameliorated by Cx 
in male mice, yielding a model in which the resulting CNS immune responses were 
dominated by CD8+ T-cells. This new variant of the CPZ model should thus prove to be a 
useful tool to investigate the inside-out theory of MS initiation. Thus, in order to refine and 
validate this model as relevant to studying the inside-out theory of MS initiation, the 
following steps should be considered: 
 
5.3.1 - Extending the time of the CPZ-feeding in male mice 
Cx and 2 weeks of CPZ-feeding began at age 4 weeks old so as to precede to onset of 
normal age-related thymic involution in males (~5 weeks). This timing although effective 
in revealing a central CD8+ T-cell mediated immune response may not be sufficient to 
activate the immunological processes that evoke CD4+ T-cell infiltration into the CNS. 
Therefore, future modifications should consider the timing (i.e. extending the time of CPZ 
feeding for at least one or two more weeks) as a potential factor to test whether CPZ-
feeding in Cx mice can also trigger a CD4+ T-cell-mediated response in the CNS in addition 
to the CD8+ response. 
 
5.3.2 - Ovariectomy and extending the time of the CPZ-feeding in female mice  
Ovariectomy in female mice may produce similar protective effects to orchiectomy in 
males (i.e. protecting the size and the functions of the thymus and spleen against the 
harmful effects of the CPZ-feeding). In addition to the ovariectomy, the experimental 
period should be extended to 3 - 4 weeks instead of 2 weeks as the timing of the onset of 
thymic atrophy in female mice is delayed to the age of ~7 weeks compared to male mice 




peripheral immune organs from CPZ-induced atrophy and lead to T-cell recruitment into 
the CNS following breach of the BBB.  
 
5.3.3 - Adoptive transfer of myelin proteins  
CPZ inhibits the clinical and pathological characteristics of EAE and Theiler’s immune 
encephalomyelitis due to suppression of the peripheral immune system. This suppression 
can be prevented by castration which protects the peripheral immune system against CPZ 
effects. Thus, an additional hypothesis to test is whether castration and CPZ-feeding plus 
BBB disruption combined with the adoptive transfer of myelin proteins (e.g. MBP, MOG, 
MAG or PLP), will also lead to central demyelination and the infiltration of CD4+ and 
CD8+ T-cells into the CNS. This strategy is anticipated to lead to demyelination plus a 
central autoimmune response (with both CD4 and CD8) that will be seen in the spinal cord 
as well, and thereby producing a still better animal model of MS.     
 
 
5.3.4 – Mechanisms of CD8+ T-cell recruitment into the CNS 
Hypothetically, CD8+ T-cells cannot infiltrate into the CNS without having been stimulated 
and activated in the periphery then extravasated through a permeable BBB. However, the 
microenvironment that facilitates CD8+ T-cell infiltration was not examined in this work. 
For example, the role of microglia-produced proinflammatory cytokines (IL-1, IL-6, TNF-
α and IFN-γ) in the process of CD8+ T-cell infiltration should be investigated by using 
different methods (e.g. enzyme-linked immunosorbent assays or immunosensoring 
methods (Zhou et al., 2010)). This would test the hypothesis that identifying the cytokine(s) 
that is/are responsible for the peripheral T-cell activation (and/or local expansion) in 
response to the myelin antigens will pinpoint the mechanism(s) of CD8+ T-cell recruitment 
into the CNS following Cx and the breach of the BBB in CPZ-fed mice. In addition, 
glymphatic and meningeal lymphoid drainage pathways (into which proinflammatory 
cytokines are drained after being released to the CSF) from the brain to the cervical lymph 
nodes should be investigated as the immune response is likely to be generated in peripheral 
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1 - Buffers and solutions that are used in the experiments of the thesis 
1.1 - Buffers 
Table 1: Solubilisation buffer. 
Chemicals  Quantity (100 ml) 
8M urea 48.8 g 
2M thiourea 15.225 g 
4% CHAPS 4 g 
Distilled water Up to 100 ml 
 
Table 2: Equilibration buffer. 
Chemicals  Quantity (100 ml) 
6M urea 36.6 g 
20% glycerol 20 ml 
2% SDS 20 ml from 10% SDS stock solution 
375mM Tris (pH=8.8) 25 ml from 1.5 M Tris stock buffer  
Distilled water Up to 100 ml 
 
Table 3: 1.5M tris stock buffer (pH 8.8). 
Chemicals Quantity (1 L) 
1.08M tris salt 130.84 g 
0.42M tris-HCL salt 66.24g 
Distilled water Up to 1 L 
 
Table 4: Transfer buffer. 
Chemicals Quantity (1 L) 
25 mM tris (pH=8.3) 3.03 g 
192  mM glycine  14.4 g 
20% Methanol 200 ml 
Distilled water Up to 1 L 
 
Table 5: Tris buffered saline-Tween-20 (TBST) buffer. 
Chemicals Quantity (1 L) 
10 mM tris (pH=8.3)  1.21 g 
150 mM NaCl 9 g 
0.1% Tween 20 1 ml 
Distilled water Up to 1 L 
 
Table 6: Lysis buffer.  
Chemicals  Amount (100 ml) 
25 mM Tris (pH=7.4) 1.666 ml from 1.5M stock solution 
1 mM EDTA 0.029 g 
1 mM EGTA 0.038 g 
1% Triton x-100 1 ml 
150 mM NaCl 0.4383 g 
Protease inhibitor  200 µl  




Table 7: 0.1M phosphate buffer (pH 7.4). 
Chemicals  Amount (1L) 
Dibasic sodium phosphate 
heptahydrate  
20.209 g 
Monobasic sodium phosphate 
monohydrate 
3,.394 g 
Sodium hydroxide  For pH adjustment 
Distilled water Up to 1 L 
 
 
1.2 - Gel solutions 
Table 8: resolving gel. 
Chemicals  Quantity (for 100 ml) 
Acrylamide solution 40% 25 ml  
375mM tris (pH 8.8) 25 ml from 1.5M stock solution 
0.1% SDS 1 ml from 10% stock solution 
APS 0.5 ml from 10% stock solution 
TEMED 50 µl 
 
Table 9: stacking gel. 
Chemicals  Quantity (for 100 ml) 
Acrylamide solution 40% 12.5 ml  
375mM tris (pH 8.8) 25 ml from 1.5M stock solution 
0.1% SDS 1 ml from 10% stock solution 
APS 1 ml from 10% stock solution 
TEMED 100 µl 
Bromophenol blue 100 µl from 1% stock solution 
 
Table 10: Low melting agarose. 
Chemicals  Quantity (for 100ml) 
375mM tris (pH 8.8) 25 ml 
0.5% agarose  0.5g 
0.1% SDS 0.1g 
 
1.3 - Coomassie staining solution 
Table 11: Coomassie staining. 
Chemicals  Quantity (for 1 L) 
30% phosphoric acid  50 ml 
20% ammonium sulphate  250 ml 
2% CBB 50 ml 
100% methanol 200 ml 

































































































































3 - Published paper (Paper 2) 
 
[234] 
 
 
 
[235] 
 
 
 
[236] 
 
 
 
[237] 
 
 
 
[238] 
 
 
 
[239] 
 
 
 
[240] 
 
 
 
[241] 
 
 
 
[242] 
 
 
 
[243] 
 
 
 
[244] 
 
 
 
[245] 
 
 
 
[246] 
 
 
 
[247] 
 
 
 
[248] 
 
 
 
[249] 
 
 
 
 
 
[250] 
 
 
 
[251] 
 
 
 
[252] 
 
 
